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Transcriptional Regulation of Azole Antifungal Resistance and Tolerance in
Candida Glabrata
Abstract
Azole antifungal resistance has emerged as a significant problem in the management of infections
caused by fungi including Candida species. In recent years, Candida glabrata has become the second
most common cause of mucosal and invasive fungal infections in humans second to Candida albicans.
Not only are systemic C. glabrata infections characterized by high mortality rates, treatment failures to
the azole class of antifungals, the most widely used antifungal for treatment of Candida infections, have
been reported. Contributing to this problem, C. glabrata exhibits intrinsic reduced susceptibility to the
azole antifungals, and the development of high-level azole resistance during therapy has been reported in
oral as well as bloodstream C. glabrata isolates in immunocompromised patients. The azole antifungals
are fungistatic against Candida species, thus C. glabrata also exhibits tolerance to the azoles which may
contribute to both therapeutic failures and ultimately the development of high-level azole resistance.
In C. glabrata clinical isolates, the predominant mechanism behind azole resistance is upregulated
expression of multidrug transporter genes CgCDR1 and CgPDH1. It was previously reported that azoleresistant mutants (MIC ≥ 64 μg/ml) of strain 66032 (MIC = 16 μg/ml) similarly show coordinate
CDR1-PDH1 upregulation, and in one of these (F15) a putative gain-of-function mutation was identified in
the single molecule homologue of Saccharomyces cerevisiae transcription factors Pdr1p–Pdr3p. Here we
show that disruption of C. glabrata PDR1 conferred equivalent fluconazole hypersensitivity (MIC = 2 μg/
ml) to both F15 and 66032 and eliminated both constitutive and fluconazole-induced CDR1-PDH1
expression. Reintroduction of wild-type or F15 PDR1 alleles fully reversed these effects; together these
results demonstrate a role for this gene in both acquired and intrinsic azole resistance. CDR1 disruption
had a partial effect, reducing fluconazole trailing in both strains while restoring wild-type susceptibility
(MIC = 16 μg/ml) to F15. In an azole-resistant clinical isolate, PDR1 disruption reduced azole MICs eightto 64-fold with no effect on sensitivity to other antifungals. To extend this analysis, C. glabrata gene
expression microarrays were generated and used to analyze genome-wide expression in F15 relative to its
parent. Homologues of 10 S. cerevisiae genes previously shown to be Pdr1p–Pdr3p targets were
upregulated (YOR1, RTA1, RSB1, RPN4, YLR346c and YMR102c along with CDR1, PDH1 and PDR1 itself)
or downregulated (PDR12); roles for these genes include small molecule transport and transcriptional
regulation. However, expression of 99 additional genes was specifically altered in C. glabrata F15; their
roles include transport (e.g. QDR2, YBT1), lipid metabolism (ATF2, ARE1), cell stress (HSP12, CTA1), DNA
repair (YIM1, MEC3) and cell wall function (MKC7, MNT3). These azole resistance-associated changes
could affect C. glabrata tissue-specific virulence; in support of this, we detected differences in F15
oxidant, alcohol and weak acid sensitivities. C. glabrata provides a promising model for studying the
genetic basis of multidrug resistance and its impact on virulence.
We next examined the genome-wide gene expression profiles in four matched azole-susceptible and
–resistant clinical isolate sets of C. glabrata in which CgCDR1 gene expression was upregulated in the
resistant isolate. Of all the genes identified in the gene expression profiles for these four matched pairs,
there were nine genes that were commonly upregulated with CgCDR1 in all four isolate sets (YOR1, LCB5,
RTA1, YIM1, YIL077c, POG1, HFD1, GLK1, and FMS1). We then sequenced CgPDR1 from each susceptible
and resistant isolate and found two alleles with novel gain-of-function mutations. A third isolate, and its
susceptible parent, harbored a CgPDR1 allele with a frameshift mutation which presumably results in a
truncated CgPdr1p. The final resistant isolate had noPDR1 mutation. CgPDR1 alleles with putative gainof-function mutations were expressed in a common background strain in which CgPDR1 had been
disrupted, and genome-wide gene expression profiles were examined to determine if different mutations
inCgPDR1 result in different target gene activation and fluconazole MICs. Microarray analysis comparing

these re-engineered strains to their respective parent strains identified a core set of commonly
differentially-expressed genes as well as genes uniquely regulated by specific mutations.
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ABSTRACT
Azole antifungal resistance has emerged as a significant problem in the
management of infections caused by fungi including Candida species. In recent years,
Candida glabrata has become the second most common cause of mucosal and invasive
fungal infections in humans second to Candida albicans. Not only are systemic C.
glabrata infections characterized by high mortality rates, treatment failures to the azole
class of antifungals, the most widely used antifungal for treatment of Candida infections,
have been reported. Contributing to this problem, C. glabrata exhibits intrinsic reduced
susceptibility to the azole antifungals, and the development of high-level azole resistance
during therapy has been reported in oral as well as bloodstream C. glabrata isolates in
immunocompromised patients. The azole antifungals are fungistatic against Candida
species, thus C. glabrata also exhibits tolerance to the azoles which may contribute to
both therapeutic failures and ultimately the development of high-level azole resistance.
In C. glabrata clinical isolates, the predominant mechanism behind azole
resistance is upregulated expression of multidrug transporter genes CgCDR1 and
CgPDH1. It was previously reported that azole-resistant mutants (MIC ≥ 64 μg/ml) of
strain 66032 (MIC = 16 μg/ml) similarly show coordinate CDR1-PDH1 upregulation, and
in one of these (F15) a putative gain-of-function mutation was identified in the single
molecule homologue of Saccharomyces cerevisiae transcription factors Pdr1p–Pdr3p.
Here we show that disruption of C. glabrata PDR1 conferred equivalent fluconazole
hypersensitivity (MIC = 2 μg/ml) to both F15 and 66032 and eliminated both constitutive
and fluconazole-induced CDR1-PDH1 expression. Reintroduction of wild-type or F15
PDR1 alleles fully reversed these effects; together these results demonstrate a role for this
gene in both acquired and intrinsic azole resistance. CDR1 disruption had a partial effect,
reducing fluconazole trailing in both strains while restoring wild-type susceptibility (MIC
= 16 μg/ml) to F15. In an azole-resistant clinical isolate, PDR1 disruption reduced azole
MICs eight- to 64-fold with no effect on sensitivity to other antifungals. To extend this
analysis, C. glabrata gene expression microarrays were generated and used to analyze
genome-wide expression in F15 relative to its parent. Homologues of 10 S. cerevisiae
genes previously shown to be Pdr1p–Pdr3p targets were upregulated (YOR1, RTA1,
RSB1, RPN4, YLR346c and YMR102c along with CDR1, PDH1 and PDR1 itself) or
downregulated (PDR12); roles for these genes include small molecule transport and
transcriptional regulation. However, expression of 99 additional genes was specifically
altered in C. glabrata F15; their roles include transport (e.g. QDR2, YBT1), lipid
metabolism (ATF2, ARE1), cell stress (HSP12, CTA1), DNA repair (YIM1, MEC3) and
cell wall function (MKC7, MNT3). These azole resistance-associated changes could affect
C. glabrata tissue-specific virulence; in support of this, we detected differences in F15
oxidant, alcohol and weak acid sensitivities. C. glabrata provides a promising model for
studying the genetic basis of multidrug resistance and its impact on virulence.
We next examined the genome-wide gene expression profiles in four matched
azole-susceptible and –resistant clinical isolate sets of C. glabrata in which CgCDR1
gene expression was upregulated in the resistant isolate. Of all the genes identified in the
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gene expression profiles for these four matched pairs, there were nine genes that were
commonly upregulated with CgCDR1 in all four isolate sets (YOR1, LCB5, RTA1, YIM1,
YIL077c, POG1, HFD1, GLK1, and FMS1). We then sequenced CgPDR1 from each
susceptible and resistant isolate and found two alleles with novel gain-of-function
mutations. A third isolate, and its susceptible parent, harbored a CgPDR1 allele with a
frameshift mutation which presumably results in a truncated CgPdr1p. The final resistant
isolate had no PDR1 mutation. CgPDR1 alleles with putative gain-of-function mutations
were expressed in a common background strain in which CgPDR1 had been disrupted,
and genome-wide gene expression profiles were examined to determine if different
mutations in CgPDR1 result in different target gene activation and fluconazole MICs.
Microarray analysis comparing these re-engineered strains to their respective parent
strains identified a core set of commonly differentially-expressed genes as well as genes
uniquely regulated by specific mutations.
Because understanding the initial stress response of C. glabrata to fluconazole
may facilitate a better understanding of how this organism is able to survive in the
presence of fluconazole, we used microarray analysis to determine how fluconazole
exposure affects the gene expression profile in C. glabrata. We identified four
transcriptional regulators, CgPDR1, UPC2, RLM1, and CRZ1, and several of their
respective putative target genes that are upregulated in response to this stress. There were
also many genes differentially expressed in response to fluconazole that encode proteins
involved in small molecule transport (CgCDR1, CgPDH1, and YOR1), lipid, fatty acid,
and sterol metabolism (ERG1, ERG2, and ERG24), cell wall maintenance (CWP1, CRH1,
and CHS1), and cell stress (DDR48). As CgPDR1 has been implicated as a key regulator
of azole resistance by activating transcription of the genes encoding ABC transporters
CgCDR1p and CgPDH1p and has been shown to be activated in response to azole
exposure, we also identified genes that respond to fluconazole exposure in a CgPDR1dependent fashion. Surprisingly, only five genes were Pdr1p-dependent in response to
fluconazole, including CgCDR1. Our results provide a more comprehensive picture of the
gene expression changes of C. glabrata in response to fluconazole.
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CHAPTER 1. INTRODUCTION
CANDIDA GLABRATA
Biology and Classification
Candida glabrata is a commensal organism found among normal flora of the
skin, mouth, vagina, and gastrointestinal tract. It is a budding yeast and belongs to the
largest taxonomic group of the Fungal Kingdom, ascomycetes, and the class
Saccharomycotina. C. glabrata is considered a non-dimorphic yeast that exist as small
blastoconidia (1 to 4 μm) both as a commensal and as a pathogen; however,
pseudohyphae have been observed in C. glabrata when grown on synthetic lowammonium dextrose agar (45). In fact, C. glabrata was once classified in the genus
Torulopsis secondary to its lack of pseudohyphae production. However, it was later
determined that the ability to produce pseudohyphae was not a reliable distinguishing
factor for members of the genus Candida and T. glabrata was reclassified in the genus
Candida (152).
The evolutionary relationship within the genus Candida was compared by Barnes
et al. on the basis of homology of 18S rRNA sequence, and it was concluded that despite
its name, C. glabrata is evolutionarily more related to Saccharomyces cerevisiae than to
other pathogenic fungi such as Candida albicans (16). However, in contrast to the
sexually active S. cerevisiae that can shift in its life cycle between diploid and haploid
forms of cells (226), C. glabrata is exclusively a haploid and asexual organism despite
the fact that genetic analyses revealed the presence of genes potentially responsible for
conjugation and mating-type switching (112, 202). Like with S. cerevisiae, C. glabrata is
a “petite-positive” yeast in that a loss of mitochondrial genome is not lethal. Interestingly,
these “petite mutants” were found to be more resistant to antifungals than the wild-type
strains (50).
Genetics and Genetic Manipulation
The genome sequence of C. glabrata strain CBS138 was published in 2004 (50).
It has 13 chromosomes encompassing a total of 12.3 Mbp and consists of approximately
207 tRNA-encoding genes and 5283 protein-encoding genes. Its G-C content is 38.8%
which is similar to S. cerevisiae (38.3%)(60). The genomes of C. glabrata and S.
cerevisiae display a high degree of synteny with a majority of the S. cerevisiae genes
having C. glabrata orthologs (60). However, C. glabrata has lost many metabolism
genes, such as genes involved in galactose and sucrose assimilation, phosphate, nitrogen
and sulfur metabolism, and thiamine, pyridoxine, and nicotinic acid biosynthesis. This is
possibly a result of its close relationship with the mammalian host.
The lack of a sexual cycle in C. glabrata is a drawback for classical genetics in
this species. Methods used in C. glabrata for gene disruption rely on integrative
1

transformation by homologous recombination. Furthermore, two methods have been
developed for transformation in C. glabrata, lithium acetate transformation and
electroporation transformation (adapted from Cryptococcus neoformans) (75, 214). There
are several gene disruption protocols that have been used in C. glabrata (82, 100, 132,
225, 230); however, all of these methods depend on the use of nutritional markers for the
selection of prototrophic transformants from auxotrophic host strains. One of these
systems, modified from a S. cerevisiae method for use in C. glabrata, has been termed
the PROmoter-dependent DIsruption of Genes (PRODIGE) method (19, 63, 119). This
method uses polymerase-chain reaction (PCR) rather than cloning to generate disruption
cassettes. These cassettes are generated with a promoterless marker gene (URA3) such
that the expression of the selection marker gene is dependent, following recombination,
on the promoter of the targeted gene. Selection then takes place on minimal medium
plates lacking uracil. One obvious drawback of this method is that it requires at least a
minimal level of promoter activity of the targeted gene for URA3 expression. Another
drawback is that using the PRODIGE method, genes can only be disrupted in C. glabrata
strains with a URA3-deficient genetic background.
It is becoming increasingly evident that strategies like the one mentioned above
that make use of auxotrophic markers may cause difficulties in the interpretation of
mutant phenotypes (204). Recently, a transformation method that makes use of a
dominant selection marker has been developed (176). This method, originally developed
for use in C. albicans, relies on the use of a cassette that contains a dominant
nourseothricin resistance marker (SAT1) for the selection of integrative transformants and
the FLP recombinase gene under the control of an inducible promoter that allows the
subsequent excision of the cassette, which is flanked by FLP target sequences, from the
genome. When used in the diploid C. albicans, two rounds of integration/excision
generate homozygous mutants that differ from the wild-type parent strain only by the
absence of the target gene, and reintegration of an intact gene copy for complementation
of mutant phenotypes is performed in the same way. Transformants are obtained after
only one day of growth on a selective medium, and integration into the target locus
occurs with high specificity after adding homologous flanking sequences on both sides of
the cassette. FLP-mediated excision of the SAT1-flipper cassette is achieved by simply
growing the transformants for a few hours in medium without selective pressure, and
nourseothricin-sensitive derivatives can easily be identified by their slower growth on
indicator plates containing a low concentration of nourseothricin. Although optimized for
the alternative codon usage in C. albicans, this method has now been successfully used in
the haploid C. glabrata, and requires only one round of integration/excision (68). This
approach has allowed for the rapid and efficient generation of disruption mutants in C.
glabrata.
Pathogenicity and Virulence
Candida species are found as part of normal microflora of human mucosal
surfaces, although sometimes they can cause infection. They enter the host through the
urogenital tract, lungs and other mucosal surfaces and induce formation of purulent
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infiltrates (83). Candida species are known to cause vaginitis, oropharyngeal infections,
thrush, urogenital tract infections and have been isolated from the feces. Furthermore, the
increasing number of immunocompromised individuals has added to the problem of
increasing fungal infections, in particular, oral and systemic candidiasis (15, 24, 191,
211). Over the past three decades, there has been an increase in non-albicans species
causing infection, with C. glabrata being the second most common cause of mucosal and
invasive fungal infections in humans. Although C. glabrata is phylogenetically closer to
S. cerevisiae than other Candida species like C. albicans, the one distinct difference is
that C. glabrata can cause infection in humans. It is likely that the differences in the S.
cerevisiae and C. glabrata genome and the similarities between C. glabrata and C.
albicans characterize the pathogenicity of C. glabrata; however, the virulence factors of
C. glabrata are poorly understood. Therefore, the following discussion describes several
known virulence factors in C. albicans and whether there are orthologs in C. glabrata.
Secreted hydrolases play an important role in virulence of C. albicans. It is
thought that secreted hydrolases can contribute to host tissue invasion by digesting host
cell membranes or cells and molecules of the host immune system, or by degrading host
surface molecules to enhance adhesion. The most significant hydrolases produced by C.
albicans are secreted aspartic proteinases (SAPs) and phospholipases. Although the C.
glabrata genome encodes multiple orthologs of the S. cerevisiae extracellular
glycosylphosphatidylinositol (GPI)-linked aspartyl proteases, C. glabrata does not
produce significant levels of extracellular proteinase activity in vivo (94, 129).
Furthermore, C. albicans secretes phospholipase B which is implicated in the spread of
the organism from the gastrointestinal tract and in hematogenous dissemination (57, 74,
142). The C. glabrata genome encodes three phospholipase B genes and it has been
shown that they do generate phospholipase activity (94). To date, no published studies
have analyzed the role of C. glabrata phospholipases in virulence; however, one
unpublished study did find an association between phospholipase B activity and
persistent C. glabrata candidemia (74).
Another virulence factor that has been identified in C. albicans is its ability to
grow in different morphological forms (i.e. yeast, pseudohyphae, and hyphae). Although
both yeast and hyphal forms of C. albicans are pathogenic, the invasive properties of
hyphae are suggested by their ability to penetrate several cell layers deeper than yeast
forms in superficial candidiasis. For example, histological examination of lingual tissue
from a patient with candidiasis shows yeast and hyphae forms within vacuolated regions
of tissue whereas only hyphae are present in deeper layers (106, 205). This observation
suggests that hyphae are more invasive than the yeast form and are thought to increase
the level of damage to host tissue. Although C. glabrata has been shown to form
pseudohyphae in response to nitrogen starvation, this form has not been found in clinical
specimens. However, components of the mitogen-activated protein (MAP) kinase
signaling cascade that regulates pseudohyphal formation of S. cerevisiae have been
studied in C. glabrata. Ste12p is a transcriptional regulator in C. glabrata and is required
for nitrogen starvation pseudohyphal formation. Interestingly, ste12 C. glabrata mutants
demonstrate attenuated virulence in a mouse model (33). The significance of C. glabrata
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pseudohyphal growth on virulence is not known, and it is possible that C. glabrata has
developed different strategies than C. albicans to invade its host.
One of the ways C. albicans regulates its virulence-associated traits such as
secretion of proteinases and hyphal formation is by phenotypic switching, a process by
which the cell can switch between epigenetic metastable states (7, 88, 140, 223). In
general, phenotypic switching allows for rapid adaptation of the organism to different
stressful environments. In C. albicans, “white cells” are ovoid, budding yeast cells that
form white, domed colonies, and “opaque cells” are large, elongated cells that form gray
flat colonies; these cells have different infectious properties and different transcriptional
profiles (200). For example, phenotypic switching from the white to the opaque form
significantly increases mating (133) and allows the organism to survive in different host
tissues (108, 109). White cells are more suited for bloodstream infection while opaque
cells are better at colonizing skin surfaces in mice (111). Similar to C. albicans, C.
glabrata can undergo phenotypic switching exhibiting different colony colors on plates
that contain copper sulphate: white (Wh), light brown (LB), dark brown (DB) and very
dark brown (vDB) (28, 110, 112). A second switch phenotype, 'irregular wrinkle' (IWr),
has been identified, which exhibits a highly wrinkled colony morphology (110). In
patients infected with a single strain of C. glabrata, differences were seen in the
proportions of switch phenotypes at oral and vaginal locations. This suggests selection of
particular switch phenotypes due to differences in microenvironments (28).
Adherence of Candida species to host cells is an important initial step in the
establishment of infection. The fungal proteins involved in mediating these adhesive
interactions are termed “adhesins”. Unlike S. cerevisiae, C. glabrata encodes adhesins,
specifically a family of GPI-anchored cell wall proteins, the EPA (Epithelial adhesin)
family. The C. glabrata genome contains at least 23 EPA-related genes most of which are
encoded in subtelomeric clusters; however, only three, EPA1, EPA6 and EPA7 have been
shown to mediate adhesion to human epithelial cells in vitro (35, 40). Due to their
subtelomeric localization, EPA genes are subject to chromatin-based transcriptional
silencing. In S. cerevisiae, silencing of subtelomeric genes is dependent on a complex of
proteins encoded by SIR2, SIR3, and SIR4 (79, 172). C. glabrata orthologs of these
silencing factors have been identified and cells with silencing mutations in these genes
are hyperadherent to a variety of cultured epithelial cells due to derepression of three
EPA genes (EPA1, EPA6 and EPA7) (35, 58). Furthermore, hyperadherent ∆SIR3
mutants have been shown to colonize the kidney more efficiently that wild-type strains in
a murine model of disseminated candidiasis (35). EPA gene expression may play an
important role in the virulence of C. glabrata. Although C. glabrata and C. albicans are
different in respect to their interactions with the host (i.e. hyphal formation and secreted
hydrolases), the aforementioned similarities are a few potential reasons to why C.
glabrata is virulent and S. cerevisiae is not.
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Infections Caused by Candida Species
Since the early 1980s, the incidence and spectrum of fungal infections have
increased significantly partly due to the improved supportive care of critically-ill patients
(165). One study showed the annual incidence of fungal sepsis in the United States
increased by 207% between 1979 and 2000 (131). The expanding number of
immunocompromised individuals has added to the problem of increasing fungal
infections due to mucosal or cutaneous barrier disruption, defects in the number and
function of neutrophils or in cell-mediated immunity, metabolic dysfunction, and
extremes of age. Moreover, increasing use of broad-spectrum antibiotics, cytotoxic
chemotherapies, and transplantation increases the risk for both common and uncommon
opportunistic fungi (123, 137, 190). Several surveillance studies have reported Candida
species as the most important cause of mycoses worldwide followed by Aspergillus and
Cryptococcus species. Although C. albicans is still the most common cause of
candidiasis, over the last two decades there has been an increase in non-albicans species
causing infection with C. glabrata being the second most common cause of mucosal and
invasive fungal infections in humans in the United States. The remainder of this section
will discuss the clinical spectrum of superficial and systemic infections caused by C.
glabrata as it compares to C. albicans.
Candida infections other than those on the skin and mucous membranes are
referred to as invasive candidiasis, which include candidemia, acute or chronic
hematogenously disseminated candidiasis, and infection of a single deep organ, either by
hematogenous seeding or direct inoculation. A majority of these infections are a result of
bloodstream invasion and hematogenous spread. The frequency of candidemia among
hospitalized patients has doubled over the last three decades (165). There are 17 Candida
species known to cause bloodstream infections; however, 90% can be attributed to five
species: C. albicans, C. glabrata, Candida parapsilosis, Candida tropicalis, and Candida
krusei (165). Furthermore, the 2004 Surveillance and Control of Pathogens of
Epidemiological Importance study identified Candida species as the fourth most common
cause of nosocomial bloodstream infection and the third most common cause of
bloodstream infections in the intensive care unit (195). Not only has the incidence of
Candida infections increased, mortality rates from disseminated candidiasis have been
reported as high as 30-40% (162). Risk factors for invasive candidiasis include immune
suppression (neutropenia, immunosuppressive drugs including glucocorticoids, cancer
and cancer chemotherapy) and changes in the physical barriers that facilitate the
organism’s access to the bloodstream (prior gastrointestinal surgery or perforation,
hemodialysis, parenteral nutrition, indwelling catheters, treatment with broad-spectrum
antibiotics, and colonization with Candida species). C. albicans account for 45-60% of
incidences of invasive candidiasis or candidemia in the United States and worldwide (35,
159, 165). In North America, C. glabrata accounts for 20-22% of cases invasive
candidiasis (35, 159, 165). C. glabrata infections are difficult to treat due to intrinsic
resistance to the most widely used antifungal, fluconazole. In fact, C. glabrata
candidemia is associated with a 43% mortality rate in adults and 13% in children (159).
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Approximately 75% of all adult women have suffered from vulvovaginal
candidiasis (VVC) at least once in their lives, with 40-50% of women experiencing
recurrence (89). Candida species can be found as a commensal in the vagina in 10-25%
of all women (151). Predisposing factors for VVC include: African American, pregnancy,
contraceptives, diabetes mellitus, and use of antibiotics. Pregnant HIV-infected women
are at higher risk for VVC with a 40-60% prevalence of vaginitis and colonization (2040% in non-HIV pregnant women). C. albicans accounts for 85-95% of yeast strains
isolated from the vagina (113, 196, 197). Non-albicans Candida species are isolated in
approximately 10-20% cases of VVC, with C. glabrata being the most common (32, 41,
153). In small clinical studies, a variety of risk factors have emerged for C. glabrata
vaginitis which include uncontrolled diabetes mellitus and douching (73).
Urinary tract infections (UTI) due to Candida species has increased over the past
three decades (13). In fact, one study found that Candida species accounts for 22% of all
UTIs in the critical care setting (6). Risk factors for development of Candida UTI are
elderly, female (vaginal colonization), pregnancy, diabetes mellitus, urinary tract disease
producing obstruction (i.e. congenital abnormalities, neurogenic bladder), urinary tract
catherization, and antibiotic exposure (9, 97, 148, 155). Unlike OPC and vaginal
candidiasis, C. albicans only accounts for about 50% of Candida UTIs with 50% caused
by non-albicans Candida species. Interestingly, C. glabrata causes approximately 25% of
Candida UTIs (199); however, no C. glabrata specific risk factors have been reported.
Symptomatic mucosal candidiasis arises in humans who are colonized with
Candida and who are immunocompromised (i.e. Human Immunodeficiency Virus (HIV)/
Acquired Immune Deficiency Syndrome (AIDS), neonates, elderly) or have local
reduction in host resistance, thereby promoting the overgrowth of their own endogenous
yeast flora. The most common mucosal infections include oropharyngeal, esophageal,
and vaginal candidiasis. Oropharyngeal candidiasis, or thrush, is the general term given
to oral infection caused by Candida species. Candida species are part of the normal
mouth flora in 25-50% of healthy individuals (151). OPC is often the first manifestation
of HIV infection with approximately 80-90% of HIV/AIDS patients ultimately
developing OPC during their disease progression (54). Although there has been a
decrease in OPC in HIV-infected individuals since the availability of antiretroviral
therapy (ART), OPC still remains a significant infection in this population (208).
The most important predisposing factor for OPC other than HIV is the wearing of
removable dentures (192). The dentures provide a surface for Candida to adhere;
therefore, sufficient hygiene care is very important (31). Patients with hematological
malignancies and solid tumors are also affected by OPC due to the breakdown of natural
barriers to colonization and invasion after anticancer therapy. C. albicans is the main
organism isolated from OPC patients; however, other species, such as C. glabrata, have
often been implicated in patients not only with HIV/AIDS but also patients undergoing
bone marrow transplantation and patients receiving therapy for head and neck cancer (31,
174, 175, 177). It is thought that the intrinsic resistance of C. glabrata to fluconazole, the
most widely used antifungal for treatment and prophylaxis of OPC, allows for the
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selection of C. glabrata in OPC (177). The emergence of fluconazole resistant organisms
remains a significant clinical problem.
The second most common site of gastrointestinal candidiasis is the esophagus.
Esophageal candidiasis occurs in patients with chronic diseases, usually after the use of
antibiotics, steroids, or omeprazole; however, the disease most frequently is seen in
individuals affected with advanced HIV infection (38). In fact 10-15% of HIV/AIDS
patients will suffer from Candida esophagitis during their disease progression (62, 66,
138). Recently, there have been case reports linking Candida esophageal candidiasis to
the use of inhaled corticosteroids (143). Like with OPC, C. albicans is the main causative
organism of esophageal candidiasis (11). C. glabrata has also been implicated in
esophagitis but the occurrence is rare (101).
Treatment of Candida Infections
Although the number of antifungal agents has increased since 2000, treatment of
fungal infections is still limited to only 15 agents currently approved for clinical use.
There are many similarities between fungal cells and mammalian cells that make the
development of antifungals difficult. They are both eukaryotes with similar organelles,
DNA replication, and protein synthesis. Antifungal agents must exploit the differences
between host and fungal cells; however, there are a few biochemical differences between
the host and the fungal pathogen. At the cellular level, the greatest difference is that
fungal cells have cell walls and mammalian cells do not. Inhibitors of bacterial cell wall
biosynthesis, such as penicillins, have been used for years with little associated toxicities.
Only recently have a few potent inhibitors of fungal cell wall biosynthesis become
available for clinical use. Other antifungal targets include inhibitors of DNA
biosynthesis, disruption of mitotic spindles, and interference with intermediary
metabolism. The most widely exploited difference between mammalian and fungal cells
is that the cell membranes contain different sterols. Mammalian cells contain cholesterol
whereas the fungal cells contain ergosterol.
The polyenes are natural antifungal compounds discovered in the early 1950s.
The two commercially-available polyenes are Amphotericin B (AmB) and nystatin. The
polyenes bind to ergosterol in the membrane bilayer and disrupt cell wall permeability by
forming oligodendromes functioning as pores, with subsequent efflux of potassium and
intracellular molecules causing fungal death (20). Due to the toxicities of nystatin, it is
only used as a topical agent. AmB is not orally or intramuscularly absorbed; therefore, it
is given intravenously or sometimes through the inhalational route. AmB has a broad
antifungal spectrum including Candida species except Candida lusitaniae. Although
AmB is an effective antifungal drug, toxicities associated with its use have limited its
utility. The most common and most serious side effect of AmB is nephrotoxicity. Some
degree of reduction of renal function occurs in more than 80% of patients receiving the
drug, and though this generally recovers after treatment has stopped, some impairment of
glomerular filtration may remain (27). To allow for higher doses of AmB and to reduce
its toxic effects to mammalian cells, AmB has been formulated in liposomes, lipid
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complexes, and colloidal suspensions. Before the development of alternative agents such
as the azole and echinocandin antifungals, AmB was the drug of choice for invasive
Candidal infections. However, the most recent candidiasis guidelines recommend the
newer and less toxic classes of antifungals for first-line use of many conditions caused by
Candida species with the exception of neonatal candidiasis (158).
Flucytosine (5FC) is a prodrug that is deaminated by 5-fluorouracil by fungal
cytosine deaminases. 5-fluorouracil is further converted to 5-fluorodeoxyuridylic acid,
which interferes with DNA synthesis in the fungus. Mammalian cells lack cytosine
deaminase allowing for selective inhibition of fungal organisms. This drug is only
available orally and has a short half-life so it must be administered frequently. 5FC has
activity against most Candida species, except C. krusei. Because of the rapid
development of resistance, 5FC is rarely used in monotherapy but used in combination
with AmB for the treatment of Candida endocarditis or meningitis (158).
The echinocandins, caspofungin, micafungin, and anidulafungin, are the only
class of fungal cell wall inhibitors. They exert their mechanism of action by noncompetitively inhibiting 1, 3-β-D glucan synthase, an enzyme that is necessary for the
synthesis of 1, 3-β-D glucan, an essential component of the fungal cell wall. The
inhibition of this enzyme destabilizes the integrity of the fungal cell wall, leaving it less
rigid and unable to resist osmotic pressure resulting in cell lysis (18); therefore, this class
of antifungals is fungicidal against most Candida species. All of the echinocandins are
available in parenteral preparations only and have very few side effects. Echinocandins
have activity against most Candida species but have less activity against some isolates of
Candida parapsilosis and Candida guilliermondii (163). Each of these drugs has been
studied in esophageal candidiasis (48, 105, 218, 219) and invasive candidiasis (107, 139,
160, 173) and each has been shown to be effective in these clinical situations. The new
updated Candidiasis guidelines recommend use of this class for refractory esophageal
disease and as an alternative for OPC or when azole-resistant pathogens are suspected or
when azole antifungals are not tolerated (158). Echinocandins are also recommended as
an alternative to fluconazole for primary therapy for most non-neutropenic adults with
candidemia or suspected invasive candidiasis. Echinocandins are favored therapy for
patients with moderate-to-severe illness, recent azole antifungal exposure, candidemia
caused by C. glabrata or C. krusei. However, fluconazole is preferred over an
echinocandin for C. parapsilosis infections. For the treatment of candidemia in a
neutropenic patient, echinocandins are the drug of choice (158).
The second class of antifungals that exert their efforts on the fungal cell
membrane are the azole antifungals. Azole antifungals work by inhibiting lanosterol
demethylase in the ergosterol biosynthesis pathway which prevents the conversion of
lanosterol to ergosterol. This mechanism results in the accumulation of toxic
methylsterols and results in inhibition of cell growth and replication. The azole
antifungals include two classes, imidazoles and triazoles. Imidazoles have a two-nitrogen
azole ring; they are predominantly used topically and have been replaced for systemic
administration by triazoles, which have three nitrogens in the azole ring. Triazoles have a
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more favorable pharmacokinetic profile than imidazoles and do not significantly inhibit
human sterol synthesis.
The triazole antifungals include fluconazole, itraconazole, voriconazole and
posaconazole. Fluconazole is water soluble and has good bioavailability regardless of
food or gastric pH (26); therefore, it is available orally and intravenously. In contrast,
itraconazole and voriconazole are poorly water soluble. Itraconazole capsule is best
absorbed with food and the oral solution is better absorbed in the fasting state (17) while
voriconazole as a tablet or solution is better absorbed without food. Both itraconazole and
voriconazole are available intravenously; however, both are formulated with cyclodextrin
derivatives and the intravenous form of both of them is contraindicated in patients with
severe renal dysfunction. Posaconazole, available only as a suspension for oral use, has
variable bioavailability and must be taken with high fat foods (42). Triazoles as a class
have numerous clinically significant drug interactions. With exception of posaconazole,
most of the interactions are due to inhibition of the CYP450 system enzymes specifically,
CYP3A4, CYP2C9, and CYP2C19. Interestingly, itraconazole and posaconazole inhibit
gastric P-glycoprotein (222). As a class, the triazoles are generally well-tolerated. Of
note, itraconazole can often cause significant nausea and vomiting and voriconazole
treatment can cause visual changes.
All the triazoles demonstrate similar activity against most Candida species, with
less activity against C. glabrata and C. krusei (64, 166). Fluconazole is considered the
standard therapy for OPC, esophageal candidiasis and VVC (76, 198). Fluconazole has
the greatest penetration into the cerebrospinal fluid and vitreous body; therefore, it is used
in the treatment of central nervous system and intraocular Candida infections (10).
Fluconazole concentrates in the urine achieving 10-20 times higher levels than in serum
making it an optimal drug for treatment of Candida UTIs (158). As few data has
examined the use of itraconazole in the treatment of invasive candidiasis, it is generally
reserved for patients with mucosal candidiasis who have failed fluconazole treatment (5).
Voriconazole is effective for both mucosal and invasive candidiasis. For treatment of
Candida infections, its major role has been used for step-down oral therapy for patients
with susceptible C. krusei and C. glabrata infections (158). The use of voriconazole
versus fluconazole for treatment of esophageal candidiasis has been evaluated (5).
Voriconazole was found to be as effective as fluconazole but was associated with more
adverse event-related discontinuation of treatment. Posaconazole does not have an
indication for primary candidiasis therapy (158).
AZOLE RESISTANCE AND TOLERANCE
Clinical Impact of Azole Resistance
Resistance to antifungals relies on two components: clinical resistance and
microbial resistance. Clinical resistance is the failure of treatment or persistence of fungal
infection despite appropriate antifungal drug therapy. Successful treatment not only
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depends on the susceptibility of the organism to the antifungal, but also on the host
immune system, drug penetration and distribution, and the absence of a protected or
persistent focus infection. Microbial resistance is a quantifiable variable and is defined by
the minimum inhibitory concentration (MIC), the lowest concentration of antimicrobial
agent which inhibits the growth of the microorganism. Ideally, microbial resistance will
be predictive of clinical resistance. In other words, above a given MIC for a fungal
pathogen or a “breakpoint”, the infection will not be cured with that antifungal. There are
three terms used to describe the susceptibility of any organism to a particular drug;
“susceptible”, “intermediate” (“susceptible-dose dependent” or SDD) or “resistant”. The
Clinical and Laboratory Standards Institute (CLSI) Subcommittee for Antifungal Testing
has developed and standardized broth microdilution, broth macrodilution and disk
diffusion methods for in vitro susceptibility testing of Candida species against
fluconazole (145, 146). Breakpoints for Candida species were determined in 1997 by the
CLSI Subcommittee for Antifungal Testing which are as follows: susceptible, MIC ≤ 8
μg/ml; SDD, MIC = 16 to 32 μg/ml; resistant, MIC ≥ 64 μg/ml. However, there were
concerns over the clinical relevance of these breakpoints in more invasive and microbial
resistant organisms as they were derived mostly (80%) from studies of mucosal
candidiasis and there was little clinical data for which the MICs were elevated (178).
Recently, further evaluation of these breakpoints for fluconazole and Candida have been
conducted including expanded MIC data and clinical efficacy studies (166). These data
more strongly validate the CLSI MIC interpretive breakpoints for fluconazole and
Candida species.
When discussing resistance in Candida species, one must also differentiate
between primary or “intrinsic resistance” and secondary or “development of resistance”.
Intrinsic resistance is the natural or innate resistance of a species to antimicrobial therapy
even though the organism has had no previous exposure to the agent. In contrast,
development of resistance develops in previously susceptible organisms after exposure to
an antimicrobial agent. For example, this occurs in patients infected with HIV who
receive multiple courses of fluconazole for recurrent OPC. It is thought that exposure to
fluconazole inhibits the growth of susceptible populations and the less susceptible
populations are allowed to grow (117). Moreover, this situation also selects for less
susceptible species, such as C. glabrata, to grow. In fact, over the past two decades there
has been an increase in fluconazole-resistant non-albicans species causing infection, with
C. glabrata being the second most common cause of mucosal and invasive fungal
infections in humans (39). The molecular basis for the intrinsic resistance of C. glabrata
to azole antifungals remains undefined; however, the molecular basis for the development
of resistance has been studied (21, 185, 215).
Clinical Impact of Azole Tolerance
Candida species inhabit a range of environments in humans and these
environments can change as the organism colonizes and spreads within a host. Candida
species have evolved responses to protect it from environmental changes that cause
physiological stress to the cell. The administration of antifungal drugs also represents a
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stress to which the cell must respond (43). The nature of these responses to antifungal
drugs depends on the organism, the dose, its duration, and the mechanism of action of the
drug. For fungicidal drugs at appropriate doses above the MIC, stress responses fail to
prevent cell death. However, for fungistatic drugs, such as the azoles, even above the
MIC, growth is inhibited but the cells are not killed. This phenomenon is referred to as
drug tolerance (186). As azole resistance mechanisms are usually due to genetic
mutations leading to constitutive gene over-expression, tolerance is mediated by
immediate reversible stress responses. These stress responses are important because they
give cells time to develop long-term genetically stable resistant mechanisms. Thus, the
development of a drug that can be used in co-therapy with fluconazole and abolish
tolerance could prevent the development of azole resistance.
Molecular Mechanisms of Azole Tolerance
Fluconazole is fungistatic against Candida species, thus C. glabrata exhibits
tolerance to azoles. It has recently been shown that the calcineurin inhibitors cyclosporine
A and FK506 exhibit potent fungicidal synergism with azoles against C. albicans, C.
glabrata, and C. krusei (44, 121, 126, 127, 154). Calcineurin is a serine/threoninespecific protein phosphatase that functions as a heterodimer composed of a catalytic
subunit and a regulatory subunit B. In the presence of calcium, the phosphatase activity
of calcineurin is activated when it binds calmodulin and it effects gene expression via
transcriptional regulators such as Crz1p. It is possible that exposure to azoles causes an
intracellular calcium spike that induces this pathway (186). In C. glabrata, disruption of
CgCRZ1 did not affect the antifungal activity of fluconazole; however, disruption of the
gene encoding the calcineurin regulatory subunit B resulted in fungicidal activity of
fluconazole (136). Thus, the precise mechanism calcineurin-dependent azole tolerance in
C. glabrata remains to be elucidated.
Molecular Mechanisms of Azole Resistance in C. glabrata
Development of high-level resistance to the azoles in C. glabrata has been
reported in oral and bloodstream isolates from head and neck radiation patients, stem cell
transplant patients, and HIV patients (21, 74, 185). Also, the development of azole
resistance has been implicated in the fluconazole treatment failure and death of a patient
suffering from C. glabrata candidemia (122). In Candida species, four primary
mechanisms of azole resistance have been identified: (i) drug efflux mechanisms, (ii)
changes in the gene expression of the target of fluconazole, lanosterol demethylase, (iii)
amino acid changes in lanosterol demethylase that alter the binding of fluconazole, (iv)
alterations in the sterol biosynthesis pathway that may bypass the accumulation of toxic
sterols. In C. glabrata, the expression of drug efflux pumps and upregulation of the gene
that encodes lanosterol demethylase, are the only two known mechanism of fluconazole
resistance.
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Azole resistance in fungi has been linked to the upregulation of membraneassociated protein pumps and, consequently, efflux of a wide range of molecules,
including azoles. These transporter proteins consist of members of the ATP-binding
cassette (ABC) or major facilitator superfamily (MFS) of transporters. ABC transporters
are found in all cells of all organisms usually in the plasma membrane but also in the
membranes of organelles. They are primary transporters that use the hydrolysis of ATP.
The basic structure of the ABC transporters consist of two cytoplasmic nucleotide
binding domains (NBDs), involved in ATP binding and hydrolysis and two
transmembrane domains (TMDs) that span the membrane via putative α-helices. The
arrangement of these domains depends on the type of ABC transporter (71, 86). In S.
cerevisiae, these ABC transporters have been divided into subfamilies: pleiotropic drug
resistance (PDR), multidrug resistance (MDR), and multidrug resistance-associated
protein (MRP). The PDR ABC transporters usually contain the domain arrangement,
from the N- terminus, (TMD-NBD)2, and the MDR and MRP ABC transporters usually
have the arrangement, (NBD-TMD)2 (49). The subfamily of ABC transporters most often
associated with antifungal drug resistance is the PDR subfamily. MFS transporters also
comprise large superfamilies of proteins with high similarity to proteins found in plants,
animals, bacteria, and fungi. These pumps are secondary transporters that utilize the
proton-motive force across the plasma membrane. There are two subfamilies of MFS
transporters involved in drug efflux. These subfamilies are defined by the number of
transmembrane spans (TMS) within the TMD: DHA1 (12 TMS) and DHA2 (14 TMS).
C. glabrata contains 18 putative ABC transporters (six in the PDR subfamily) and
15 putative MFS transporters (10 in the DHA1 subfamily and five in the DHA2
subfamily) as predicted by comparison of the C. glabrata and S. cerevisiae genomes (72).
Only four of these transporters have been implicated in fluconazole resistance in C.
glabrata; the ABC transporters CgCdr1p, CgPdh1p, CgSnq2p, and CgAus1p. RNA
analyses of fluconazole-resistant C. glabrata clinical isolates suggest that the
predominant basis for azole resistance is the upregulation of CgCDR1 and to a lesser
extent CgPDH1 (21, 135, 184, 185, 187, 216, 221). Deletion of CgCDR1 or CgCDR1CgPDH1 renders fluconazole-resistant C. glabrata isolates susceptible to fluconazole
(90, 185). Interestingly, one study found a fluconazole-resistant isolate that did not overexpress CgCDR1 or CgPDH1, but upregulated another ABC transporter, CgSNQ2 (210).
Disruption of CgSNQ2 decreased azole resistance. The expression of these transporters is
controlled by CgPDR1 which will be discussed in detail in a later section.
Although not an efflux pump, CgAUS1 is a homolog of a S. cerevisiae gene that
encodes an ABC transporter involved in uptake of sterols and anaerobic growth.
Nakayama et al. investigated the effects of CgAUS1 under the control of a tetracyclineregulatable promoter. In the presence of bovine serum, they found that cells were more
susceptible to fluconazole in the CgAUS1 “knockdown” strain suggesting that sterol
transport can counteract ergosterol deficiency and azole toxicity.
CgERG11 is the gene encoding the target of the azole antifungal agents,
lanosterol demethylase. Two studies have shown an increase in CgERG11 expression in
azole-resistant C. glabrata isolates (130, 174). In one of these studies this upregulation

12

was due to duplication of the entire chromosome containing the ERG11 gene; however,
loss of the duplicated chromosome was seen when the isolate was grown in fluconazolefree medium (130). Increased expression of CgERG11 may also be due to point
mutations in the CgERG11 gene itself or in upregulation of a transcriptional regulator
that controls CgERG11. While several point mutations in ERG11 have been linked to
azole resistance in C. albicans, such mutations in C. glabrata have not been identified. A
recent study examined a collection of azole resistant C. glabrata isolates and found no
point mutations in CgERG11 that were associated with the azole-resistant phenotype
(187). Recently, our laboratory found a single-nucleotide substitution in one UPC2 allele
in C. albicans that resulted in an amino acid exchange in the encoded protein.
Complementation of the mutated allele into a fluconazole susceptible strain resulted in
upregulation of ERG11 (61). The molecular basis for constitutive upregulation of
CgERG11 has not been elucidated in C. glabrata.
TRANSCRIPTIONAL REGULATORS OF AZOLE RESISTANCE
Gene Expression
The over-expression of aforementioned ABC transporters, CgCDR1, CgPDH1,
and CgSNQ2 could be due to several mechanisms: gene amplification, increased half-life
of mRNA, or increased transcription. Gene amplification occurs when there is
chromosomal duplication. Recently, Polakova et al. found that while gene sequences
were well-conserved among different strains of C. glabrata, their chromosome structures
differed drastically (171). Aneuploidy by gain of small chromosomes and segmental
aneuploidy were the most prevalent events on the left arm of chromosome F.
Chromosome F encodes the ABC transporters, CgAUS1 as well as CgPDH1. The isolate
carrying the minichromosome could tolerate 129.6 mg/L of fluconazole; however, the
isolate which had lost the minichromosome could only tolerate 14.4 mg/L of fluconazole
suggesting a role for aneuploidy in tolerance to azoles. However, when this isolate was
grown in the absence of azoles, the loss of minichromosome was observed in 70% of the
progeny. Although this study raises the possibility of aneuploidy contributing to the overexpression of these ABC transporters in the presence of azoles, it does not explain the
constitutive over-expression of these genes in fluconazole-resistant isolates.
Another possibility of increased expression of these transporters could be the
possibility of posttranscriptional control. Large amounts of the ABC transporter proteins
could correlate with increased stability of its mRNA and protein. One study has
demonstrated that the over-expression of CgCDR1 in fluconazole-resistant C. albicans
isolates is in part due to decreased mRNA turnover (125). However, transcriptional
regulation is considered to be the key step accounting for basal and induced patterns of
ABC transporter expression. There are two prominent families of transcriptional
regulators in yeast that regulate PDR: zinc-cluster proteins and basic region-leucine
zipper proteins. Since only the zinc-cluster proteins have been found to regulate
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fluconazole PDR in C. glabrata, the remainder of this review will focus on this class of
transcriptional regulators.
Zinc-Cluster Transcription Factors
Zinc-binding proteins represent one of the largest families of transcriptional
regulators in eukaryotes. They all contain a zinc finger motif in which they are
categorized into various families according to these motifs. One family, the zinc-cluster
or binuclear cluster protein family, are found only in fungus and possess a well-conserved
motif, CysX2CysX6CysX5-12CysX2CysX6-8Cys (120). These cysteine residues bind to two
zinc atoms and coordinate folding of the domain involved in DNA binding. At least 12 of
these zinc-cluster proteins have been implicated multidrug resistance in S. cerevisiae
(120).
Zinc-cluster proteins contain a DNA-binding domain (DBD), a regulatory
domain, and an acidic domain. The cysteine-rich DBD is separated into three regions: the
zinc finger, linker, and dimerization regions and is usually located at the N- terminus.
There are six cysteine residues that are important for DNA binding and protein function
(14, 51). The linker region, located C-terminally to the zinc-cluster motif, has no
similarities to linker regions of other zinc-cluster proteins, and changes in this region alter
the DNA-binding specificity (123). Therefore, it is proposed that this region provides a
rigid scaffold that mediates DNA binding to a preferred sequence (123). The dimerization
region is typically positioned C-terminally to the linker. Most zinc proteins contain this
region and it is made up of heptad repeats that form a highly conserved coiled-coiled
structure that is most likely for dimerization and protein-protein interaction (189).
The regulatory domain displays lesser homology among most members of the
zinc-cluster protein class which is why it also termed the middle homology region
(MHR). This domain is thought to play an inhibitory role since removal of this domain
renders the zinc-cluster proteins constitutively active (169). Finally, the acidic domain
acts as an activation domain (189). This domain is not well-defined as its function and
structure within this superfamily is varied. Interestingly, gain-of-function mutations for
Pdr1p and Pdr3p, transcriptional regulators involved in PDR, have been identified which
make these transcriptional regulators constitutively activated.
Zinc-cluster proteins recognize elements containing trinucleotide sequences
usually CGG triplets that can be everted, inverted, or direct repeats (120). The orientation
of the trinucleotide sequences and the spacing between the triplets are very important
determinants of DNA-binding specificity. There are several DNA-binding motifs (also
termed “response elements”) that have been identified in S. cerevisiae zinc-cluster
transcription factors (120).
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Zinc-Cluster Transcription Factors and Azole Resistance
S. cerevisiae. Due to the phylogenetically close relationship, S. cerevisiae
represents a well-characterized model for studying C. glabrata. S. cerevisiae is also one
the most intensively studied eukaryotic model organisms in molecular and cell biology.
The availability of the S. cerevisiae genome sequence and the complete set of deletion
mutants have further enhanced the power of S. cerevisiae as a model for understanding
the regulation of eukaryotic cells. Fluconazole resistance in S. cerevisiae is usually due to
gain-of-function mutations within some of the zinc-cluster transcriptional regulators. Two
of these, Pdr1p and Pdr3p, have been named the master regulators of drug resistance in S.
cerevisiae. Together these proteins are responsible for the regulation of multiple genes in
the PDR network, including the ABC transporters, PDR5, SNQ2, and YOR1. In fact, each
of these genes contains at least one PDRE, pleiotropic drug response element, in its
promoter region. Pdr1p and Pdr3p act by binding to PDREs in the promoters of target
genes (95) . The PDRE contains the consensus sequence TCCGCGGA, which displays
CGG triplets in an everted repeat orientation. The PDR3 gene promoter also contains two
PDREs allowing for autoregulation as well as regulation by Pdr1p (95). Several studies
have shown that single point mutations in the regulatory domain and in the activation
domain of both ScPdr1p and ScPdr3p make these transcription factors hyperactive (34,
46, 65).
Although our understanding of the molecular basis of regulation of ScPdr1p and
ScPdr3p is incomplete, there have been several interesting observations regarding their
regulation. Cells that have lost their mitochondrial genome (known as petite mutants and
designated “ρ0”) strongly induce levels of ScPDR5 in a ScPdr3p-dependent manner (81).
Also, zinc-cluster transcription factors, including Pdr3p, have been found to be negatively
regulated by the Hsp70 protein Ssa1p (193). Most recently, downstream effectors of these
transcription factors have been identified. Thakur et al. showed that regulation of
ScPdr1p is similar to regulation of multidrug resistance (MDR) in vertebrates by the PXR
nuclear receptor where ScPdr1p directly binds to fluconazole resulting in stimulation of
drug efflux pumps. They also found a specific role of the Gal11p/MED15 subunit of the
mediator co-activator and its activator-targeted KIX domain in antifungal-dependent
regulation of MDR (207).
Yrr1p is a zinc-cluster transcriptional regulator found to also induce the
expression of PDR genes in S. cerevisiae (228). Many Pdr1p, Pdr3p, and Yrr1p targets
overlap suggesting cross-talk between regulators. YRR1, like PDR3, is also self regulated
and contains a putative Yrr1p response element (YRRE) as well as a PDRE in its
promoter (228). In addition, Yrr1p is regulated by zinc-cluster protein Yrm1p (228).
Furthermore, Yrr1p has been shown to have point mutations in the regulatory domain
which cause it to act as a hyperactive transcriptional regulator (228).
Other zinc-cluster proteins known to regulate drug resistance in S. cerevisiae
include Pdr8p, Stb5p, Rds1p, Rds2p, and Rds3p and Rdr1p (120). Pdr8p is known to bind
the promoters of PDR genes such as the ABC transporters YOR1, PDR15, and AZR1
(MFS transporter) and disruption of this gene in S. cerevisiae increases ketoconazole
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susceptibility (87). Disruption of STB5 leads to reduced expression of the ABC
transporters SNQ5, PDR16, and PDR5 and increased susceptibility to cycloheximide but
not ketoconazole. Furthermore, this same study showed evidence that Stb5p binds to the
SNQ2 promoter in vivo (114). Disruption of RDS1 and RDS3 (Regulators of Drug
Sensitivity) are involved in conferring resistance to cycloheximide while disruption of
RDS2 confers resistance to ketoconazole. Lastly, a negative regulator of PDR genes has
been identified named RDR1 for repressor of drug resistance (85). Disruption of RDR1
significantly increased the expression of five genes which encode membrane or
membrane-associated proteins and increased resistance to cycloheximide. Rdr1p appears
to bind to the same PDREs as Pdr1p and Pdr3p and the authors of this study postulate the
formation of heterodimers between Rdr1p and Pdr1p or Pdr3p that would impair the
activation of target genes. However, whether Rdr1p represses the gene expression of its
target genes by directly binding the PDRE has not been determined (85).
S. cerevisiae can also overcome the effects of fluconazole by up-regulating genes
in the ergosterol biosynthesis pathway. Several zinc- cluster transcriptional regulators are
involved in this process. The ERG genes of the ergosterol biosynthesis pathway are
regulated by two highly homologous zinc-cluster proteins, Upc2p and Ecm22p. They
regulate transcription by binding to sterol response elements (SREs) in the promoters of
their targets (217). Eleven of the ERG genes encoding enzymes in the ergosterol
biosynthesis pathway contain putative sterol response elements in their promoters. Upc2p
also plays a role in the uptake of exogenous sterols through the activation of the ABC
transporters, AUS1 and PDR11. Furthermore, it also has role in the upregulation of
DAN/TIR genes. A gain-of-function mutation has been identified in Upc2p that was
responsible for the upregulation of AUS1 and PDR11, DAN/TIR genes, as well as Upc2p
itself in S. cerevisiae. Hap1p is another zinc-cluster transcriptional regulator known to
regulate ERG11 which encodes the target of the azoles (213). HAP1 is also overexpressed
in the presence of the Upc2p gain-of-function mutation, and it is postulated that a
regulatory interaction may exist between Hap1p and Upc2p (224). Interestingly, Stb5p
has also been identified as a regulator of ergosterol biosynthesis as it is a direct activator
of ERG genes in the presence of oxidative stress (114).
C. glabrata. Multiple studies have linked the development of high-level azole
resistance to the over-expression of ABC transporter genes in C. glabrata, such as
CgCDR1, CgPDH1, and CgSNQ2 (21, 68, 210, 212, 215). These are homologs to the
ScPDR5, ScPDR15, and ScSNQ2, respectively. These mechanisms are closely related to
the resistance mechanisms described above for S. cerevisiae. A significant difference
between S. cerevisiae and C. glabrata is that CgPdr1p represents a single best homolog
of the ScPdr1p and ScPdr3p transcription factor heterodimer found in S. cerevisiae (216).
Like with S. cerevisiae, single point mutations in the regulatory domain of CgPDR1
make this transcription factor hyperactive resulting in high-level transcription of
CgCDR1 and CgPDH1 as well as increased resistance to azoles (68, 210, 212, 215). The
majority of this dissertation (Chapters 2 and 3) discusses the role of these gain-offunction mutations in azole resistance in C. glabrata.
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As with S. cerevisiae, the over-expression of ABC transporters in C. glabrata
petite mutants has been documented (184). CgPDR1 has been shown to be required for
azole resistance due to mitochondrial deficiency (212). Moreover, it has also been shown
that the regulation of CgPDR1 is analogous to the regulation of ScPDR1 where CgPDR1
also directly binds to fluconazole resulting in stimulation of drug efflux pumps. The study
also found a specific role of the Gal11p/MED15 subunit of the mediator co-activator and
its activator-targeted KIX domain in antifungal-dependent regulation of MDR in C.
glabrata (207).
CENTRAL HYPOTHESIS AND RESEARCH OBJECTIVES
C. glabrata has emerged as the second major cause of mucosal and invasive
fungal infection in the United States. The azole class of antifungal agents has proven
effective management of Candida infections. Recent reports have described the
acquisition of azole resistance in C. glabrata clinical isolates from hematopoietic stem
cell transplant patients, AIDS patients, and patients receiving radiation for head and neck
cancer. Not only does C. glabrata have the ability to develop high-level resistance, this
fungal pathogen also displays an intrinsic reduced susceptibility to azole antifungal
agents which makes this a significant problem in the management of candidiasis.
Furthermore, fluconazole is fungistatic against Candida species. The fungistatic nature of
the azoles allows the organism to survive in the presence of drug, a phenomenon known
as drug tolerance. Yeasts have developed ways to adapt to its environment. Such
adaptations are often regulated at the transcriptional level. For example, in S. cerevisiae,
multidrug resistance is mostly due to gain-of-function mutations of the transcriptional
regulators, Pdr1p and Pdr3p. It is likely that multiple transcriptional activation networks
are involved in both azole resistance and azole tolerance in C. glabrata. Therefore, my
central hypotheses are as follows: 1) Gain-of-function mutations in activators of
transcriptional activation networks represent the primary mechanism for the development
of high-level resistance in C. glabrata and 2) Key transcriptional activation networks are
activated in C. glabrata in the presence of azole antifungal agents which allow this
organism to survive at higher azole concentrations as compared to other Candida species.
It is hoped that identification of transcriptional activation networks found to influence
azole susceptibility will serve as targets for future work towards the development of
compounds that will both abrogate resistance and enhance the therapeutic utility of this
class of antifungal agent.
It has been previously reported that azole-resistant C. glabrata mutants (MIC ≥ 64
μg/ml) of strain 66032 (MIC = 16 μg/ml) similarly show coordinate CgCDR1-CgPDH1
upregulation, and in one of these (F15) a putative gain-of-function mutation was
identified in the single homolog of S. cerevisiae transcriptional regulators, Pdr1p-Pdr3p
(216). In the first chapter, we hypothesized that CgPdr1p plays a central role in
development of azole resistance as well as intrinsic resistance to fluconazole. Our
research aims were several-fold. First, we characterized the effect of PDR1 disruption as
well as gene replacement on fluconazole susceptibility and the expression of the ABC
transporters CgCDR1 and CgPDH1 in the fluconazole susceptible isolate 66032 as well
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as the resistant isolate F15. To more directly assess the role of acquired or intrinsic
resistance of the ABC transporter CgCDR1, we also characterized the effect of CgCDR1
disruption in these same isolates. Next, we used genome-wide expression studies in C.
glabrata to identify other putative Pdr1p targets that are co-regulated with CgCDR1. This
work was the first to identify CgPdr1p as a key regulator of the ABC transporter genes
CgCDR1 and CgPDH1 and azole resistance.
Since the publication of the above study, many novel gain-of-function mutations
in C. glabrata clinical isolates have been reported (68, 210, 212). These mutations cause
upregulation of the ABC transporters, CgCDR1, CgPDH1, and CgSNQ2, but to varying
degrees. For example, one mutation resulted in upregulation of CgSNQ2 but not CgCDR1
and CgPDH1. In Chapter 3, I hypothesized that the not only do these gain-of-function
mutations in CgPDR1 result in different levels of azole resistance, but also different
target gene expression. To determine genes co-regulated with CgCDR1, I examined the
genome-wide gene expression profiles in four matched azole-susceptible and –resistant
clinical isolate sets of C. glabrata in which CgCDR1 gene expression was upregulated in
the resistant isolate. Next, we identified two gain-of-function mutations in two of the
fluconazole resistant isolates and identified putative target genes specific to each
mutation. We found that the different mutations do result in different levels of azole
resistance and different target gene expression.
Understanding the initial stress response of C. glabrata to fluconazole may
facilitate a better understanding of how this organism copes with such stresses to its
environment. In Chapter 4, I hypothesized that C. glabrata responds to fluconazole
treatment by upregulating transcriptional regulators that allow for this organism to
survive in the presence of fluconazole. I examined the stress response of C. glabrata to
exposure to fluconazole. Among the upregulated genes were the transcriptional regulators
CgPDR1, RLM1, CRZ1, UPC2, CgAP1, and CIN5 and putative target genes for each of
these regulators. Because the transcriptional regulator CgPdr1p is upregulated in response
to fluconazole and has previously been shown to be involved in fluconazole intrinsic
resistance, we studied the role of CgPDR1 in the initial response to fluconazole. Using a
C. glabrata strain disrupted for CgPDR1, we identified putative CgPdr1p targets that
respond to fluconazole in a CgPdr1p-dependent and –independent manner. Together this
work suggests other transcriptional pathways associated with azole intrinsic resistance
and azole tolerance.
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CHAPTER 2. PDR1 REGULATES MULTIDRUG RESISTANCE IN CANDIDA
GLABRATA: GENE DISRUPTION AND GENOME-WIDE EXPRESSION
STUDIES
INTRODUCTION
Increasing numbers of individuals are immunocompromised in association with
AIDS, organ and tissue transplantation, aggressive treatments for cancer and immunerelated diseases, diabetes, premature birth and advanced age. These individuals are at
high risk for opportunistic fungal infection, in particular mucosal or systemic candidiasis.
In the previous decade, Candida glabrata emerged as a common cause of these infections
(10–30% of yeast isolates), trailing only Candida albicans (156, 168, 179, 183). In some
populations such as diabetics and the elderly, C. glabrata may be the dominant pathogen
(55, 77, 78, 104). In C. glabrata candidemia, mortality rates of 38–53% have been
reported (102, 182, 220). Nevertheless, the basis for C. glabrata pathogenicity is not yet
clear, because it is deficient in the virulence factors implicated in C. albicans infection:
dimorphism, strong adhesion, secreted hydrolases and biofilm formation (59, 99, 150,
188). On the other hand, C. glabrata demonstrates relative resistance to azoles, the most
widely used antifungal group which includes topical imidazoles such as miconazole and
oral/parenteral triazoles such as fluconazole. Specifically, the fluconazole MIC inhibiting
50% of clinical isolates is 8 μg/ml, compared with 0.25 μg/ml for C. albicans (156, 167).
Azoles inhibit lanosterol demethylase, product of the ERG11 gene (CYP51 in moulds),
which results in depletion of the membrane component ergosterol and accumulation of
toxic sterol products (3). The emergence of C. glabrata (from ≤ 5% of yeast isolates in
the 1980s) parallels the introduction in the early 1990s of fluconazole and over-thecounter imidazoles, along with widespread application of agricultural azole fungicides.
Indeed, its intrinsic low-level azole resistance, the molecular basis for which remains
undefined, may represent a C. glabrata 'virulence factor'.
C. glabrata also demonstrates a high capacity for acquired high-level azole
resistance, with 8–27% of isolates demonstrating a fluconazole MIC ≥ 64 μg/ml (156,
164, 182). RNA analysis of these clinical isolates suggests that the predominant basis for
acquired azole resistance is the constitutively upregulated expression of multidrug
transporter genes CgCDR1 and, to a lesser extent, CgPDH1 (135, 175, 184, 185, 187,
216). In support of this, CgCDR1 or CgCDR1-CgPDH1 disruption was shown to confer
azole hypersensitivity (90, 184). In this respect, C. glabrata resembles C. albicans and
other fungi in which azole resistance has been attributed to upregulated expression of
multidrug transporters (3). Initial laboratory studies of C. glabrata acquired azole
resistance using standard glucose-supplemented medium yielded a virulent respiratorydeficient mitochondrial mutants (30, 184). Using glycerol-supplemented medium, we
isolated respiratory-competent mutants with coordinately upregulated CgCDR1-CgPDH1
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analogous to that observed in azole-resistant clinical isolates (216). Coordinate
upregulation of these genes was also observed following brief exposure of susceptible
cells to azoles, representing a potential basis for intrinsic low-level resistance.
Coordinate CgCDR1-CgPDH1 upregulation implies a common transcription
factor. Although very distinct in terms of niche and human pathogenicity, C. glabrata is
an evolutionary close relative of Saccharomyces cerevisiae (16, 60). In the latter, the
coordinate upregulation of multidrug transporter genes PDR5 and SNQ2 is mediated by
the paralogous Pdr1p and Pdr3p zinc-cluster transcription factors (103). Many gain-offunction mutations within Pdr1p–Pdr3p have been identified that result in constitutive
upregulation of PDR5-SNQ2 along with a diverse group of additional genes (34, 52, 53).
Our analysis of the recently released C. glabrata genome sequence (60) revealed a single
PDR1–PDR3 homolog, and a putative gain-of-function mutation in this gene was
identified in azole-resistant laboratory mutant F15 (216). Here we demonstrate the central
role of C. glabrata PDR1 in acquired azole resistance, and identify a likely role in
intrinsic resistance, by characterizing Δpdr1 derivatives of laboratory strains and clinical
isolates. Furthermore, we report the first application of microarrays to this organism,
which identified multiple genes co-regulated with CgCDR1-CgPDH1 that are likely to
impact C. glabrata virulence. This work was done in collaboration with Dr. Tom Edlind
at Drexel University who created the disruption and reintegrated CgPDR1 and CgCDR1
mutants and performed the broth microdilution assays.
MATERIALS AND METHODS
Media, Inhibitors, and Strains
For most experiments, the medium employed was YPD (1% yeast extract, 2%
peptone, 2% dextrose). Gene disruptants and ura3 mutants were selected on DOB
(synthetic defined medium with dextrose) with complete supplement mixture (CSM) or
CSM lacking uracil/uridine (-URA) (Qbiogene BIO 101). Drugs were obtained from the
following sources: fluconazole (Pfizer), itraconazole (Janssen), terbinafine (Novartis);
caspofungin (Merck), amphotericin B, miconazole and cyloheximide (Sigma-Aldrich).
They were dissolved in dimethyl sulphoxide (DMSO); the final DMSO concentration
was ≤ 0.5% in all experiments which had no detectable effect on growth. Sorbic acid,
lactic acid, acetic acid and hydrogen peroxide (Sigma) were diluted as necessary in water.
Strains were previously described (203) or constructed as described below.
Isolation of ura3 Strains
Wild-type URA3 yeast strains are sensitive to 5-fluoroorotic acid (5FOA). To
isolate 5FOA-resistant mutants, a single colony from a fresh YPD plate was streaked on
DOB + CSM agar containing 0.1% 5FOA (Research Products International) and
incubated at 35°C for 3 days. Colonies were streaked for isolation on YPD and DOB-
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URA; those that failed to grow on the latter were then tested for URA3 complementation
by transformation with pRS416 (shuttle vector with S. cerevisiae URA3) and selection on
DOB-URA plates. Yeast transformations employed the Frozen-EZ Yeast Transformation
II Kit (Zymo Research) as previously described (63).
Gene Disruption and Replacement
The PRODIGE method for PCR product-mediated gene disruption was employed
(Figure 2-1) (63). Briefly, primers (80 mers; Table 2-1) were designed to precisely
replace, after homologous recombination, a C. glabrata coding sequence (CDS) with the
selection marker CDS. These primers consisted of approximately 60 nucleotides at the 5'
end complementary to C. glabrata sequences directly upstream and downstream of the
targeted CDS and approximately 20 nucleotides at the 3' end complementary to the S.
cerevisiae URA3 CDS contained in plasmid template pRS416. PCR products generated
with these primers were used to transform C. glabrata ura3 strains. Following selection
on DOB-URA medium, transformants were screened by PCR with specific primer pairs
(Table 2-1; Figure 2-1) to confirm replacement of the targeted CDS with URA3 CDS.
DNA was generally prepared by phenol extraction of glass bead-disrupted cells (63);
some screens employed colony PCR in which a small volume of cells was added directly
to the PCR mix.
For PDR1 replacement, a PCR product representing the PDR1 CDS plus 430–680
bp upstream and downstream sequence was amplified with primers PDR1uF-PDR1dR
(Table 2-1) from 66032 or F15 genomic DNA. These products were used to transform
66032Δpdr1 strain with selection on 1 μg/ml cycloheximide-containing YPD plates.
Colonies were screened as above with primer pair PDR1uF2-PDR1iR (Table 2-1).
Broth Microdilution Assay
Fresh overnight cultures from a single colony were diluted 1:100 in YPD,
incubated for 3 h with aeration, and then counted in a haemocytometer and diluted again
to 1 × 104 cells/ml. Aliquots of 100 μl were distributed to wells of a 96-well flatbottomed plate, except for row A which received 200 μl. Inhibitor was added to row A to
the desired concentration and then serially twofold diluted to rows B through G; row H
served as inhibitor-free control. Plates were incubated at 35°C for the indicated times.
Absorbance at 630 nm was read with a microplate reader; background due to medium
was subtracted from all readings. The MIC (minimum inhibitory concentration) was
defined as the lowest concentration inhibiting growth at least 80% relative to the drugfree control.
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Figure 2-1. Disruption of PDR1 and effects on azole sensitivity. A. Diagram illustrating
PRODIGE primer design for disruption of PDR1 with URA3 CDS amplified from
pRS416. Also shown are the upstream forward and two internal reverse primers used to
screen transformants. B. PCR screen of representative ∆pdr1 transformants selected on
DOB-URA and their parent 66032 and F15. DNA was purified from isolated colonies,
amplified with the indicated primer pairs, and analyzed by gel electrophoresis; loss of the
PdR1uF-PDR1iR product and formation of the PDR1uF-URA2iR product identified
∆pdr1 clones. C. Broth microdilution assays examining fluconazole sensitivities of parent
66032, azole-resistant mutant F15, and their respective ∆pdr1 disruptants. Absorbance at
630nm was recorded after 24 or 48 h incubation as indicated; growth was plotted as
percentage of drug-free control.
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Table 2-1. Primers used in this study (grouped by application).
Primer name
PRODIGE-based gene disruption
PDR1-URA3F
PDR1-URA3R
CDR1-URA3F
CDR1-URA3R
PCR screening and PDR1 replacement
PDR1uF
PDR1uF2
PDR1iR
PDR1dR
URA3iR
CDR1uF
CDR1iR
DNA probes for RNA hybridization
ACT1F
ACT1R
CDR1F
CDR1R
PDH1F
PDH1R
PDR1F
PDR1R
YLR346F

Primer sequence
5'-GCCTTTTTTTTTAGAATATATTGGTAAAGTCATTCTTTAGC
TACGTTATTGAGAGAATATGTCGAAAGCTACATATAAGG-3'
5'-TGATTTTTCAGATTAAATATAAAATTATACAGGCTATGCAC
ACTGTCTAAATTAATAGCATTAGTTTTGCTGGCCGCATC-3'
5'-TACTTACAGGAAAAAGAATTTACAACTCTTGATATATACAAA
GTAAAGAAAAGTAACAATGTCGAAAGCTACATATAAGG-3'
5'-TTTTCCGAATGCAATATGTATTAATACCAGAGCCAGATTAT
GAGCGCAGGCTAAATAAATTAGTTTTGCTGGCCGCATC-3'
5'-GGCGTATTCATAGAATCCGAA-3'
5'-GGTCCTTCTAATAGTCATCTTT-3'
5'-CCATAGTATTCGTCGAGAGCA-3'
5'-GACCTCTGTGAAAAGCTACTG-3'
5'-CAGCAACAGGACTAGGATGAG-3'
5'-GCAGCTATGAGTTGAGGAAG-3'
5'-ACGCCACATCGGCATCCTT-3'
5'-TTGACAACGGTTCCGGTATG-3'
5'-CCGCATTCCGTAGTTCTAAG-3'
5'-ACAATGTCTCTTGCAAGTGAC-3'
5'-AAGTGTTTTCTGATGTGCTTT-3'
5'-GTGATGAACCCCGATGA-3'
5'-TTCTTGATCTCGTTGGGCGT-3'
5'-AGTGCCACCACTAAGTCACT-3'
5'-CCATAGTATTGCTGCAGAGCA
5'-GGAACTGAAACGCAGAACCA-3'
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Table 2-1 (continued).
Primer name
DNA probes for RNA hybridization, continued
YLR346R
YOR1F
YOR1R
YNL134F
YNL134R
YML131F
YML131R
RTA1F
RTA1R
MEC3F
MEC3R
YJL163F
YJL163R
Real-time RT-PCR
18SrtF
18SrtR
CDR1rtF
CDR1rtR
PDH1rtF
PDH1rtR
CSR1rtF
CSR1rtR
PDR1rtF
PDR1rtR
KAD2rtF
KAD2rtR
YOR1rtF

Primer sequence
5'-ATCCTTCCATGTGTCGGCAT-3'
5'-GAACAAGCCACAGACGTATC-3'
5'-CAAATTGCCAAGATGGCTGG-3'
5'-CCACCATGAAAGCTGCTGTA-3'
5'-AACTTAGGATCAGCTGGCAG-3'
5'-AATGAACCCACACCGGGTTA-3'
5'-TTCACCAGTTGCATCAACCAT-3'
5'-CGTTCGCGGTGTTGTTTCTT-3'
5'-CATCTTCAATATCGGCTTCGA-3'
5'-TAGCGTCATTACGGAGCCTT-3'
5'-TATCGGGACCGCTTTCTTGT-3'
5'-TAGGTGCCTCGCATTCTGAT-3'
5'-ATCTTGCCAGCTAATCCAGG-3'
5'-TCGGCACCTTACGAGAAATCA-3'
5'-CGACCATACTCCCCCCAGA-3'
5'-CATACAAGAAACACCAAAGTCGGT-3'
5'-GAGACACGCTTACGTTCACCAC-3'
5'-ACGAGGAGGAAGACGACTACGA-3'
5'-CTTTACTGGAGAACTCATCGCTGTT-3'
5'-TGGATTTTTTCTCCCATCTGGA-3'
5'-ACCACAGGGTCAAGCCATTTT-3'
5'-TTTGACTCTGTTATGAGCGATTAC-3'
5'-TTCGGATTTTTCTGTGACAATGG-3'
5'-AACCCGCAGTCATCGTGG-3'
5'-CCTGTCTCTCAGTTCTTGGAAACC-3'
5'-CCATCGGTGCTTGTGTAATGTTA-3'
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Table 2-1 (continued).
Primer name
Real-time RT-PCR, continued
YOR1rtR
RTA1rtF
RTA1rtR
QDR2rtF
QDR2rtR
SUT1rtF
SUT1rtR
RPN4rtF
RPN4rtR
SAC7rtF
SAC7rtR
YBT1rtF
YBT1rtR
MET8rtF
MET8rtR

Primer sequence
5'-TTGAGAGGCGTGGAAAAAATG-3'
5'-TCCTGTTTGTCATTAGGGTTAGGG-3'
5'-TGGCAATTTTGTTCTTATTCCTCAG-3'
5'-GACGAATGAGGACGAGGCTG-3'
5'-GGTTGGACCTGGTTCTGTAAATAGG-3'
5'-ACGAGAGCCAGAAGTTGATGG-3'
5'-TGGAGGCGATAGGAATTGGT-3'
5'-AGCCAGTATGCTGACCCGAG-3'
5'-ACACGCCACATCGCCC-3'
5'-CGCTGGAGACGCCTGG-3'
5'-TCGTATCCGCTTGCTGTTCC-3'
5'-AAGTGCTTCTTCCGCCTCATT-3'
5'-AACAGGAGCTGGTGTAGTACCCA-3'
5'-TCCACCGCTATGCGATTTCT-3'
5'-GGAGATGACCCATTGGATGAA-3'
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RNA Hybridization
Log-phase cultures in YPD at 35°C were adjusted to 3 × 106 cells/ml and
incubated for an additional 3 h. In some studies, cultures were divided into equal portions
to which either fluconazole or a comparable volume of DMSO was added, followed by
incubation for the indicated times. In all studies, culture volumes corresponding to 3 ×107
cells were removed and centrifuged to pellet cells. RNA preparation and hybridization
analysis were as previously described (195). Briefly, cell pellets were suspended in
sodium acetate-EDTA buffer and stored frozen. After thawing, RNA was extracted by
vortexing in the presence of glass beads, SDS and buffer-saturated phenol alternating
with incubation at 65°C for 10–15 min. Samples were cooled on ice and centrifuged, and
RNA was ethanol precipitated from the aqueous phase. RNAs were dissolved in water
and denatured in formaldehyde-SSPE with incubation for 15 min at 65°C. Either 40 μl
(for ACT1 probing) or 200 μl (for other probes) of denatured RNA (approximately 4 or
20 μg, respectively) was applied to nylon membrane by using a slot blot apparatus.
Membranes were rinsed in SSPE, UV cross-linked, hybridized to purified PCR products
(Table 2-1) labeled with 32P by random priming (Takara), and exposed to film.
Construction of C. glabrata Microarrays
The nucleotide sequences corresponding to 5272 C. glabrata ORFs were
downloaded from the Génolevures Consortium (http://cbi.labri.fr/Genolevures/about.php,
Build 2). Following the Affymetrix Design Guide, two separate probe sets for each ORF
were designed, each consisting of 13 perfect match and 13 mismatch overlapping 25 base
oligonucleotides targeted to the 3' 600 bp region. For ORFs < 600 bp the sequence was
divided in two equal segments for subsequent design procedures. For quality control and
normalization purposes, we designed two to three additional probe sets spanning the C.
glabrata 18 s rRNA, TDH1 and ACT1 genes in addition to standard Affymetrix controls
(BioB, C, D, cre, DAP, PHE, LYS, THR). The probe selection was performed by the
Chip Design group at Affymetrix, using their proprietary algorithm to calculate probe set
scores, which includes a probe quality metric, cross-hybridization penalty, and gap
penalty. The probe sets were then examined for cross-hybridization against all other
sequences in the C. glabrata genome as well as a number of constitutively expressed
genes and rRNA from other common organisms. Duplicate probe sets are made to
distinct regions of the ORF, thereby allowing two independent measurements of the
mRNA level for that particular gene. C. glabrata custom Affymetrix NimbleExpress
Arrays were manufactured by NimbleGen Systems per our specification (4).
RNA Preparation for Microarrays
Total RNA was isolated using the hot SDS-phenol method (190). Frozen cells
were suspended in 12 ml of 50 mM sodium acetate (pH 5.2), 10 mM EDTA at room
temperature, after which 800 μl of 25% sodium dodecyl sulphate and 12 ml of acid
phenol (Fisher Scientific) were added. This mixture was incubated 10 min at 65°C with
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vortexing each minute, cooled on ice for 5 min, and centrifuged for 15 min at 12 000g.
Supernatants were transferred to new tubes containing 15 ml of chloroform, mixed and
centrifuged at 200 × g for 10 min. The aqueous layer was removed to new tubes, RNA
was precipitated with 1 volume isopropanol and 0.1 volume 2M sodium acetate (pH 5.0),
and then collected by centrifugation at 17 000g for 35 min at 4°C. The RNA pellet was
suspended in 10 ml of 70% ethanol, collected again by centrifugation, and suspended in
diethyl pyrocarbonate-treated water.
cRNA Synthesis and Labeling
Immediately prior to cDNA synthesis, the purity and concentration of RNA
samples were determined from A260/A280 readings and RNA integrity was determined by
capillary electrophoresis using the RNA 6000 Nano Laboratory-on-a-Chip kit and
Bioanalyzer 2100 (Agilent Technologies) as per the manufacturer's instructions. First and
second strand cDNA was synthesized from 15 μg total RNA using the SuperScript
Double-Stranded cDNA Synthesis Kit (Invitrogen) and oligo-dT24-T7 primer (PrOligo)
according to the manufacturer's instructions. cRNA was synthesized and labeled with
biotinylated UTP and CTP by in vitro transcription using the T7 promoter-coupled
double stranded cDNA as template and the Bioarray HighYield RNA Transcript Labeling
Kit (ENZO Diagnostics). Double stranded cDNA synthesized from the previous steps
was washed twice with 70% ethanol and suspended in 22 μl of Rnase-free water. The
cDNA was incubated as recommended with reaction buffer, biotin-labeled
ribonucleotides, dithtiothreitol, RNase inhibitor mix and T7 RNA polymerase for 5 h at
37°C. The labeled cRNA was separated from unincorporated ribonucleotides by passing
through a CHROMA SPIN-100 column (Clontech) and ethanol precipitated at −20°C
overnight.
Oligonucleotide Array Hybridization and Analysis
The cRNA pellet was suspended in 10 μl of RNase-free water and 10 μg was
fragmented by ion-mediated hydrolysis at 95°C for 35 min in 200 mM Tris-acetate (pH
8.1), 500 mM potassium acetate, 150 mM magnesium acetate. The fragmented cRNA
was hybridized for 16 h at 45°C to the C. glabrata NimbleExpress GeneChip arrays.
Arrays were washed at 25°C with 6 × SSPE, 0.01% Tween 20 followed by a stringent
wash at 50°C with 100 mM MES, 0.1 M NaCl, 0.01% Tween 20. Hybridizations and
washes employed the Affymetrix Fluidics Station 450 using their standard EukGEWS2v5 protocol. The arrays were then stained with phycoerythrein-conjugated
streptavidin (Molecular Probes) and the fluorescence intensities were determined using
the GCS 3000 high-resolution confocal laser scanner (Affymetrix). The scanned images
were analyzed using software resident in GeneChip Operating System v2.0 (GCOS;
Affymetrix). Sample loading and variations in staining were standardized by scaling the
average of the fluorescent intensities of all genes on an array to a constant target intensity
(250). The signal intensity for each gene was calculated as the average intensity
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difference, represented by [Σ(PM – MM)/(number of probe pairs)], where PM and MM
denote perfect-match and mismatch probes.
Microarray Data Analysis
The scaled gene expression values from GCOS software were imported into
GeneSpring 7.2 software (Agilent Technologies) for preprocessing and data analysis.
Probesets were deleted from subsequent analysis if they were called absent by the
Affymetrix criterion and displayed an absolute value below 20 in all experiments. The
expression value of each gene was normalized to the median expression of all genes in
each chip as well as the median expression for that gene across all chips in the study.
Pairwise comparison of gene expression was performed for each matched experiment
(F15 vs. 66032). Genes were included in the final data set if their expression changed by
at least twofold between strain F15 and strain 66032 in two independent experiments.
Quantitative Real-Time RT-PCR
First strand cDNAs were synthesized from 2 μg total RNA in a 21 μl reaction
volume using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen) as
per the manufacturer's instructions. Quantitative real-time PCR was performed in
triplicate using the 7000 Sequence Detection System (Applied Biosystems). Independent
amplifications were performed using the same cDNA for both the gene of interest and
18S rRNA, using the SYBR Green PCR Master Mix (Applied Biosystems). Genespecific primers were designed for the gene of interest and 18S rRNA using Primer
Express software (Applied Biosystems) and the Oligo Analysis and Plotting Tool
(Qiagen). The PCR conditions consisted of AmpliTaq Gold activation at 95°C for 10
min, followed by 40 cycles of denaturation at 95°C for 15 s and annealing/extension at
60°C for 1 min. A dissociation curve was generated at the end of each cycle to verify that
a single product was amplified using software provided with the 7000 Sequence
Detection System. The change in fluorescence of SYBR Green I dye in every cycle was
monitored by the system software, and the threshold cycle (CT) above background for
each reaction was calculated. The CT value of 18S rRNA was subtracted from that of the
gene of interest to obtain a ΔCT value. The ΔCT value of an arbitrary calibrator (e.g.
untreated sample) was subtracted from the ΔCT value of each sample to obtain a ΔΔCT
value. The gene expression level relative to the calibrator was expressed as 2–ΔΔCT.
RESULTS AND DISCUSSION
PDR1 Disruption in F15 and Parent
The laboratory selection of spontaneous fluconazole-resistant mutants of C.
glabrata ATCC strain 66032 was previously described (216). One of these mutants, F15,
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exhibited strong upregulation of CgCDR1 and CgPDH1, modest upregulation of PDR1,
and a single base change predicted to alter the Pdr1p amino acid sequence. We reasoned
that disruption of CgPDR1 in F15 and parent 66032 would provide an initial test of the
hypothesis that this single base change is responsible for the fluconazole resistance. To
accomplish this, ura3 derivatives of F15 and 66032 were isolated by selection on 5FOA
and screening for complementation by a URA3-encoding plasmid. Homologous
recombination is relatively non-specific in C. glabrata, especially with short homology
regions, but can be enhanced by promoter-dependent disruption of genes (PRODIGE) as
previously described (63). This method was used to disrupt CgPDR1 (Figure 2-1A).
Transformants were screened by polymerase chain reaction (PCR); loss of the uFPDR1iR product and generation of the PDR1uF-URA3iR product confirmed PDR1
disruption (Figure 2-1B).
Broth microdilution assays were used to examine fluconazole susceptibility of
F15Δpdr1, 66032Δpdr1 and their parents (Figure 2-1C). Similar to previous results with
their parents (216), the 66032 and F15 ura3 derivatives generated 24 h fluconazole MICs
of 8–16 and > 64 μg/ml, respectively. In contrast, their Δpdr1 derivatives were
fluconazole hypersusceptible, with equivalent MICs of 2 μg/ml. Although susceptible,
66032 exhibited trailing growth typical of many Candida species (178), and by 48 h was
fully grown at all fluconazole concentrations tested (Figure 2-1C). Trailing growth was
absent in the PDR1 disruptants. These results support the role of CgPdr1p in F15
fluconazole resistance. Furthermore, the reduced MIC and trailing growth associated with
PDR1 disruption in 66032 suggests that CgPdr1p is an important contributor to the
intrinsic low-level resistance that is characteristic of this species.
As hypothesized, RNA analysis showed that PDR1 disruption reversed the
constitutive upregulation of CgCDR1 and CgPDH1 in untreated mutant F15
(Figure 2-2A). Moreover, expression of these genes was reduced relative to their
expression in untreated parent 66032. This can explain the greater susceptibility of the
Δpdr1 derivatives relative to 66032. As previously described (216), fluconazole treatment
induced the expression of CgCDR1 and CgPDH1, most clearly in strains 66032 and F15
respectively (Figure 2-2A). CgPDR1 disruption completely blocked this treatmentdependent upregulation. Finally, we note that CgPDR1 itself, which is upregulated in F15
(216), is also induced by fluconazole treatment in 66032 and F15 (Figure 2-2A).
CgCDR1 Disruption
To more directly assess the role in acquired or intrinsic azole resistance of
multidrug transporter gene CgCDR1, it was similarly disrupted in the ura3 derivatives of
66032 and F15 (Figure 2-3A). This reversed the fluconazole resistance of F15
(Figure 2-3B), although the MIC (16 μg/ml) remained eightfold above that observed with
PDR1 disruption (Figure 2-1C). With respect to 66032, CgCDR1 disruption had minimal
effect on fluconazole MIC at 24 h, but trailing growth most apparent at 48 h was
eliminated as it was with PDR1 disruption. These results are consistent with CgCDR1
being a major but not exclusive contributor to F15 azole resistance.
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Figure 2-2. Expression of multidrug transporter genes CDR1 and PDH1 and
transcriptional activator gene PDR1 in parent 66032, mutant F15 and their respective
∆pdr1 disruptants. A. RNA was isolated from log phase cultures, slot-blotted to
membranes, and hybridized to the indicated gene probes: ACT1 served as loading control.
U, untreated cultures; T, treated with 256 μg/ml fluconazole for 2.5 h. B. Quantitative
real-time RT-PCR analysis of relative CgCDR1 and PDH1 expression in F15 versus
66032, F15∆pdr1 versus 66032, and 66032∆pdr1 versus 66032. Data are shown as mean
± SD.
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Figure 2-3. Disruption of CgCDR1 and effects on azole sensitivity. A. PCR screen of
representative ∆cdr1 transformants selected on DOB-URA and their parents 66032 and
F15. DNA was purified from isolated colonies, amplified with the indicated primer pairs,
and analyzed by gel electrophoresis; loss of CDR1uF-CDR1iR product and formation of
CDR1uF-URA3iR product identified ∆cdr1 clones. B. Broth microdilution assays
examining fluconazole sensitivities of parent 66032, azole-resistant mutant F15, and their
respective ∆cdr1 disruptants. Absorbance at 630nm was recorded after 24 or 48 h
incubation as indicated; growth was plotted as percentage of drug-free control.
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PDR1 Replacement
To rigorously test the role of F15 PDR1 in azole resistance, we employed gene
replacement. The 66032Δpdr1 strain was transformed with PCR products representing
wild-type and F15 PDR1, including 5' and 3' flanking sequences which should direct
PDR1 to its native locus (Figure 2-4A). We initially attempted to select homologous
recombinants on fluconazole-containing medium. However, this was precluded by a
background of spontaneous fluconazole-resistant mutants in control (no added DNA)
transformations. As an alternative, the protein synthesis inhibitor cycloheximide is a
known substrate for Cdr1p-like multidrug transporters, and indeed C. glabrata Δpdr1
strains are cycloheximide-hypersensitive (63). In contrast to fluconazole, cycloheximidecontaining plates yielded no spontaneous mutants while five or six transformants were
obtained with addition of wild-type or F15 PDR1 respectively. PCR screening of these
transformants confirmed homologous recombination into the native locus (Figure 2-4B).
All F15 PDR1 replacements demonstrated fluconazole resistance comparable to F15
itself, while all but one of the wild-type PDR1 replacements demonstrated wild-type
sensitivity (Figure 2-4B). Sequencing of a representative F15 PDR1 replacement
confirmed there were no mutations other than the previously described P927L (216).
Characterization of CgPdr1p-Independent Azole Resistance
As noted above, a background of resistant mutants arose on fluconazolecontaining YP-glycerol medium in control transformations of strain 66032Δpdr1, which
involved plating approximately 2 × 107 cells. To more rigorously examine this CgPdr1pindependent resistance, equivalent numbers (3 × 105) of 66032 and 66032Δpdr1 cells
were plated on YP-glycerol medium with fluconazole ranging from 0 to 256 μg/ml (184).
After 4 days incubation, the MIC was 32 μg/ml for 66032, and about 30 mutant colonies
(frequency = 1 × 10−4) were observed on each of the four plates at or above this
concentration. With 66032Δpdr1, the MIC was 4 μg/ml, one or two colonies were
observed at 4 and 8 μg/ml, and no colonies at 16–256 μg/ml (frequency < 3 × 10−6).
Thus, CgPdr1p-independent azole resistance occurs at significantly reduced frequency.
PDR1 Disruption in Azole-Resistant Clinical Isolates
Strain BG14, a model for C. glabrata pathogenesis (48), is a ura3 derivative of a
clinical isolate from a patient who failed fluconazole therapy (32). Consistent with this,
BG14 is fluconazole-resistant (MIC = 256 μg/ml), the molecular basis for which is
unknown. PDR1 disruption in BG14, conferring cycloheximide hypersensitivity, was
previously reported (63). Here we show that this disruption also largely reversed BG14
azole resistance. The fluconazole MIC decreased 16-fold to 16 μg/ml (Figure 2-5A); i.e.
comparable to the typical clinical isolate but eightfold above that observed for
66032Δpdr1. Ketoconazole, itraconazole and miconazole MICs were similarly reduced in
BG14Δpdr1, but susceptibilities to unrelated antifungals terbinafine, caspofungin and
amphotericin B were unchanged. Expression of CgCDR1 and ERG11 was examined by
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Figure 2-4. PDR1 replacement confirms role in azole resistance. A. Diagram illustrating
replacement and PCR screening strategies. B. PCR screen of representative PDR1
replacements 66032R and F15R (wild-type and F15-derived PDR1, respectively) selected
on cycloheximide-containing plates, and their parent 66032∆pdr1; strains 66032 and F15
were included as positive controls. DNA was purified from isolated colonies, amplified
with PDR1uF2-PdR1iR primer pair, and analyzed by gel electrophoresis; formation of
product confirmed replacement of PDR1 into its native locus in 66032∆pdr1. C. Broth
microdilution assay showing that replacement into 66032∆pdr1 of 66032-derived
(66032R) or F15-derived (F15R) PDR1 conferred the expected low or high-level
fluconazole resistance associated with 66032 and F15. Absorbance at 630 nm was
recorded after 24 h incubation; growth was plotted as percentage of drug-free control.
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Figure 2-5. Antifungal sensitivities and CgCDR1-ERG11 expression in a Δpdr1
derivative of azole-resistant clinical isolate BG14. A. MIC values (at 24 h) determined by
broth microdilution for BG14 and BG14Δpdr1. A log scale was used to facilitate
comparison of MICs over a wide range. Numbers above the BG14Δpdr1 bars indicate the
fold-change relative to BG14. FLU, fluconazole; ITR, itraconazole; KET, ketoconazole;
MIC, miconazole; TER, terbinafine; AMB, amphotericin B; and CAS, caspofungin. B.
RNA was isolated from log-phase BG14 and BG14Δpdr1 cultures exposed to 256 μg/ml
fluconazole for 0–2.5 h, slot-blotted to membranes, and hybridized to the indicated gene
probes.
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RNA hybridization (Figure 2-5B). In BG14, constitutive expression of CgCDR1 appeared
to be modestly upregulated, but remained responsive to fluconazole-dependent
upregulation. Both of these were strongly reduced in the Δpdr1 derivative, while no
effects on ERG11 expression were observed.
Strain 8512 represents a second azole-resistant clinical isolate with high
constitutive CgCDR1-CgPDH1 expression (216). Following 5FOA-mediated conversion
to ura3, PDR1 was disrupted in strain 8512 (not shown). Broth microdilution assays
demonstrated reduction of fluconazole MIC from > 256 to 32 μg/ml. Taken together,
these data suggest that PDR1 is a major determinant of azole sensitivity in C. glabrata,
although additional gene mutations may contribute to clinical resistance.
Microarray Analysis: Upregulated Genes
In light of the major role played by transcription activator gene PDR1 in C.
glabrata azole sensitivity, an examination of genome-wide changes in gene expression in
mutant F15 was warranted. We first attempted this with S. cerevisiae microarrays,
because these two yeasts are closely related. However, the only confirmable change was
upregulation of the PDR5 (18-fold) and PDR15 (ninefold) homologs (data not shown);
both of these genes share 73% nucleotide identity with CgCDR1.
Therefore, C. glabrata microarrays were developed for the Affymetrix platform
(see Materials and Methods) and used to examine changes in F15 relative to 66032. In
F15, 78 genes were upregulated ≥ twofold relative to 66032. These genes are listed in
Table 2-2, grouped by probable function and ordered by expression level. Among the
upregulated are homologs of nine genes previously identified in microarray studies of S.
cerevisiae Pdr1p–Pdr3p gain-of-function mutants (52, 53). Five of these nine genes
encode putative membrane proteins with roles in small molecule transport or lipid
metabolism. These include, in addition to CgCDR1 and CgPDH1, the upregulated genes
YOR1 involved in oligomycin efflux, RSB1 involved in sphingoid base-resistance, and
RTA1 involved in 7-aminocholesterol resistance (see Saccharomyces Genome Database
(SGD) website (http://www.yeastgenome.org) for further information on these genes and
references).
The four remaining genes upregulated in both S. cerevisiae and C. glabrata gainof-function mutants include PDR1 itself (as previously reported; (216)), the stressinduced RPN4 encoding a proteasome gene transcription factor, and the uncharacterized
open reading frames (ORFs) YLR346C and YMR102C. The latter encodes a relatively
large and evolutionarily conserved protein with a WD40 domain commonly found in
signaling proteins, and its disruption has been associated with fluconazole resistance in S.
cerevisiae (8). The YLR346C product, in contrast, is not conserved; indeed, the C.
glabrata and S. cerevisiae genes are not detectably homologous in terms of sequence but
rather in terms of chromosomal synteny, flanked in both yeast by unambiguous
YLR345W and YLR347C homologs. Also, both YLR346C products are short (101 and 112
amino acids) and highly charged in their C-terminal regions. In S. cerevisiae, Ylr346cp is
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Table 2-2. C. glabrata genes upregulated ≥ twofold in fluconazole-resistant mutant F15.
Group
Small molecule transport

Lipid, fatty acid, and
sterol metabolism

Cell stress

Transcription

DNA replication and
damage response
Protein synthesis,
modification, or
degradation

Expressionb

Systematic
name

S. cerevisiae
homologa

C. glabrata
designation

Description

IPF6352
IPF9719
IPF1620
IPF8922
IPF982
IPF3303
IPF5152
IPF2180
IPF4136
IPF8678
IPF8367
IPF1002
IPF4884
IPF2739
IPF2620
IPF6847
IPF3173
IPF4605
IPF6629
IPF4140
IPF8736
IPF5558
IPF5076
IPF5932
IPF3325
IPF7202
IPF6366
IPF2113
IPF118
IPF9036
IPF9035
IPF2521
IPF785
IPF3014
IPF6742
IPF3846
IPF3072
IPF8484

d

CAGL0M01760g
CAGL0F02717g
CAGL0G08624g
CAGL0G00242g
CAGL0C03289g
CAGL0K11616g
CAGL0K00715g
CAGL0K03509g
CAGL0L10142g
CAGL0K05995g
CAGL0M10219g
CAGL0C02981g
CAGL0D05918g
CAGL0L03135g
CAGL0D00946g
CAGL0J04202g
CAGL0K09702g
CAGL0K12958g
CAGL0C00275g
CAGL0L10186g
CAGL0H02387g
CAGL0E00803g
CAGL0K01727g
CAGL0I04246g
CAGL0A00451g
CAGL0M05005g
CAGL0M01870g
CAGL0I01980g
CAGL0H08866g
CAGL0M09713g
CAGL0M09735g
CAGL0E04576g
CAGL0B03355g
CAGL0A01738g
CAGL0J08096g
CAGL0G01540g
CAGL0K08866g
CAGL0M12749g

ABC transporter involved in azole/multidrug resistance
ABC transporter involved in azole/multidrug efflux
MFS transporter involved in quinidine/multidrug efflux
ABC transporter involved in multidrug efflux
ABC transporter involved in bile acid transport
Mitochondrial inner membrane transporter
Over-expression confers 7-aminocholesterol resistance
Putative mitochondrial fatty aldehyde dehydrogenase
Sphingolipid flippase
Minor sphingoid long-chain base kinase
Ceramide synthase component
acyl-CoA:sterol acyltransferase; sterol esterification
Alcohol acetyltransferase; steroid detoxification
Phospholipase D
Phosphatidylinositol transfer protein
Stress-induced membrane protein
Alcohol dehydrogenase motif; stress-induced
Alcohol dehydrogenase motif, stress-induced
Possible chaperone and cysteine protease
Uncharacterized; stress-induced
Trehalose-6-phosphate synthase/phosphatase subunit
Small cytosolic stress-induced chaperone
Transcription factor for proteasomegenes
Transcription factor involved in sterol uptake
Transcription factor involved in multidrug resistance
Subunit of TFIID and SAGA complexes
Uncharacterized; potential zinc finger
Activates transcription through DNA-bound Snf1
Transcription factor involved in osmostress response
Implicated in DNA damage response
DNA damage checkpoint
Regulatory subunit of Cdc7p-Dbf4p kinase complex
DNA polymerase II subunit
Mannosyltransferase of cis-Golgi apparatus
Recognition of polyubiquitinated proteins
Carbonic anhydrase-like; non-classical protein export
Non-ATPase regulatory subunit of 26S proteasome
Possible shared subunit of Cop9 signalosome and eIF3

PDR5 (CDR1)
PDR15(PDH1)
QDR2
d
YOR1
YBT1
OAC1
d
RTA1
HFD1
d
RSB1
LCB5
LAC1
ARE1
ATF2
SPO14
CSR1
HSP12
YNL134c
YML131W
HSP31
YOR052C
TPS3
HSP42
d
RPN4
SUT1
d
PDR1
TAF9
YPR013C
SIP3
HOT1
YIM1
MEC3
DBF4
DPB3
OCH1
UFD1
NCE3
RPN8
PCI8
d

F15

F15/66032

41
29
23
16
13
4.7
22
13
12
12
5.7
4.6
3.1
0.8
0.4
29
14
7.3
3.5
2.3
1.5
0.6
16
15
9.6
1.0
0.8
0.4
0.1
40
1.6
0.7
0.2
5.2
4.4
3.1
2.9
0.2

2.5
9.6
4.5
11
7.7
2.5
7.0
5.6
2.8
2.4
2.5
4.6
9.6
2.6
3.8
4.0
9.5
9.1
2.0
3.2
4.4
4.9
3.9
2.4
2.3
6.3
2.9
2.2
4.9
12
15
2.4
2.7
2.5
2.2
2.9
2.9
2.4

PDREc
134, 298, 388, 516
521, 557
848
648
450
839
300, 379
218
641, 881
804
531
114
30, 195, 560, 772
–
239
849
541
594
–
–
–
–
378, 394, 552
–
557, 701
–
–
–
228
127, 179
110, 162
–
–
–
–
–
–
–
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Table 2-2 (continued).
Group
Vesicular and protein
transport

Signal transduction

Mitochondrial
Cell wall
Amino acid and
carbohydrate metabolism
Chromatin/chromosome
structure
Other metabolism

Uncharacterized

Expressionb

Systematic
name

S. cerevisiae
homologa

C. glabrata
designation

Description

IPF7414
IPF8257
IPF8439
IPF4445
IPF4173
IPF3260
IPF271
IPF1489
IPF8227
IPF351
IPF2382
IPF512
IPF5914
IPF2122
IPF7121
IPF9549
IPF496
IPF4499
IPF5315
IPF8319
IPF390
IPF8077
IPF2730
IPF6032
IPF6034
IPF1279
IPF4182
IPF6116
IPF8009
IPF2520
IPF2196
IPF3019
IPF3875
IPF3655
IPF1546
IPF2382
IPF4149
IPF6420
IPF2249

GSF2
YPT52
MEH1
VPS28
VTI1
GYL1
VPS51
BAG7
CDC25
GAC1
YNL234W
GPG1
KIN3
FMP48
YGR046W
FLO1
PYC1
STR3
MET8
SMD3
SPC19
SPC97
SPC34

CAGL0L01485g
CAGL0G07689g
CAGL0L02211g
CAGL0H05181g
CAGL0L10604g
CAGL0K10934g
CAGL0H06809g
CAGL0I07249g
CAGL0D06512g
CAGL0F04917g
CAGL0J07502g
CAGL0F07117g
CAGL0I04422g
CAGL0K04301g
CAGL0G03861g
CAGL0E00209g
CAGL0F06941g
CAGL0L06094g
CAGL0K06677g
CAGL0M04631g
CAGL0F05467g
CAGL0I02464g
CAGL0L03223g
CAGL0M14091g
CAGL0M14047g
CAGL0A02816g
CAGL0L10736g
CAGL0M12947g
CAGL0M08426g
CAGL0E04554g
CAGL0K03377g
CAGL0A01650g
CAGL0G01122g
CAGL0B01078g
CAGL0G09603g
CAGL0J07502g
CAGL0L10318g
CAGL0I10604g
CAGL0K02563g

ER membrane, hexose transporter secretion
GTPase required for vacuolar protein sorting
Component of the EGO complex; microautophagy
Component of ESCRT-I complex; protein trafficking
Involved in cis-Golgi membrane traffic
putativegAP for Ypt1 involved in polarized exocystosis
Golgi-associated retrograde protein complex
GAP for Rho1; cell wall and cytoskeleton homeostasis
Membrane bound GEF for Ras1-Ras2
Regulatory subunit forglc7 protein phosphatase
Similar toglobins with haem-binding domain
Subunit of heterotrimericg protein, interacts withgrp1
Protein kinase
Ser/Thr protein kinase; mitochondrial
Essential protein involved in mitochondria transport
Flo1-like family of cell wall proteins
Pyruvate carboxylase isoform
Cystathionine beta-lyase
Bifunctional dehydrogenase and ferrochelatase
Core Sm spliceosome protein Sm D3
Component of Dam1 spindle pole complex
Component of microtubule-nucleating Tub4 complex
Component of Dam1 spindle pole complex
Putative quinone reductase/NADPH dehydrogenase
NADPH-dependent cinnamyl alcohol dehydrogenase
2-methylbutyraldehyde reductase
Peripheral membrane protein of peroxisomes
Uncharacterized
Uncharacterized; ARS in promoter
Uncharacterized; no similarities
Transcribed along with MDRgenes by Yrr1/Yrm1
Uncharacterized; no similarities
Uncharacterized; syntenic but minimal similarities
Uncharacterized
Uncharacterized; very weak similarity to Yor186w
Similar toglobins with haem-binding domain
Uncharacterized
Uncharacterized
Uncharacterized; mammalian BRAP2 homolog

ADH6
YPR1
INP1
YIL077C
YJL163C
d

YMR102C

d
YLR346C
YLR177W

YNL234W
YOR059C
YGR126W
YHL010C

F15

F15/66032

10
1.6
0.5
0.5
0.3
0.3
0.2
1.6
1.2
0.9
0.5
0.4
0.2
11
0.4
2.6
4.6
0.7
0.2
0.9
0.5
0.5
0.4
3.8
2.3
0.6
0.2
20
9.1
8.8
8.1
7.2
3.3
2.7
2.1
0.5
0.5
0.1
0.1

2.4
2.8
5.7
2.2
6.7
4.0
6.1
2.9
5.8
4.7
3.1
2.6
5.6
2.8
4.4
3.0
2.3
5.0
7.8
3.7
13.1
2.8
2.5
9.8
2.7
5.6
5.5
38
10
6.4
4.4
4.4
22
2.5
6.1
3.1
2.4
19
5.0

PDREc
208
–
–
–
741
–
–
–
–
–
–
–
–
–
–
284, 419
–
–
–
–
–
–
–
244, 532
–
–
–
472, 502
450
–
898
564
793, 803
–
–
–
–
–
–
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Table 2-2 (continued).
a

Parentheses indicate a previously named C. glabrata gene.
Expression in C. glabrata 66032 is represented in arbitrary microarray units (for comparison, actin and β-tubulin gene homologs
ACT1 and TUB2 had average expression levels of 66 and 8.6 respectively). F15/66032 represents the ratio of expression in the
fluconazole-resistant mutant vs. its parent (for comparison, ACT1 and TUB2 had ratios of 0.6 and 0.8 respectively).
c
Promoter regions (900 bp) were searched for matches to the S. cerevisiae PDRE consensus TCCRYGSR. Numbers indicate the
distance (in bp) upstream of the ATG start codon of the PDRE; hyphens (–) indicate the absence of a PDRE.
d
Genes similarly upregulated in S. cerevisiae Pdr1p–Pdr3p gain-of-function mutants (52, 53).
b
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mitochondria-localized and forms a two-hybrid interaction with MAP kinase Slt2p,
suggesting a possible role in mitochondria-nucleus retrograde signaling.
Among the 69 genes whose upregulation appears to be C. glabrata F15-specific
(i.e. not similarly upregulated in S. cerevisiae) are three additional homologs encoding
small molecule transporters including quinidine and bile acid efflux protein genes QDR2
and YBT1. Additional lipid metabolism genes include ARE1 whose disruption in S.
cerevisiae confers azole hypersensitivity (T. Edlind, unpublished data) and ATF2
involved in fatty acid and steroid detoxification. A third group of well-represented genes
are involved in the cell stress response, including membrane protein gene HSP12, and
YML131W-YNL134C; the latter two are unrelated by blast but share an ADH_zinc_N
domain (identified by CD-search; (128)) characteristic of zinc-dependent alcohol
dehydrogenases-oxidoreductases. YML131W-YNL134C are also coordinately upregulated
in S. cerevisiae in response to diverse stresses including heat, oxidizing agents, ethanol,
nitrogen depletion and stationary phase ((70); see Expression Connection at
http://www.yeastgenome.org). A similarly regulated S. cerevisiae gene is GRE2, also
encoding an oxidoreductase and among the genes upregulated in Pdr1p–Pdr3p gain-offunction mutants (52, 53). This provides an example of analogous but non-homologous
genes upregulated in C. glabrata F15 and S. cerevisiae Pdr1p–Pdr3p mutants.
Notable among the remaining upregulated genes with significant expression
levels are: SUT1 encoding a transcription factor involved in sterol uptake and hypoxic
gene expression, YIM1 implicated in DNA damage response, OCH1 and GSF2 involved
in Golgi-ER functions, proteasome-related genes UFD1 and RPN8, putative
mitochondrial protein kinase gene FMP48, a quinone reductase-like gene curiously
lacking in other fungal genomes but present in many bacteria and vertebrates, and the
uncharacterized YIL077C whose product has been mitochondria-localized but interacts
with a nuclear transcriptional complex.
Microarray Analysis: Downregulated Genes
There were 31 genes downregulated ≥ twofold in F15 relative to parent 66032
(Table 2-3). Only one of these was also downregulated in S. cerevisiae Pdr1p–Pdr3p
gain-of-function mutants: membrane transporter gene PDR12 involved in efflux of weak
organic acids such as sorbate. Additional genes with significantly downregulated
expression include zinc transporter gene ZRT1, major facilitator genes including FLR1
implicated in fluconazole efflux, and homologs of cell surface protein genes MUC1EPA2 and MKC7 implicated in adhesion and aspartic protease activity respectively.
Finally, a gene was downregulated whose product has clear homology to the WRY
family of putative membrane-anchored proteins previously identified only in C. albicans
(unpublished annotation in NCBI database). This family has nine paralogs in C. albicans
and seven in C. glabrata but none, surprisingly, in S. cerevisiae, suggesting a possible
role in mammalian colonization.
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Table 2-3. C. glabrata genes downregulated ≥ twofold in fluconazole-resistant mutant F15 compared with parent 66032.
Group
Small molecule
transport

Cell stress

Carbohydrate
metabolism
Cell cycle control
RNA processing

Cell surface and
cytoskeleton

Uncharacterized

a

Expressionb

Systematic
name

S. cerevisiae
homologa

C. glabrata
designation

Description

IPF5505
IPF4392
IPF6218
IPF7808
IPF867
IPF1568
IPF3249
IPF11021
IPF9018
IPF9641
IPF5937
IPF986
IPF6117
IPF290
IPF2555
IPF8796
IPF1130
IPF9324
IPF5272
IPF9500
IPF8398
IPF807
IPF3539
IPF810
IPF821
IPF5228
IPF7581
IPF493
IPF3428
IPF7665
IPF5688

ZRT1
FLR1
d
PDR12
YHR048W
ATR1
SNG1
CTA1
CRS5
LTV1
SLG1
CUP2(AMT1)
SDH2
DOG2
PCK1
SDS22
PNO1
AAR2
DIM1
NOP8
MKC7

CAGL0E01353g
CAGL0H06017g
CAGL0M07293g
CAGL0J00363g
CAGL0B02343g
CAGL0G09273g
CAGL0K10868g
CAGL0H04257g
CAGL0J00891g
CAGL0F01507g
CAGL0I04180g
CAGL0C03223g
CAGL0M12925g
CAGL0H06633g
CAGL0D00264g
CAGL0K09460g
CAGL0A04543g
CAGL0L07678g
CAGL0B01397g
CAGL0J01793g
CAGL0E01771g
CAGL0B03003g
CAGL0G02101g
CAGL0B02992g
CAGL0B02882g
CAGL0B01969g
CAGL0L08338g
CAGL0F06897g
CAGL0G06468g
CAGL0L06864g
CAGL0G05269g

High-affinity zinc transporter
Multidrug efflux pump of major facilitator superfamily
ABC transporter of weak organic acids
Uncharacterized; major facilitator superfamily
Multidrug efflux pump of major facilitator superfamily
Nitrosoguanidine resistance; putative transporter
Catalase A
Copper-binding metallothionein-like protein
Required for growth at low temperature
Sensor of stress-activated Pkc1-Slt2 pathway
Metal-activated transcriptional factor
Succinate dehydrogenase iron-sulphur protein subunit
2-deoxyglucose-6-phosphate phosphatase
Phosphoenolpyruvate carboxykinase
Nuclear regulatory subunit ofglc7 phosphatase
Nucleolar protein required for pre-rRNA processing
Component of the U5 snRNP
Essential 18S rRNA dimethylase
Nucleolar protein required for ribosome biogenesis
Muc1/Epa2-like putative cell surface protein
GPI-anchored aspartyl protease
α-1,3-mannosyltransferase involved in O-glycosyltation
Promoter insertion mutant is calcofluor-hypersensitive
α-1,3-mannosyltransferase involved in O-glycosyltation
C. albicans WRY family; transmembrane domain
Insertion mutant is calcofluor hypersensitive
Minor isoform of tropomyosin
Uncharacterized; alcohol dehydrogenase domain
Uncharacterized; related to ECM3
Uncharacterized; interacts withglc7 and Snf1
Uncharacterized; mitochondrial

MNT3
ECM4
MNT3
ECM18
TPM2
YIR035C
YNL095C
SIP5
FMP16

PDRE
F15

F15/66032

10
6.1
4.5
2.2
1.8
1.3
8.8
3.4
1.0
0.8
0.9
4.9
1.6
1.2
0.3
3.0
1.0
1.0
0.7
4.2
3.6
3.1
1.6
1.4
0.5
0.3
0.3
3.3
2.7
0.4
0.3

0.5
0.4
0.2
0.4
0.4
0.1
0.4
0.4
0.4
0.5
0.2
0.4
0.3
0.3
0.2
0.4
0.4
0.5
0.4
0.3
0.3
0.4
0.3
0.3
0.1
0.3
0.4
0.4
0.4
0.3
0.3

–
–
–
–
–
–
–
–
656
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

Parentheses indicate a previously named C. glabrata gene.
Expression in C. glabrata 66032 is represented in arbitrary microarray units (for comparison, actin and β-tubulin gene homologs
ACT1 and TUB2 had average expression levels of 66 and 8.6 respectively). F15/66032 represents the ratio of expression in the
fluconazole-resistant mutant vs. its parent (for comparison, ACT1 and TUB2 had ratios of 0.6 and 0.8 respectively).
c
Promoter regions (900 bp) were searched for matches to the S. cerevisiae PDRE consensus TCCRYGSR. Numbers indicate the
distance (in bp) upstream of the ATG start codon of the PDRE; hyphens (–) indicate the absence of a PDRE.
d
Genes similarly downregulated in S. cerevisiae Pdr1–Pdr3 gain-of-function mutants (52, 53).
b
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Confirmation of Microarray Results
As our studies represent the first application of these C. glabrata microarrays, it
was important to validate the results by independent methods. RNA blots or real-time
reverse transcription (RT)-PCR were used to examine the expression of selected genes
identified as upregulated in the microarray (other than already confirmed CgCDR1,
CgPDH1 and CgPDR1). For five of seven genes tested (YLR346C, YOR1, YNL134C,
YML131W and RTA1), RNA blots confirmed F15 upregulation relative to the parent
66032 strain (Figure 2-6A). The two exceptions (MEC3 and YJL163C) represent genes
whose expression in both parent and F15 were below the level of detection by RNA blot
(not shown).
For all nine genes tested by real-time RT-PCR (YOR1, RTA1, RPN4, QDR2,
MET8, BAG7, CSR1, PDR1 and YBT1), the upregulation observed by microarray was
confirmed (Figure 2-5B). For most of these, the results were quantitatively similar; e.g.
YOR1 was upregulated 16-fold by microarray and 17-fold by RT-PCR and CSR1 was
upregulated 3.8-fold by microarray and 2.9-fold by RT-PCR. Expression of ERG11
encoding the azole target lanosterol demethylase was essentially unaltered by RT-PCR
(not shown), in agreement with microarray analysis (F15/66032 = 0.6) and RNA
hybridization (216). One anomaly in the microarray analysis was the relatively low
upregulation of CgCDR1 (2.5-fold) compared with its high upregulation (approximately
20-fold) in both RNA blots and RT-PCR (Figure 2-2). Furthermore, CgCdr1p was
strongly upregulated on the protein level, as shown by SDS-PAGE of membrane
preparations followed by mass spectrometric identification of eluted bands (181).
Potential explanations for this anomaly include degradation or masking of the CgCDR1
mRNA region targeted by the microarray, or a saturation effect due to the relatively high
CgCDR1 basal expression.
Promoter Sequence Analysis
To identify a Candidate C. glabrata Pdr1p response element (PDRE), we took
advantage of the F15 microarray data, the available genome sequence, and the
evolutionary relatedness of this yeast to S. cerevisiae. The promoter regions (900 bp
upstream of the start codon) for all genes listed in Tables 2-2 and 2-3 were searched for a
match to the consensus S. cerevisiae PDREs (52, 53): TCC(GA)(CT)G(GC)(AG). At
least one match to this sequence was identified in 31 of the 78 genes (40%) upregulated ≥
two-fold. Moreover, one or more PDRE were identified in all nine genes upregulated in
both C. glabrata and S. cerevisiae gain-of-function mutants, in 14 of 15 genes in the
small molecule transport and lipid metabolism groups, and in 26 of 34 genes with
expression level > 3 (arbitrary microarray units). Conversely, only one PDRE was
identified among the 31 downregulated gene promoters (Table 2-3); similarly, none was
identified in the promoters of representative housekeeping genes (ACT1, TEF1, TDH3) or
azole target gene ERG11. This analysis therefore identifies TCC(AG)(TC)G(GC)(AG) as
a strong Candidate for the C. glabrata PDRE. More specifically, we note a clear
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Figure 2-6. Confirmation of F15/66032 microarray results for selected genes by RNA
hybridization and real-time RT-PCR. A. RNA was isolated from log phase cultures, slotblotted to membranes, and hybridized to the indicated gene probes; ACT1 served as
loading control. B. Quantitative real-time RT-PCR analysis of relative gene expression in
F15 versus 66032. Data are shown as mean ± SD.
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preference for G as the penultimate base (95% of PDREs) and A as the final base (84%),
although two of the four PDREs within the CgCDR1 promoter have G as the final base.
Two exceptions warrant discussion. The promoters of C. glabrata upregulated
genes RPN8 and YOR052C lack a PDRE but include perfect matches to the S. cerevisiae
Rpn4p transcription factor-binding site GGTGGCAAA (124); perfect or near-perfect
matches are also found in the promoters of their S. cerevisiae homologs. As noted above,
Rpn4p is upregulated in both C. glabrata Pdr1p and S. cerevisiae Pdr1p–Pdr3p gain-offunction mutants. Thus, RPN8-YOR052C upregulation is likely Rpn4p-mediated and only
indirectly Pdr1p-mediated.
Candida glabrata F15 Exhibits Additional Phenotypes Predicted by Microarray
Analysis Which May Alter Virulence
As coordinate CgCDR1-CgPDH1 upregulation is commonly observed in C.
glabrata azole-resistant clinical isolates (21, 187, 216), the responsible mutations must
have minimal effects on fitness. On the other hand, these mutations could alter C.
glabrata in subtle ways that affect, for example, its relative virulence in the bloodstream
versus mucosa. The F15 microarray results provided us with an opportunity to begin to
test this general hypothesis. Specifically, we looked for phenotypes other than azole
susceptibility predicted to be associated with altered expression of genes co-regulated
with CgCDR1-CgPDH1.
Upregulation of the YOR1 transporter 11-fold (Table 2-2) predicts that azoleresistant F15 should be cross-resistant to oligomycin, an inhibitor of mitochondrial F1F0
ATPase and known S. cerevisiae Yor1p substrate. This was confirmed by broth
microdilution assay (MIC = 0.5 μg/ml for F15 vs. 0.125 μg/ml for parent 66032), using
medium with glycerol as respiratory carbon source. Yor1p also confers tolerance in S.
cerevisiae to a wide range of organic anions such as leptomycin B and acetic acid, along
with cadmium (47). PDR12, downregulated fivefold in F15, similarly encodes an efflux
pump with specificity for organic acids, in particular sorbic acid (170). Spot assays
(Figure 2-7) confirmed sorbate hypersensitivity of F15, although the effects on MIC were
modest (4 mM for F15 vs. 8 mM for 66032). With respect to organic acid sensitivity,
PDR12 downregulation may be largely offset by YOR1 upregulation. There was no
detectable change in sensitivity to acetic, boric, or lactic acids (MICs = 64, 16 and 250
mM respectively).
YML131W and YNL134C homologs were similarly upregulated approximately
nine-fold in F15. As noted above, the products of these uncharacterized genes share a
domain characteristic of alcohol dehydrogenases/oxidoreductases; furthermore, they are
co-regulated in response to environmental stresses including heat shock and treatment
with reactive oxygen species or ethanol (Expression Connection, SGD website).
Conversely, catalase gene CTA1 was downregulated 2.5-fold. Consistent with this, F15
demonstrated hypersensitivity to hydrogen peroxide by spot assay (Figure 2-7) and broth
microdilution (MIC = 16 mM vs. 32 mM for 66032). Similarly, F15 demonstrated
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Figure 2-7. Spot assays examining sensitivity of 66032 and its azole-resistant mutant
F15 to hydrogen peroxide, ethanol and sorbic acid. Approximately 300 cells were spotted
on YPD agar with the indicated inhibitor. Plates were incubated for 2–4 days at 35°C. For
comparison, 66032Δpdr1, F15Δpdr1 and the 66032Δpdr1-PDR1 replacement strains
66032R and F15R were examined in parallel.
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hypersensitivity to ethanol (Figure 2-7; MIC = 2% vs. 4% for 66032). Equivalent results
were obtained with F15 PDR1 replacement clone F15R as compared with wild-type
PDR1 replacement clone 66032R (Figure 2-7), confirming that these altered phenotypes
resulted from the PDR1 gain-of-function mutation. (Note that the ura3 phenotype of
66032R can account for its variable growth relative to 66032, an effect also observed
with the 66032 ura3 strain; not shown.) Finally, we examined sensitivity to heat shock by
exposing mid-log or early stationary phase cultures to 50°C for 10 min, following by
plating on YPD with incubation at 35°C for 3 days to obtain colony counts. For F15
versus 66032, viability was 6 versus 0.3% and 16 versus 5% in log and stationary phase
cultures respectively. Taken together, these data suggest that regulatory mutations
conferring azole resistance in C. glabrata may have both positive and negative effects on
fitness and virulence.
CONCLUSIONS
An important 'virulence factor' for the emerging opportunist C. glabrata appears
to be its capacity for intrinsic low-level and acquired high-level azole resistance. The
studies completed here with laboratory mutant F15, and initial studies with representative
clinical isolates, identify the zinc-cluster transcriptional activator CgPdr1p as a key
regulator of azole/multidrug transporter genes CgCDR1 and CgPDH1. Constitutive
upregulation of these genes is observed in most azole-resistant clinical isolates;
furthermore, they are transiently upregulated in sensitive isolates following azole
exposure. Consistent with this, in PDR1 disruptants acquired resistance was reversed and
intrinsic resistance was reduced. We have shown that F15 CgPdr1p has a gain-offunction mutation analogous to those previously characterized in S. cerevisiae Pdr1p–
Pdr3p, and this mutation is sufficient to confer azole resistance. CgPdr1p mutation is not,
however, necessary for resistance, because at least one resistant strain analyzed had
unchanged CgPDR1(216). Azole resistance may potentially arise from mutations in
upstream signaling proteins or transcription cofactors, both of which remain to be defined
(although histone modifying enzymes represent likely cofactors). Moreover, we observed
here that PDR1 disruptants, although azole hypersensitive, continued to yield
spontaneous azole-resistant mutants at reduced frequency. These Pdr1p-independent
resistance mechanisms, and their clinical relevance, warrant further study.
Microarray analysis of genome-wide gene expression has become a central tool in
molecular genetics, and the arrays developed and tested here should be particularly useful
in studies of C. glabrata in large part because of its close evolutionary relatedness to S.
cerevisiae. Most genes with altered expression in F15 had well-characterized S.
cerevisiae homologs. This allowed us to predict F15 phenotypes, a number of which were
tested including sensitivity to organic acids, alcohols and oxidants. Ultimately, these data
should help us to understand and possibly exploit the consequences for C. glabrata of
regulatory mutations leading to azole resistance. F15 hypersensitivity to hydrogen
peroxide is of particular interest, because this implies hypersensitivity to immune cells
such as neutrophils and environments such as the lactobacillus-colonized vaginal tract in
which hydrogen peroxide plays an important role. Although the relatedness of C.
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glabrata and S. cerevisiae is invaluable in terms of predicting gene function, microarray
analysis indicated that the Pdr1p and Pdr1p-Pdr3p gain-of-function mutants of these
yeasts are more different than similar. This no doubt reflects the very different pressures
placed on these organisms by their very different niches; e.g. the skin of a grape versus
the human mucosa.
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CHAPTER 3. GENOME-WIDE EXPRESSION PROFILE ANALYSIS OF THE
CANDIDA GLABRATA PDR1P REGULON
INTRODUCTION
Over the past two decades, there has been an increase in Candida infections
caused by non-albicans species with Candida glabrata being the second most common
cause of mucosal and invasive fungal infections in humans (162). Development of highlevel resistance to the azoles, the most widely-used antifungal class for treatment of
Candida infections, has been reported in C. glabrata oral and bloodstream isolates from
head and neck radiation patients, stem cell transplant patients, and human
immunodeficiency virus (HIV) patients (21, 175, 185). Furthermore, the development of
azole resistance has been implicated in the fluconazole treatment failure and death of a
patient suffering from C. glabrata candidemia (122).
Studies to determine the mechanisms of high level azole resistance in C. glabrata
have demonstrated frequent constitutive over-expression of the ATP-binding cassette
(ABC) transporters, CgCDR1, CgPDH1, and CgSNQ2, all of which contribute to this
phenotype (135, 175, 185, 210, 216). These transporters are regulated by the zinc
binuclear cluster transcription factor Pdr1p, a single-gene homologue of Saccharomyces
cerevisiae Pdr1p and Pdr3p heterodimeric transcription factor (215, 216). CgPDR1,
CgCDR1, CgPDH1, and CgSNQ2 all contain at least one pleiotropic drug response
element sequence (PDRE) in their promoters suggesting CgPdr1p may regulate its own
expression, as well as that of the transporters, through binding these regulatory elements
(210, 215). Recently it was shown that C. glabrata Pdr1p (and S. cerevisiae Pdr1p)
directly bind to fluconazole resulting in activation of drug efflux pumps, a mechanism
similar to regulation of multidrug resistance (MDR) by the PXR nuclear receptor in
vertebrates (207). Furthermore, single point mutations in the putative functional domains
of CgPDR1 result in increased transcription of CgCDR1, CgPDH1, and CgSNQ2 as well
as increased resistance to azoles (68, 212, 215). A recent study demonstrated a high
variability in these mutations and showed the Pdr1p gain-of-function mutations not only
have an effect on azole susceptibility but also virulence (68). Collectively these studies
indicate that Pdr1p is uniquely important to the ability of C. glabrata to not only resist
antifungal therapy but to also cause disease.
With these aforementioned studies in mind, we endeavored to delineate the core
genes of the Pdr1p regulon by first using genome-wide gene expression profiling to
identify genes co-regulated with CgCDR1 among clinical matched azole-susceptible and
–resistant C. glabrata isolates. We then identified mutations in CgPDR1 among these
clinical isolates that conferred resistance to fluconazole. Gene expression profiling was
again used to identify genes that were differentially expressed in the presence of these
mutations. Our results identified a more comprehensive picture of the molecular effects
of Pdr1p mutations in azole-resistant isolates and suggest other cellular functions in C.
glabrata.
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MATERIALS AND METHODS
Antifungal Agents
Fluconazole was obtained from MP Biomedicals (Solon, Ohio). Stock solutions of
10 mg/ml were made in dimethyl sulfoxide (DMSO, Sigma; St. Louis, Missouri) and
stored at -20˚C.
Strains and Growth Media
The isolates and strains used in this study are listed in Table 3-1. Three of these
matched fluconazole-susceptible and -resistant clinical isolate sets have been described
previously (122, 175, 209). Clinical isolates 62-16 and 62-17 were kindly provided by
Dr. John Mohr at the University of Texas Health Science Center, Houston, TX. All
isolates/strains used in these studies were grown in YPD (1% yeast extract, 2% peptone,
and 1% dextrose) broth at 30˚C and stored as 20% glycerol stocks at -80˚C. One Shot®
Escherichia coli TOP10 chemically competent cells (Invitrogen; Carlsbad, California)
were used as a host for plasmid construction and propagation. These strains were grown
in Luria-Bertani (LB) broth or on LB plates supplemented with 100 μg/ml ampicillin
(Sigma) or 50 μg /ml kanamycin (Fisher BioReagents; Fair Lawn, New Jersey) when
required.
Plasmid Constructions
All primer sequences are listed in Table 3-2. The CgPDR1 deletion cassette was
constructed as follows: The upstream flanking region, containing ~900 bp upstream as
well as the first 50 nucleotides of the PDR1 coding region, was amplified by PCR from
C. glabrata isolate SM1 genomic DNA with the primers CgPDR1A and CgPDR1B.
Likewise, the downstream flanking region of the PDR1 gene containing the last 50
nucleotides of the PDR1 coding region as well as ~900 bp downstream, was amplified by
PCR from genomic DNA from C. glabrata isolate SM1 using the primers CgPDR1C and
CgPDR1D. Each PCR product was cloned using the TA cloning® kit (Invitrogen) as per
the manufacturer’s instructions. The resulting downstream plasmid DNA was digested at
the introduced SacI and SacII restriction sites and cloned downstream of the SAT1flipper cassette in the corresponding SacI and SacII sites in plasmid pSFS2A (176) to
generate pPDR1CDS2. The upstream flanking sequence was digested at the introduced
ApaI and XhoI restriction sites and cloned upstream of the SAT1 flipper cassette in the
corresponding ApaI and XhoI sites in plasmid pPDR1CDS2 to generate pPDR1S2. The
PDR1 replacement cassette was constructed in the following manner: The PDR1 ORF
plus ~500 bp upstream and ~500 bp downstream of the PDR1 coding sequence was
amplified by PCR from genomic DNA from each C. glabrata clinical isolate using Pfu
DNA polymerase (Stratagene; La Jolla, California) with the primers CgPDR1E and
CgPDR1F. The resulting PCR product was cloned using the ZeroBlunt® TOPO®
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Table 3-1. C. glabrata isolates/strains used in this study.
Strain/Isolate
SM1
SM3
6856
6955
7754
7755
62-16
62-17
SM1∆pdr1
SM1∆PDR1SM1
SM1pdr1/ PDR1T2837C
SM1∆PDR16856
SM1pdr1/ PDR1G822T

Parent
-SM1
-6856
-7754
-62-16
SM1
SM1∆pdr1
SM1∆pdr1
SM1∆pdr1
SM1∆pdr1

Relevant characteristics or genotype
Clinical isolate, fluconazole susceptible
Clinical isolate, fluconazole resistant
Clinical isolate, fluconazole susceptible
Clinical isolate, fluconazole resistant
Clinical isolate, fluconazole susceptible
Clinical isolate, fluconazole resistant
Clinical isolate, fluconazole susceptible
Clinical isolate, fluconazole resistant
pdr1: : FRT
pdr1∆/PDR1 SM1-caSAT1
pdr1∆/PDR1 T2837C-caSAT1
pdr1∆/PDR1 6856-caSAT1
pdr1∆/PDR1 G822T-caSAT1

Reference
(122)
(175)
(209)
This study
This study
This study
This study
This study
This study
This study
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Table 3-2. Primers used in this study.
Primer/Gene

Primer paira,b

Amplicon
size (bp)

Primers used for plasmid construction
CgPDR1A
F, 5′-AAACATTTCCTCATAGggCccATCTTTTAC-3′ 1080
CgPDR1B
R, 5′-ATTACATTTTATTTTCCTCgagCTACAGC-3′
CgPDR1C
F, 5′-CACTTATAAccgcGGAACTTTAGATGAGT-3′ 1000
CgPDR1D
R, 5′-AACCCGATACTGagcTcTTAAGTAAGGA-3′
CgPDR1E
F, 5′-ATAATTGTGGGTAccACTAGGTATTAGG-3′ 4295
CgPDR1F
R, 5′-TATAATAAATGggCccATCAACGAAGGT-3′
Primers used for quantitative real-time PCR expression analysis
18S rRNA
F, 5′-TCGGCACCTTACGAGAAATCA-3′
R, 5′-CGACCATACTCCCCCCAGA-3′
F, 5′-TTTGACTCTGTTATGAGCGATTACG-3′
CgPDR1
R, 5′-TTCGGATTTTTCTGTGACAATGG-3′
F, 5′-CATACAAGAAACACCAAAGTCGGT-3′
CgCDR1
R, 5′-GAGACACGCTAACGTTCACCAC -3′
F, 5′-ACGAGGAGGAAGACGACTACGA-3′
CgPDH1
R, 5′-CTTTACTGGAGAACTCATCGCTGT-3′
F, 5′-CGTCCTATGTCTTCCTTACACCATT-3′
CgSNQ2
R, 5′-TTTGAACCGCTTTTGTCTCTGA-3′
Primers used for sequencing CgPDR1
CgPDR1seq
F, 5′-GGTAAAGTCATTCTTTAGCTACG-3′
R, 5′-TACAGGCTATGCACACTGTCT-3′
CgPDR1seqA1 F, 5′-GAAACTCCTATGTCCTCAACA-3′
CgPDR1seqA2 F, 5′-AAACTGATGAAAGAGACCT-3′
CgPDR1seqA3 F, 5′-ACATCTGTTGCTTCTTCTTGA-3′
CgPDR1seqA4 F, 5′-TAAAGAAGATACAGCAGCAGC-3′
CgPDR1seqA5 F, 5′-TCTACCTCCGATGCTTCTA-3′
CgPDR1seqB1 R, 5′-TACAGGAAGGCATTGACTTG-3′
CgPDR1seqB2 R, 5′-TCTGCCATATTGATTAGCCT-3′
CgPDR1seqB3 R, 5′-TTCAAAACCATAGTATTCGTCG-3′
CgPDR1seqB4 R, 5′-TGGCTCATAAAGGTGAACAC-3′
CgPDR1seqB5 R, 5′-CAGAAAGACCTCTATGGCAT-3′
a
F, Forward; R, Reverse
b
Restriction sites introduced into primers are underlined.
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cloning kit (Invitrogen) as per manufacturer’s instructions. The resulting plasmid DNA
was digested at the introduced KpnI and ApaI sites and cloned upstream of the SAT1
flipper cassette in the corresponding KpnI and ApaI sites of plasmid pPDR1ABS2 to
generated pPDR1SM1S2 (containing the CgPDR1 gene from isolate SM1),
pPDR1SM3S2 (containing the CgPDR1 gene from isolate SM3), and pPDR16955S2
(containing the CgPDR1 gene from isolate 6955).
PDR1 Gene Disruption and Replacement by the SAT1-Flipper Method
Gene disruption and replacement was performed via the SAT1-flipper method
described by Reuss et al. (2004). C. glabrata cells were transformed by the lithium
acetate method (12) using about 1 μg DNA. Transformants were selected on YPD agar
containing 200 μg/ml nourseothricin (Nou200) as described previously (176). The correct
genomic integration was confirmed by Southern hybridization. Subsequently, correct
integrants were grown in YPD for 6-24 hours in order to induce expression of the flipper
recombinase (FLP gene). Individual colonies were replica plated on both YPD agar and
YPD + Nou200 agar plates to select for cells in which successful excision of the SAT1flipper cassette had taken place; further confirmation of cassette excision was performed
by Southern hybridization.
Isolation of Genomic DNA and Southern Hybridization
Genomic DNA from C. glabrata was isolated as previously described (134). For
confirmation by Southern hybridization, approximately 10 μg of genomic DNA was
digested with the appropriate restriction enzymes, separated on a 1% agarose gel
containing ethidium bromide, transferred by vacuum blotting onto a nylon membrane and
fixed by UV-crosslinking. Hybridization was performed with the Amersham ECL Direct
Nucleic Acid Labeling and Detection System (GE Healthcare; Little Chalfont
Buckinghamshire, UK) as per manufacturer’s instructions.
Drug Susceptibility Tests
Microdilution broth susceptibility testing was performed in duplicate according to
the CLSI M27-A3 method in RPMI 1640 (Sigma) growth medium buffered with MOPS
(Sigma). Microtiter trays containing serial dilutions of fluconazole were inoculated and
incubated at 37˚C, and the minimum inhibitory concentration (MIC) was read at 24 and
48 hours. The MIC was defined as the lowest concentration of drug that causes a
significant decrease in turbidity (> 50%) compared to growth control. Candida krusei
ATCC 6258 served as the quality control isolate.
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Culture Growth for Microarray Experiments
For microarray performed on clinical isolates, one colony was grown overnight in
YPD. Cells were then grown to mid-log phase (OD600 = 0.6-1.0) in 200 ml YPD and were
harvested by centrifugation at 3,500 x g at 4˚C for 5 minutes. The medium was
completely removed by aspiration and the cell pellets were stored at -80˚C until RNA
preparation.
RNA Preparation for Microarrays
Total RNA was isolated using the hot phenol method (190). Cells were suspended
in 12 ml AE buffer (50 mM sodium acetate (pH 5.2), 10 mM EDTA), 800 μl 25% sodium
dodecyl sulphate, and 12 ml acid phenol (Fisher Scientific) was added. This mixture was
incubated for 10 min at 65˚C, vortexing every minute, stored on ice for 5 min, and
subjected to centrifugation for 15 minutes at 12 000 x g. Supernatants were transferred to
new tubes containing 15 ml chloroform, mixed, and subjected to centrifugation for 10
minutes at 200 x g. The aqueous layer was transferred to a new tube containing 0.1
volume 2M sodium acetate and 1X volume room temperature isopropanol and mixed.
Total RNA was then collected by centrifugation at 17 000 x g for 40 minutes at which
point the supernatant was discarded. The RNA pellet was washed with 5 ml 70% ethanol,
and the resulting RNA was suspended in diethyl pyrocarbonate (DEPC)-treated water.
Microarray cRNA Synthesis and Hybridization
C. glabrata microarrays were constructed as described previously (215). These
custom Affymetrix NimbleExpress Arrays were manufactured by NimbleGen Systems
per our specification (4). Two independent sets of RNA were used in these studies to
prepare two independent cDNA samples. The purity and concentration of the RNA was
examined by capillary electrophoresis using the RNA 6000 Nano laboratory-on-a-Chip
kit and Bioanalyzer 2100 (Agilent Technologies; Waldbronn, Germany) as per
manufacturer’s instructions. Fifteen μg total RNA was used for first- and second-strand
cDNA synthesis using the SuperScript Double-Stranded cDNA synthesis kit (Invitrogen)
and an oligo-dT24-T7 primer (Sigma) according to the manufacturer’s instructions.
Using the T7 promoter-coupled double stranded cDNA as a template and the Bioarray
High Yield RNA Transcript labeling kit (ENZO Diagnostics; Farmingdale, NY), cRNA
was synthesized and labeled with biotinylated-UTP and -CTP by in vitro transcription.
The synthesized double stranded cDNA was washed twice with 70% ethanol and
suspended in 22 μl of DEPC-treated water. Reaction buffer, biotin-labeled
ribonucleotides, dithiothreitol, RNase inhibitor mix and T7 RNA polymerase were added
to the cDNA and incubated for 5 hours at 37˚C. The labeled cRNA was purified using a
CHROMA SPIN-100 column (Clontech; Mountain View, CA) and precipitated with
ethanol overnight at -20˚C.
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After the cRNA pellet was suspended in 10 μl of RNase-free water, 10 μg was
fragmented by ion-mediated hydrolysis at 95˚C for 35 min in 100 mM Tris-acetate (pH
8.1), 500 mM potassium acetate, 150 mM magnesium acetate. Using the Affymetrix
Fluidics Station 450 and its standard EukGEWS2v5 protocol, the fragmented cRNA was
hybridized to the C. glabrata NimbleExpress GeneChip arrays for 16 hours at 45˚C and
then washed at 25˚C with 6X SSPE (1X SSPE: 0.18M NaCl, 10 mM NaH2PO4, 1 mM
EDTA (pH 7.7)) + 0.01% Tween-20 followed by a stringent wash at 50˚C with 100 mM
MES (2-(N-morpholino)ethanesulfonic acid), 0.1 M NaCl, 0.01% Tween-20. The arrays
were stained with phycoerythrein-conjugated streptavidin (Molecular Probes; Eugene,
OR) and the fluorescence intensities were determined using the GCS 3000 highresolution confocal laser scanner (Affymetrix, Santa Clara, CA). These images were
analyzed using software resident in GeneChip Operating System v2.0 (GCOS;
Affymetrix). Sample loading and variations in staining were standardized by scaling the
average of the fluorescent intensities of all genes on an array to a constant target intensity
of 250. The signal intensity for each gene was calculated as the average intensity
difference, represented by [Σ(PM – MM)/number of probe pairs)], where PM and MM
denote perfect-match and mismatch probes.
Microarray Data Analysis
The scaled gene expression values from GCOS software were processed and
analyzed using GeneSpring 7.2 software (Agilent Technologies). Probe sets were
removed from analysis if they were called absent by the Affymetrix criterion and
displayed an absolute value below 20 in all experiments. The expression value of each
gene was normalized to the median expression of all genes in each chip as well as the
median expression of that gene across all chips in the study. Pairwise comparison of gene
expression was performed for each matched experiment.
Quantitative Real-Time RT-PCR
An aliquot of RNA samples used in the microarray experiments was saved for
follow-up quantitative RT-PCR studies along with a set of independently-obtained RNA
samples from the same strains analyzed by microarray. First strand cDNAs were
synthesized from 2 μg total RNA using the SuperScript First-Strand Synthesis System for
RT-PCR (Invitrogen) as per the manufacturer’s instructions. All quantitative real-time
PCR experiments were performed in triplicate using the 7000 Sequence Detection
System (Applied Biosystems, Inc.; Foster City, CA). Independent PCRs were performed
using the same cDNA for both the gene of interest and 18S rRNA, using the SYBR
Green PCR Master Mix (Applied Biosystems). Gene-specific primers were designed for
the gene of interest and 18S rRNA using Primer Express software (Applied Biosytems).
The PCR conditions were as follows: AmpliTaq Gold activation at 95˚C for 10 minutes,
40 cycles of a combination of denaturation at 95˚C for 15s and annealing/extension at
60˚C for 1 min. A dissociation curve was generated at the end of each cycle to verify that
a single product was amplified using the software provided with the 7000 Sequence
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Detection System. The system software monitored the change in fluorescence of SYBR
Green I dye in every cycle, and the threshold cycle (CT) above background for each
reaction was calculated. The CT value of 18S rRNA was subtracted from that of the gene
of interest to obtain ∆CT value. The ∆CT of an arbitrary calibrator (e.g. fluconazolesusceptible isolate or untreated sample) was subtracted from the ∆CT value of each
sample to obtain a ∆∆CT value. The gene expression level relative to the calibrator was
expressed as 2-2∆∆CT. Statistical analysis was performed using Microsoft Office Excel
2007. Relative changes were compared using the Student’s t-test. The statistical
significance threshold was fixed at α -0.05.
Sequence Analysis of C. glabrata CgPDR1
PDR1 coding sequences were amplified by PCR (Pfu DNA polymerase;
Stratagene) of C. glabrata genomic DNA using the primers PDR1seqF and PDR1seqR
(Table 3-2). Products were cloned into pCR-BLUNTII-TOPO® using the Zero Blunt®
TOPO® PCR Cloning Kit (Invitrogen) and transferred into E. coli TOP10 cells with
selection on LB agar plates containing 50 μg/ml kanamycin. Plasmid DNA was purified
(QIAprep®; Qiagen; Germantown, MD) and sequenced on the ABI Model 3130XL
Genetic Analyzer using the universal primers M13R and T7 and a set of ten primers
(Table 3-2) that span both strands of the PDR1 coding sequence. The sequencing was
performed using three sets of clones derived from three independent PCRs for each
strain/isolate sequenced.
RESULTS
Genes Coregulated with CgCDR1 among Matched Sets of Clinical Isolates
As over-expression of CgPDR1 and several efflux pump genes regulated by
Pdr1p (CgPDR1, CgCDR1, CgPDH1, and CgSNQ2) have previously been shown to be a
mechanism of high-level azole resistance (21, 185, 210, 215), we first examined
expression of these genes by real-time RT-PCR in four azole-resistant C. glabrata
isolates as compared to their azole-susceptible parents. Genes were considered to be
differently expressed if the expression of that gene changed by at least ≥ 1.5 in the
resistant isolate when compared to the matched susceptible isolate in three independent
experiments. We observed distinctly different expression patterns for CgPDR1,
CgCDR1, CgPDH1, and CgSNQ2 in each of the azole-resistant isolates we examined
(Figure 3-1). For example, CgPDR1 and CgPDH1 were upregulated in isolates SM3, 6217, 7755, but not 6955, CgCDR1 was upregulated in all four of the clinical azole-resistant
isolates, and CgSNQ2 was only upregulated in isolate SM3.
Because CgCDR1 was upregulated in all four azole-resistant isolates, we analyzed
the genome-wide gene expression profiles of each isolate pair using microarray analysis
in order to identify genes co-regulated with this transporter gene. Two independent RNA
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Gene Expression
(Relative Fold Change)
Log 2 scale

Set 1

Set 2

Set 3

Set 4

Figure 3-1. Quantitative real-time RT-PCR analysis of CgPDR1, CgCDR1, CgPDH1,
and CgSNQ2 in SM3 versus SM1 (Set 1), 62-17 versus 62-16 (Set 2), 7755 versus 7754
(Set 3), and 6955 versus 6856 (Set 4). Data are shown as mean +/- standard error.
Relative changes were compared using the Student’s t-test. Gene expression values with
an asterisk indicate statistical significance (P < 0.05) in all three experiments.
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samples per isolate were hybridized to custom C. glabrata Affymetrix microarrays and
analyzed as detailed in the Materials and Methods section. Genes were considered to be
differentially expressed if the expression of that gene changed by at least ≥ 1.5 in the
resistant isolate when compared to the matched susceptible isolate in both independent
experiments. There were 495 upregulated genes and 477 down-regulated genes in isolate
SM3 compared to isolate SM1, 463 upregulated genes and 386 down-regulated genes in
isolate 6955 compared to isolate 6856, 599 upregulated genes and 592 down-regulated
genes in isolate 7755 compared to isolate 7754, and 181 upregulated genes and 152
down-regulated genes in isolate 62-17 compared to isolate 62-16 (Figure 3-2). Genes that
were upregulated and down-regulated in at least three of the four clinical isolate sets are
listed in Tables 3-3 and 3-4, respectively.
Of all the genes identified in the gene expression profiles for these four matched
pairs, there were nine genes that were commonly coordinately upregulated with
CgCDR1: YOR1, LCB5, RTA1, YIM1, YIL077c, POG1, HFD1, GLK1, and FMS1. One of
these genes encodes the homolog of S. cerevisiae Yor1p, which like CgCDR1 is a plasma
membrane ABC transporter. Another encodes the homolog of S. cerevisiae Lcb5p which
is a minor sphingoid long-chain base kinase involved in synthesis of long-chain base
phosphates which function as signaling molecules (144). RTA1, YIM1, and YIL077c are
homologs of S. cerevisiae genes and encode molecules involved in stress response. For
example, the S. cerevisiae homolog of RTA1 is involved in 7-aminocholesterol resistance
(201). In addition to the aforementioned upregulated genes, there were three downregulated genes common to all four sets of clinical isolates. These include the
uncharacterized gene CAGL0A03608g and homologs of S. cerevisiae SNG1 and SUR7.
There were 43 genes upregulated in at least three of the clinical matched sets of
isolates. Among these genes were CgPDR1 and the ABC transporter, CgPDH1, both
consistent with our real-time RT-PCR results. In addition to CgPDH1, there were two
other upregulated genes encoding transporters, namely, YBT1 and QDR2. Also,
upregulated in this set were RPN4 and YMR102c, genes whose S. cerevisiae homologs
were previously shown to be ScPdr1p and ScPdr3p targets (8, 157). Other notable genes
upregulated in at least three sets included MNT3 and MKC7, whose S. cerevisiae
homologs are involved in cell wall function, and YMR102c and YML131w, each encoding
putative alcohol dehydrogenases involved in stress responses. There were 16 genes
down-regulated in at least three of the matched sets; among these are genes encoding the
major facilitator transporters HXT3 and FLR1, genes encoding cell wall organization
molecules UTR1 and ZEO1, the cytochrome c oxidase gene COX12, and the ironregulating gene FRA2.
Identification of PDR1 Mutations in Azole Resistant Clinical Isolates
The findings that the expression of CgCDR1 and CgPDH1 as well as homologs of
other known S. cerevisiae Pdr1p and Pdr3p targets were increased in many of the
fluconazole-resistant clinical isolates suggested that the resistant isolate in each set may
contain CgPDR1 gain-of-function mutations. We therefore sequenced the CgPDR1gene

56

Figure 3-2. Venn Diagram showing the number of genes that are upregulated (A) or
down-regulated (B) in the fluconazole-resistant isolates SM3, 62-17, 7755, and 6955 as
compared to their matched fluconazole-susceptible isolates SM1, 62-16, 7754, and 6856,
respectively.
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Table 3-3. Genes upregulated in all four of the clinical matched isolate sets (A) and in at least three of the clinical matched sets (B, C,
D, and E).
Letter
designationc

Systematic
name

S. cerevisiae
homologa

C. glabrata
designation

Descriptionb

A
A
A
A
A
A
A
A
A
A
B
B
B
B
B
B
B
B
C
D
D
D
D
D
E
E
E

IPF1617
IPF2180
IPF3783
IPF5152
IPF6116
IPF6352
IPF8922
IPF9036
IPF9610
IPF8678
IPF2441
IPF2464
IPF3052
IPF5973
IPF7416
IPF926
IPF3655
IPF8402
IPF8399
IPF1455
IPF4638
IPF8257
IPF4699
IPF6780
IPF119
IPF1620
IPF1748

POG1
HFD1
GLK1
RTA1
YIL077c
PDR5 (CDR1)
YOR1
YIM1
FMS1
LCB5
IMH1
ECM29
YCR061w
FLO10 (EPA1)
RSE1
MNT3
YLR177w
MKC7
YAP3
MAG1
CAK1
YPT52
DOG2
YNL305c
DDR48
QDR2
YML018c

CAGL0G08646g
CAGL0K03509g
CAGL0F00605g
CAGL0K00715g
CAGL0M12947g
CAGL0M01760g
CAGL0G00242g
CAGL0M09713g
CAGL0M07612g
CAGL0K05995g
CAGL0E03454g
CAGL0E03828g
CAGL0K09218g
CAGL0E06644g
CAGL0L01507g
CAGL0C03916g
CAGL0B01078g
CAGL0E01837g
CAGL0E01793g
CAGL0I06809g
CAGL0K12496g
CAGL0G07689g
CAGL0D04092g
CAGL0M03839g
CAGL0H08844g
CAGL0G08624g
CAGL0F03641g

Putative transcriptional activator
Putative fatty aldehyde dehydrogenase
Glucokinase
Protein involved in 7-aminocholesterol resistance
Putative protein of unknown function
Plasma membrane ATP-binding cassette (ABC) transporter
Plasma membrane ATP-binding cassette (ABC) transporter
Protein of unknown function
Polyamine oxidase
Minor sphingoid long-chain base kinase
Protein involved in vesicular transport
Major component of the proteasome
Protein of unknown function
Lectin-like protein with similarity to Flo1p, thought to be involved in flocculation
Protein involved in pre-mRNA splicing
Alpha-1,3-mannosyltransferase
Putative protein of unknown function
GPI-anchored aspartyl protease (yapsin) involved in protein processing
Aspartic protease
3-methyl-adenine DNA glycosylase
Cyclin-dependent kinase-activating kinase
GTPase
2-deoxyglucose-6-phosphate phosphatase
Putative protein of unknown function
DNA damage-responsive protein
Multidrug transporter of the major facilitator superfamily
Putative protein of unknown function
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Table 3-3 (continued).

a

Letter
designationa

Systematic
name

S. cerevisiae
homologb

C. glabrata
designation

Descriptionc

E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E

IPF2196
IPF2382
IPF2392
IPF3019
IPF3173
IPF3325
IPF3846
IPF3875
IPF4064
IPF4550
IPF4605
IPF4884
IPF5076
IPF6034
IPF6722
IPF734
IPF7414
IPF7952
IPF7953
IPF8009
IPF9549
IPF9719
IPF982
IPF558
IPF6631
IPF6862

YMR102c
YNL234w
ZWF1
N/A
YNL134c
PDR1
NCE3
N/A
AIM6
UTH1
YML131w
ATF2
RPN4
ADH6
MET2
MET3
EFF2
YNL144c
IRC24
YJL163c
FLO1
PDR15 (PDH1)
YBT1
EAR1
CPS1
WTM2

CAGL0K03377g
CAGL0J07502g
CAGL0J07612g
CAGL0A01650g
CAGL0K09702g
CAGL0A00451g
CAGL0G01540g
CAGL0G01122g
CAGL0C05533g
CAGL0L05434g
CAGL0K12958g
CAGL0D05918g
CAGL0K01727g
CAGL0M14047g
CAGL0J08316g
CAGL0B03839g
CAGL0L01485g
CAGL0J05830g
CAGL0J05852g
CAGL0M08426g
CAGL0E00209g
CAGL0F02717g
CAGL0C03289g
CAGL0F07799g
CAGL0C00319g
CAGL0J03960g

Protein of unknown function
Similar to globins and has a functional heme-binding domain
Glucose-6-phosphate dehydrogenase (G6PD)
Uncharacterized
Putative protein of unknown function
Zinc-cluster transcription factor
Carbonic anhydrase
Uncharacterized
Putative protein of unknown function
Mitochondrial outer membrane and cell wall localized SUN family member
Putative protein of unknown function
Alcohol acetyltransferase
Transcription factor that stimulates expression of proteasome genes
NADPH-dependent medium chain alcohol dehydrogenase
L-homoserine-O-acetyltransferase
ATP sulfurylase
ER localized integral membrane protein
Putative protein of unknown function
Putative benzil reductase
Putative protein of unknown function
Lectin-like protein involved in flocculation
Plasma membrane ABC transporter
Transporter of the ABC family involved in bile acid transport
Specificity factor required for Rsp5p-dependent ubiquitination
Vacuolar carboxypeptidase yscS
Transcriptional modulator

Letters correspond to Figure 3-2A.
Parentheses indicate a previously named C. glabrata gene.
c
Descriptions of S. cerevisiae homologs (see SGD website http://www.yeastgenome.org).
b
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Table 3-4. Genes down-regulated in all four of the clinical matched isolate sets (A) and in at least three of the clinical matched sets
(C, D, and E).
Letter
designationa

Systematic
name

S. cerevisiae
homolog

C. glabrata
designation

Description b

A
A
A
C
D
D
D
D
D
D
D
D
D
D
D
E
E
E
E

IPF1222
IPF1568
IPF7418
IPF14492
IPF1070
IPF14989
IPF1884
IPF2023
IPF2970
IPF3326
IPF4392
IPF453
IPF8122
IPF126
IPF3165
IPF14693
IPF3506
IPF9174
IPF9228

N/A
SNG1
SUR7
N/A
UTR2
COX12
CIT1
NDH1
HXT3
PUF4
FLR1
FET3
PNS1
PUF2
SHE2
FRA2
FMP45
ZEO1
BUD22

CAGL0A03608g
CAGL0G09273g
CAGL0L01551g
CAGL0I00550g
CAGL0C02211g
CAGL0A03542g
CAGL0H03993g
CAGL0I00748g
CAGL0A02321g
CAGL0A00473g
CAGL0H06017g
CAGL0F06413g
CAGL0L04378g
CAGL0H08778g
CAGL0K07612g
CAGL0I06985g
CAGL0G05566g
CAGL0E02255g
CAGL0M07678g

Uncharacterized
Protein involved in nitrosoguanidine (MNNG) resistance
Putative integral membrane protein
Uncharacterized
Cell wall protein that functions in the transfer of chitin to beta(1-6)glucan
Subunit VIb of cytochrome c oxidase
Citrate synthase
Mitochondrial external NADH dehydrogenase
Low affinity glucose transporter of the major facilitator superfamily
Member of the PUF protein family
Plasma membrane multidrug transporter of the major facilitator superfamily
Ferro-O2-oxidoreductase
Protein of unknown function
Member of the PUF protein family
RNA-binding protein that binds specific mRNAs and interacts with She3p
Protein involved in negative regulation of transcription of iron regulon
Integral membrane protein localized to mitochondria (untagged protein)
Peripheral membrane protein of the plasma membrane that interacts with Mid2p
Protein involved in bud-site selection

a

Letters correspond to Figure 3-2B.
Descriptions of S. cerevisiae homologs (see SGD website http://www.yeastgenome.org).

b
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from each of the susceptible and resistant isolates. Of the four resistant isolates, two
contained nucleotide changes in CgPDR1 as compared to their corresponding susceptible
parent isolates. Isolate SM3 contained a T2837C mutation which is predicted to result in
the amino acid substitution L946S, located in the putative transcriptional activation
domain of Pdr1p as assumed by similarity with ScPdr1p and ScPdr3p (216). Isolate 6955
contained a G822T mutation which is predicted to result in the amino acid substitution
K274N, located near the putative inhibitory domain (Figure 3-3). Although no mutation
was found in the resistant isolate 62-17, the susceptible isolate 62-16 was found to
contain a nucleotide deletion, resulting in a frameshift which would presumably lead to a
truncated Pdr1p in this isolate. We also aligned the sequences from all published
CgPDR1 sequences from fluconazole-susceptible isolates and identified two mutations
unique to CgPdr1p in 62-16 and 62-17 that resulted in N768D and S888L amino acid
substitutions (68, 210, 212). Surprisingly, no PDR1 mutation was found in isolate 7755
when compared to the susceptible matched isolate 7754.
T2837C and G822T Are Gain-of-Function Mutations in CgPDR1 and Each Confer
Increased Resistance to Fluconazole
Single point mutations in CgPDR1 in C. glabrata have previously been shown to
play a role in azole resistance (68, 215). Therefore, to test whether the L946S and K274N
substitutions in CgPdr1p are responsible for the increase in fluconazole MIC in isolates
SM3 and 6955, respectively, we expressed the mutated CgPDR1 from SM3 and 6955 in
the isolate SM1 background. For this purpose, we deleted CgPDR1 from isolate SM1
using the SAT1-flipping method strategy to generate strain SM1pdr1(176). The mutated
CgPDR1 alleles, PDR1T2837C and PDR1G822T, were then introduced individually into the
CgPDR1 locus in strain SM1pdr1 to generate strains SM1pdr1/ PDR1L946S and
SM1pdr1/ PDR1K274N. We also created the corresponding control strains by introducing
CgPDR1 alleles from the susceptible isolates SM1 and 6856 to generate strains
SM1pdr1/ PDR1SM1 and SM1pdr1/ PDR16856. Replacement of the different CgPDR1
mutations was verified by sequencing the cloned CgPDR1 ORF PCR product as detailed
in the Materials and Methods section.
Introduction of the two PDR1 mutations into the susceptible background
(SM1pdr1) resulted in fluconazole MICs equivalent to those of the strains from which
each CgPDR1 was originally identified (Table 3-5). Specifically, introduction of
PDR1L956S resulted in a fluconazole MIC of 64 g/ml, and introduction of PDR1K274N
resulted in a fluconazole MIC of 16 g/ml; whereas, the fluconazole MICs of SM1pdr1/
PDR1SM1 and SM1pdr1/ PDR16856 were measured as 2 g/ml and 1 g/ml, respectively
(Table 3-5). As introduction of the CgPDR1 mutated alleles in the SM1 isolate
background resulted in increased fluconazole MICs as compared to introduction of the
alleles from isolates SM1 and 6856 in the same background, we have demonstrated that
these CgPDR1 gain-of-function mutations are responsible for conferring decreased
susceptibility to fluconazole in these C. glabrata isolates. Expression of the 62-17
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K274N W297S L328F R376W F575L

DB

ID

Y584C T588A T607S

P822L

MH

D876Y

P927L L946S D1082G

E1083Q

AD

Figure 3-3. Location of gain-of-function mutations found in previous studies (63, 197, 199, 202) and in the present study (bolded).
Putative DBD (DNA binding domain) and MHR (Middle homology region) were previously found by Pfam analysis (63). Putative
AD (transcriptional activation domain) and ID (inhibitory domain) were previously inferred by similarity with Pdr1p and Pdr3p from
S. cerevisiae (202). The region with diagonal lines corresponds to the xenobiotics binding domain (XBD) (194).
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Table 3-5. Fluconazole MICs for each of the revertant strains as compared to the parent strains.
Isolate set
1

Isolate names
SM1
SM1∆pdr1

WT MIC (μg/ml)
2
0.5

SM1∆pdr1/PDR1 MIC (μg/ml)

64
0.5

64

2

SM3
62-16

16
16

16

3

62-17
7254

> 64
1

N/A

4

7255
6856
6955

16

16

63

CgPDR1 allele in the susceptible background also showed an increase in fluconazole
resistance suggesting that this also represents a gain-of-function mutation (Table 3-5).
Identification of Putative CgPDR1 Target Genes
In order to identify putative CgPDR1 target genes whose expression is affected by
these gain-of-function mutations, we compared gene expression profiles of SM1pdr1/
PDR1T2837C and SM1pdr1/ PDR1G822T to SM1pdr1/ PDR1SM1 and SM1pdr1/
PDR16856, respectively. Again, two independent RNA samples per isolate were
hybridized to custom C. glabrata Affymetrix microarrays and analyzed as detailed in the
Methods section. Genes were considered to be differentially expressed if the expression
of that gene changed by at least ≥ 1.5 when compared to the strains expressing the wildtype CgPDR1 allele in the two independent experiments. There were142 genes were
upregulated in the reconstituted strain expressing PDR1T2837C and of these genes 39 were
also upregulated in SM3 compared to SM1. Thirty-four genes are upregulated in the
reconstituted strain expressing PDR1G822T, and of these genes only six were also
upregulated in 6955 compared to 6856. 626 genes were down-regulated in the
transformants expressing PDR1T2837C, and of these genes 58 are also down-regulated in
SM3 compared to SM1. Seventy-two genes are down-regulated in the transformants
expressing PDR1G822T, and of these, ten genes are also down-regulated in 6955 compared
to 6856. We defined putative core CgPdr1p target genes to be the genes that were not
only upregulated in the transformants but also in the clinical isolate sets. These are
summarized in Tables 3-6 and 3-7. As seen for SM3 compared to SM1, real-time RTPCR confirmed upregulation of CgCDR1, CgPDH1, and CgSNQ2 in SM1pdr1/
PDR1T2837Ccompared to SM1pdr1/ PDR1SM1. Also, as expected, real-time RT-PCR
confirmed upregulation of CgCDR1 but not CgPDH1 and CgSNQ2 in SM1pdr1/
PDR1G822T compared to SM1pdr1/ PDR16856 (Figure 3-4).
In order to determine which genes’ promoters contain a putative PDRE, the
promoter region (defined for this purpose as 1000 bp immediately upstream from the start
codon of the ORF) of each gene listed in Tables 3-6 and 3-7 was examined for a match to
the consensus S. cerevisiae PDRE. Twenty-two of the 39 genes in Table 3-6 and four of
the six genes in Table 3-7 contained at least one consensus sequence.
DISCUSSION
C. glabrata Pdr1p is the single-gene homolog of two S. cerevisiae zinc cluster
transcription factors ScPdr1p and ScPdr3p, which regulate the expression of genes
involved in multidrug resistance. ScPdr1p and ScPdr3p act by binding to PDREs in the
promoters of target genes (95). Furthermore, it has been found that ScPdr1p is
constitutively bound to its target DNA (65). In S. cerevisiae, gain-of-function mutations
in Pdr1p and Pdr3p can result in decreased susceptibility to fluconazole by up-regulation
of multidrug efflux pumps. In C. glabrata, CgPdr1p has been shown to regulate to
varying degrees the expression of the ABC transporter genes CgCDR1, CgPDH1, and
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Table 3-6. Genes upregulated in SM1pdr1/ PDR1L946S compared to SM1pdr1/ PDR1SM1as well as SM3 compared to SM1.
Expression
Group
Transport

Transcription
Response to
stress

Lipid
metabolism

Heterocycle
metabolism
Other

C. glabrata
designation

S. cerevisiae
homolog

Description

CAGL0G08624g
CAGL0I04862g
CAGL0M01760g
CAGL0G00242g
CAGL0J09900g
CAGL0F02717g
CAGL0C03289g
CAGL0A00451g
CAGL0L05434g
CAGL0K01727g
CAGL0H08844g
CAGL0I05874g
CAGL0J04202g
CAGL0M09713g
CAGL0E00209g
CAGL0D05918g
CAGL0K00715g
CAGL0M12947g
CAGL0I10120g
CAGL0H04653g
CAGL0E04334g
CAGL0J11770g
CAGL0A00429g
CAGL0F01793g
CAGL0I02970g
CAGL0M10219g
CAGL0K12100g
CAGL0M14047g
CAGL0K03509g
CAGL0K10164g
CAGL0M07942g

QDR2
SNQ2
PDR5
YOR1
POR1
PDR15
YBT1
PDR1
UTH1
RPN4
DDR48
RHR2
HSP12
YIM1
FLO1
ATF2
RTA1
YIL077c
AGA1
ERG6
ERG11
PLB1
ERG4
ERG3
ERG24
LAC1
HEM13
ADH6
HFD1
SED1
FRE8

MFS transporter
ABC transporter
ABC transporter
ABC transporter
Mitochondrial porin
ABC transporter
ABC transporter
Transcription factor
Mitochondrial outer membrane and cell wall protein
Transcription
DNA damage-responsive protein
DL-glycerol-3-phosphatase
Plasma membrane localized protein
Protein of unknown function
Lectin-like protein
Alcohol acetyltransferase
Protein involved in 7-aminocholesterol resistance
Putative protein of unknown function
Anchorage subunit of a-agglutinin of a-cells
Delta(24)-sterol C-methyltransferase
Lanosterol 14-alpha-demethylase
Phospholipase B
C-24(28) sterol reductase
C-5 sterol desaturase
C-14 sterol reductase
Ceramide synthase component
Coproporphyrinogen III oxidase
NADPH-dependent medium chain alcohol dehydrogenase
Putative fatty aldehyde dehydrogenase
Major stress-induced structural GPI-cell wall glycoprotein
Protein with sequence similarity to iron/copper reductases

SM3
vs.
SM1
3.5
3.7
10.2
10.5
1.6
10.5
8.1
5.2
2.9
3.1
5.1
2.0
4.1
11.5
10.0
7.2
5.0
23.5
4.7
1.6
1.9
2.3
2.0
1.9
1.9
2.3
2.9
3.0
4.4
2.6
2.0

PDR1SM3
vs.
PDR1SM1
2.7
5.4
8.6
5.1
2.6
7.4
3.9
3.6
2.3
3.4
1.7
1.8
16.4
11.8
1.9
6.8
3.6
26.0
1.8
2.1
1.9
2.8
1.8
3.6
2.0
3.1
1.9
5.4
6.2
1.9
1.6

PDRE
848
218, 792
134, 227, 387, 515, 969
648
521, 557
450
557, 701
378, 394, 552
849
127, 179
292, 427
30, 195, 560, 722
300, 379
472, 502
_
754
_
226
531
218
1046
-
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Table 3-6 (continued).
Expression
Group
Biological process
unknown

C. glabrata
designation

S. cerevisiae
homolog

Description

SM3
vs.
SM1

CAGL0K09702g
CAGL0G02717g
CAGL0F01287g
CAGL0G01122g
CAGL0M08426g
CAGL0G07667g
CAGL0D06402g
CAGL0A04906g

YNL134c
SGA1
GAS5
N/A
YJL163c
PRY1
MET25
STA1

Putative protein of unknown function
uncharacterized
1,3-beta-glucanosyltransferase
uncharacterized
Putative protein of unknown function
Protein of unknown function
Methionine and cysteine synthase
GPI-anchored cell surface glycoprotein (flocculin)

13.0
2.5
1.7
4.2
9.1
2.2
4.9
25.9

PDR1SM3
vs.
PDR1SM1
7.6
2.6
5.8
3.9
3.3
2.2
1.7
11.7

PDRE
549
803, 793
450
-
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Table 3-7. Genes upregulated in SM1pdr1/ PDR1L946S compared to SM1pdr1/ PDR16856as well as 6955 compared to 6856.
Group
Transport
Response to stress
RNA metabolism
Other

S. cerevisiae
homolog

C. glabrata
designation

Description

PDR5
YOR1
YIM1
PRP39
FLO10
FLO5

CAGL0M01760g
CAGL0G00242g
CAGL0M09713g
CAGL0L01441g
CAGL0E06644g
CAGL0M14069g

Plasma membrane ABC transporter
ABC transporter
Protein of unknown function
U1 snRNP protein involved in splicing
Lectin-like protein
Lectin-like cell wall protein (flocculin)

Expression
6955 vs. PDR16955 vs.
6856
PDR16856
2.1
6.8
1.8
2.4
2.8
3.0
1.7
1.6
1.9
3.3
2.1
1.6

PDRE
969, 515, 387, 227, 134
648
179, 127
571
-
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Gene
Gene Expression
Expression
(Relative
(Relative Fold
Fold Change)
Change)
Log
Log 22 scale
scale

*

*
*

*

*
*

Set 1

Set 2

Set 4

Figure 3-4. Quantitative real-time RT-PCR analysis of CgPDR1, CgCDR1, CgPDH1,
and CgSNQ2 in SM1pdr1/ PDR1T2837Ccompared to SM1pdr1/ PDR1SM1 (Set 1),
SM1pdr1/ PDR162-17compared to SM1pdr1/ PDR162-16 (Set 2), SM1pdr1/ PDR1G822T
compared to SM1pdr1/ PDR16856 (Set 4). Data are shown as mean +/- standard error.
Relative changes were compared using the Student’s t-test. Gene expression values with
an asterisk indicate statistical significance (P < 0.05) in all three experiments.
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CgSNQ2 and has been shown to be responsible for azole resistance in this organism.
Recently, strains with CgPdr1p gain-of-function mutations were shown to not only result
in fluconazole treatment failure in a mouse model but also to result in increased virulence
in mice as compared to isolates with wild type alleles (68).
Previously, we examined the gene expression profile of a set of fluconazolesusceptible and laboratory-derived, fluconazole-resistant C. glabrata strains (215). In that
analysis, we identified genes co-regulated with CgCDR1 in the F15 fluconazole-resistant
strain which carries a CgPdr1p allele with a P927L amino acid substitution. In the present
study we delineated core genes of the Pdr1p regulon by first using genome-wide gene
expression profiling to identify genes co-regulated with CgCDR1 among four clinical
matched fluconazole-susceptible and –resistant C. glabrata isolate pairs. We identified
nine genes co-regulated with CgCDR1 in all four of the matched sets of clinical isolates.
Of these nine genes, six of these, HFD1, RTA1, YIL077c, LCB5, YOR1, and YIM1, were
also co-regulated with CgCDR1 in the laboratory-derived, fluconazole-resistant C.
glabrata strain. Likewise, of the three genes found to be down-regulated in all four of the
matched sets of isolates in this study, only one, SNG1, was found to be down-regulated in
strain F15. Also in this study we identified 43 genes upregulated in at least three sets of
clinical isolates. Of these, 13 genes, YLR177w, YPT52, PDR1, FLO1, YMR102c, RPN4,
QDR2, YBT1, ATF2, CgPDH1, YNL134c, YJL163c, and NCE3 were also upregulated in
strain F15. Likewise, of the 16 genes down-regulated in at least three sets, only one,
FLR1, was also down-regulated in strain F15. These findings suggest a broad repertoire
of genes regulated by Pdr1p, but with subsets of these genes being differentially regulated
possibly depending on how Pdr1p is activated.
Two novel gain-of-function mutations in CgPdr1p have been described in this
study. Not only do these mutated CgPDR1 alleles cause up-regulation of CgCDR1 when
expressed in a susceptible wild-type isolate, but they also result in the same fluconazole
MIC as the original isolate from which the mutated allele was identified. In previous
studies, 12 distinct experimentally confirmed activating CgPdr1p mutations from
fluconazole-resistant isolates have collectively been identified that lead to constitutive
up-regulation of ABC transporter genes as well as decreased susceptibility to fluconazole
(68, 210, 212, 216). Three of these mutations were found in the putative inhibitory
domain, four were found in the xenobiotic binding domain, and five were found in the
putative activation domain of CgPdr1p. Interestingly, when examined collectively, the
gain-of-function mutations identified in previous studies and the present study
demonstrate varying patterns of ABC transporter expression. For example, in one of the
previous studies, one gain-of-function mutation led to the over-expression of SNQ2 but
not CgCDR1 and CgPDH1 (210). In our study, we identified mutations resulting in an
amino acid substitution near the putative inhibitory domain (K274N) and in an amino
acid substitution in the putative activation domain (L946S) of Pdr1p (68, 216). The
K274N amino acid substitution resulted in up-regulation of CgCDR1, CgPDH1, and
CgSNQ2 while the L946S amino acid substitution resulted in up-regulation of only
CgCDR1. These findings suggest that different amino acid changes in CgPdr1p may each
result in the activation of a unique subset of genes. Like Pdr1p in S. cerevisiae, CgPdr1p
may bind constitutively to the promoters of a repertoire of genes and activate a subset of
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them based on the mechanism by which Pdr1p is activated (65). Gain-of-function
mutations in the activation domain may result in constitutive activation of CgPdr1p,
while mutations in the inhibitory domain may block inhibitory proteins from binding thus
allowing transcription of CgPDR1. Another possibility for constitutive activation of
CgPdr1p is gain-of-function mutations in the xenobiotic binding domain. It has been in
shown that Pdr1p in S. cerevisiae and C. glabrata bind directly to ketoconazole resulting
expression of ABC transporters. In the aforementioned studies, four mutations have been
identified in this domain; these gain-of-function mutations may allow for constitutive
activation of CgPdr1p without the binding of xenobiotics to this domain (68, 212).
Using genome-wide analysis of these different mutations in the same background
strain, we were able to identify a core set of Pdr1p activated genes that are co-regulated
with CgCDR1. YOR1, YIM1, CgPDR1, and YNL134c were all co-regulated with CgCDR1
specifically in the presence of both of these two mutations. In S. cerevisiae, YOR1
encodes an ABC transporter that is involved in oligomycin resistance (96), and YIM1 and
YNL134c encode proteins of unknown function; however, both genes may play a role in
the stress response to DNA damaging drugs (22, 115). All five of these genes contain at
least one PDRE in their promoters suggesting CgPdr1p may regulate their expression
through binding these regulatory elements. Of note, both YOR1 and YIM1 were also
upregulated in all four of the matched sets of clinical isolates. Further studies are needed
to determine if these genes contribute to fluconazole resistance.
Table 3-6 summarizes the genes found to be both upregulated due to the L946S
amino acid substitution and genes found to be upregulated in the resistant isolate SM3
when compared to the susceptible isolate SM1. We have defined these genes as the core
Pdr1p putative target genes activated in this resistant isolate. Interestingly, there were
several ABC transporters co-regulated with CgCDR1 by Pdr1p, including CgSNQ2,
CgPDH1, YOR1, and YBT1. Also, upregulated was the MFS transporter, QDR2. All of
these transporters contain at least one PDRE in their promoter region. The role of
CgCdr1p, CgPdh1p, and CgSnq2p in azole resistance has been established in C. glabrata
(90, 210, 215). In the first of these studies, disruption of CgPDR1 in a resistant C.
glabrata isolate resulted in fluconazole hypersusceptibility with an MIC of 2 g/ml,
whereas the susceptible isolate had an MIC 16 g/ml; however, disruption of CgCDR1 in
this same strain resulted in an MIC of 16 g/ml (215). This suggested CgPdr1p targets
other than CgCDR1 play a role in the fluconazole resistance. Indeed, disruption of
CgSNQ2 in a fluconazole-resistant clinical isolate that does not over-express CgCDR1 or
CgPDH1 decreased azole resistance (210). Furthermore, disruption of CgPDH1 in a
fluconazole resistant strain had no effect on susceptibility to fluconazole; however,
restoring CgPDH1 expression in a mutant disrupted for both CgCDR1 and CgPDH1
decreased susceptibility to fluconazole as compared to the double disruptant. The role of
YBT1 and QDR2 in fluconazole resistance has yet to be studied in C. glabrata.
In S. cerevisiae, Upc2p is a zinc-cluster protein known to not only regulate
expression of ergosterol biosynthesis genes, including the target of the azoles encoded by
the gene ERG11, but also genes encoding proteins involved in exogenous sterol uptake,
cell wall mannoproteins (DAN/TIR genes), as well Upc2p itself (224). Interestingly,
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UPC2 as well as its known S. cerevisiae homolog target genes, ERG11, ERG3, AUS1,
DAN4, TIR3, and TIR4 are upregulated in SM3 (1, 217, 224). Also upregulated in isolate
SM3 are the zinc-cluster protein-encoding genes HAP1 and STB5. In S. cerevisiae, HAP1
encodes a transcription factor that regulates expression of the ERG11 gene, and it has
been postulated that this may occur by an interaction with Upc2p (213, 217). In S.
cerevisiae, STB5 also encodes a transcription factor that has been identified as a regulator
of ergosterol biosynthesis as it is a direct activator of ERG11 in the presence of oxidative
stress (114). Based on the hypothesis that mutations in one of these transcription factors
may be responsible for the over-expression of ERG11 in SM3, we sequenced both UPC2
S. cerevisiae homologs (CAGL0C01199g and CAGL0G07018g), ERG11
(CAGL0E04334g), HAP1 (CAGL0K05841g), and STB5 (CAGL0I02552g) from isolates
SM1 and SM3. However, no mutations were found in these genes in SM3 as compared to
SM1 (data not shown). Surprisingly, several genes encoding proteins involved in the
ergosterol biosynthetic pathway were also found to be CgPdr1p-dependent unique to this
gain-of-function mutation including ERG11 and four enzymes downstream from Erg11p
in this biosynthetic pathway encoded by the genes ERG24, ERG6, ERG3, and ERG4. Of
these only ERG24 contains a PDRE in its promoter region. Further study will be needed
to determine if ERG11 is directly or indirectly regulated by this hyperactive CgPDR1
allele.
Other genes found to be Pdr1p-dependent unique to this gain-of-function mutation
included the S. cerevisiae homolog of the transcription factor RPN4 which also contains
two PDREs in its promoter. In S. cerevisiae, RPN4 is a transcription factor whose
expression is dependent on ScPdr1p and ScPdr3p, that stimulates expression of
proteasome genes, and is required for normal cell tolerance to various cytotoxic
compounds including cycloheximide, a known ABC transporter substrate (157). Together
these findings suggest the proteosome may be influenced by Pdr1p via RPN4 expression;
however, its role in azole resistance has not been elucidated. Lastly, other genes found to
be CgPdr1p-dependent unique to this gain-of-function mutation included the homologs of
the S. cerevisiae genes that encode proteins involved in stress response such as DDR48,
HSP12, YIM1, FLO1, ATF2, and RTA1. As with YIM1, RTA1 is also upregulated in all
four of the matched sets of clinical isolates. In S. cerevisiae, RTA1, which is also known
to be regulated by ScPdr1p and ScPdr3p, encodes a protein member of the fungal lipidtranslocating exporter family and is involved in 7-aminocholesterol resistance; however,
the role of RTA1 in azole resistance has not been studied in S. cerevisiae or C. glabrata.
In C. albicans, over-expression of RTA2, which encodes a S. cerevisiae homolog of
RTA1, in a C. albicans strain with deletions of CDR1, CDR2, and MDR1 conferred
increased resistance to azoles suggesting a role for this protein family in azole resistance
(92).
Recently, it was shown that C. glabrata strains expressing hyperactive CgPDR1
alleles were more virulent in mice than the C. glabrata strains expressing wild-type
alleles (68). Our study has also allowed for the identification of CgPdr1p targets that may
play a role in virulence. Of note, PLB1, the homolog of the S. cerevisiae gene that
encodes phospholipase B, is not only upregulated in the resistant isolate SM3 but also
was found to be CgPdr1p-dependent. Moreover, PLB1 contains a PDRE in its promoter.
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In C. albicans, phospholipase B activity is involved in the spread of the organism from
the gastrointestinal tract as well as in hematogenous dissemination (57, 142). To date, no
published studies have analyzed the role of PLB1 in C. glabrata; however, one
unpublished study did find an association between phospholipase B activity and
persistent C. glabrata candidemia (74).
Consistent with the idea that adhesion of C. glabrata to host epithelial tissue plays
an important role in virulence, the genes FLO1, FLO5, FLO9, FLO10, and FLO11, were
found to be Pdr1p dependent. The C. glabrata FLO genes are homologs of S. cerevisiae
genes encoding proteins involved in cell adhesion (80). Only FLO1 and FLO10 contain
PDREs in their promoters. In S. cerevisiae, FLO1, FLO5, FLO9, and FLO10 are all
involved in cell-cell adhesion (flocculation), while FLO11 is involved in adhesion to
substrates. Although FLO10 in S. cerevisiae is involved in flocculation, in C. glabrata
this gene (named CgEPA1) is required for efficient in vitro adherence to human epithelial
cells proving a role for CgEPA1 in adherence to abiotic materials (40). FLO5 and FLO9
(CgEPA13) have been reported as members of the EPA family of adhesion proteins in C.
glabrata; however, their role in adherence has not been directly studied. Moreover, the
SM3 CgPDR1 hyperactive allele causes up-regulation of FLO1, FLO9, and FLO11, and
the 6955 CgPDR1 hyperactive allele causes up-regulation of FLO5 and FLO10.
Adhesion proteins in C. albicans have been shown to confer distinct adhesion profiles
towards human proteins and cells (194). This may explain the difference in adhesion gene
expression in our study as these isolates were isolated from different human tissues, SM3
was isolated from the blood, and 6955 was isolated from the oral mucosa.
In this study, we also found two fluconazole-resistant isolates that did not contain
a CgPDR1 mutation when compared to its susceptible match; however, both sets overexpressed CgPDR1, CgCDR1, and CgSNQ2 when comparing the resistant isolate to its
susceptible counterpart. However, the susceptible isolate 62-16 was found to have a
nucleotide deletion resulting in a putative truncated CgPdr1p which may lead to its
inactivation; this finding is consistent with the fluconazole MIC of this isolate. We
compared the coding sequences of CgPDR1 in this isolate set to all published CgPDR1
sequences and found two unique mutations whose expression in the susceptible
background resulted in an increase in fluconazole MIC as well as over-expression of
CgCDR1, suggesting that one or both of these represent gain-of-function mutations.
Isolate 7755 had no mutation when compared to not only the susceptible isolate 7754 but
all the published CgPDR1 sequences from susceptible isolates. Interestingly, CgPDR1 is
constitutively overexpressed in isolate 7255 suggesting the existence of alternate
mechanisms by which CgPDR1 can be activated.
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CHAPTER 4. GENOME-WIDE GENE EXPRESSION PROFILING OF THE
RESPONSE TO FLUCONAZOLE IN CANDIDA GLABRATA
INTRODUCTION
Azole antifungal resistance has emerged as a significant problem in the
management of infections caused by fungal species including Candida glabrata (21, 175,
185). Unlike Candida albicans, C. glabrata exhibits intrinsic reduced susceptibility to
the azoles, including fluconazole. Consistent with this observation, multiple studies have
shown that fluconazole use is a risk factor for development of invasive candidiasis caused
by non-albicans candida species, including C. glabrata (25, 36, 147, 203). Furthermore,
due to the fungistatic nature of fluconazole, C. glabrata and other Candida species
demonstrate tolerance to this antifungal. Tolerance is defined as the capacity of an
organism to survive in the presence of a drug at growth-inhibiting concentrations. Azole
tolerance may limit the efficacy of this class of antifungals, especially in
immunocompromised patients, where the organism is able to survive in the presence of
the drug and the immune system less able to clear the fungus. This may also contribute to
the development of high level azole resistance in this patient population.
The ability of any organism to alter gene expression allows for adjustment to
changes in its environment which is essential for its survival. Genome-wide expression
studies of drug responses in Saccharomyces cerevisiae and Candida albicans have shown
that such responses may be specific, reflecting the molecular target of the drug or may
represent a more general stress response (2, 118). Moreover, the organism can also cope
to changes in the environment with mechanisms that are neither general nor specific to
the stressor. For example, not only do C. albicans upregulate genes in the ergosterol
biosynthesis pathway in response to fluconazole, an antifungal drug that inhibits the
ergosterol biosynthesis pathway, but also induces expression of drug efflux pumps (118).
Understanding the initial stress response of C. glabrata to fluconazole may facilitate a
better understanding of how this organism copes with such stresses to its environment.
Moreover, such information may provide insight into the problem of intrinsic low-level
resistance as well as azole tolerance in C. glabrata.
In an effort to characterize the initial stress responses of C. glabrata to
fluconazole, we used microarray analysis to examine the gene expression profile of C.
glabrata after exposure to this drug. As CgPDR1, a zinc cluster transcription factor, has
been implicated as a key regulator of azole resistance and has been shown to be activated
in response to azole exposure, we also identified genes that respond to fluconazole
exposure in a CgPDR1-dependent fashion. Our results provide a more comprehensive
picture of the gene expression changes of C. glabrata in response to fluconazole. Genes
found to influence both intrinsic reduced susceptibility and tolerance to azoles will
ultimately serve as targets for future work toward the development of compounds that
will both abrogate resistance and enhance the therapeutic utility of this class of antifungal
agent.
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MATERIALS AND METHODS
Antifungal Agent
Fluconazole was obtained from MP Biomedicals (Solon, Ohio). Stock solutions of
10 mg/ml were made in dimethyl sulfoxide (DMSO, Sigma; St. Louis, Missouri) and
stored at -20˚C.
Strains and Growth Media
Strain 200989 (ura3/his3∆/trp1∆) was obtained from ATCC and strain
200989∆pdr1 was kindly provided by Dr. Tom Edlind at Drexel University, Philadelphia,
PA (63, 100). All isolates/strains used in these studies were grown in YPD (1% yeast
extract, 2% peptone, and 1% dextrose) broth. All isolates/strains were grown at 30˚C and
stored in 20% glycerol stocks at -80˚C.
Cell Culture and Fluconazole Exposure for Microarray Experiments
A total of six 100 ml cultures of YPD medium were inoculated from an overnight
(saturated) culture of C. glabrata to an initial A600 0.005 and grown at 30˚C until the A600
reached 1.0 (~ 12 hours). The culture was then diluted to an A600 of 0.1 and grown until
an A600 of 0.2 was reached (~ 2 hours). Fluconazole was then added at a final
concentration of 64 μg/ml (two times the MIC) to three of the flasks). An equal volume
of DMSO was added to the remaining three flasks to serve as the diluent control. DMSO
concentrations were less than 0.05% and did not affect the growth curves of control
cultures (data not shown). The cultures were grown for 2.5 hours. All cultures were
harvested by centrifugation at 3,500 x g at 4˚C for 5 minutes. The medium was
completely removed by aspiration and the cell pellets were stored at -80˚C until RNA
preparation.
Microarray cRNA Synthesis and Hybridization
C. glabrata microarrays were constructed as described previously (215). These
custom Affymetrix NimbleExpress Arrays were manufactured by NimbleGen Systems
per our specification (4). Two independent sets of RNA were used in these studies to
prepare two independent cDNA samples. The purity and concentration of the RNA was
examined by capillary electrophoresis using the RNA 6000 Nano laboratory-on-a-Chip
kit and Bioanalyzer 2100 (Agilent Technologies; Waldbronn, Germany) as per
manufacturer’s instructions. Fifteen μg total RNA was used for first- and second-strand
cDNA synthesis using the SuperScript Double-Stranded cDNA synthesis kit (Invitrogen)
and oligo-dT24-T7 primer (Sigma) according to the manufacturer’s instructions. Using
the T7 promoter-coupled double stranded cDNA as a template and the Bioarray High
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Yield RNA Transcript labeling kit (ENZO Diagnostics; Farmingdale, NY), cRNA was
synthesized and labeled with biotinylated-UTP and -CTP by in vitro transcription. The
synthesized double stranded cDNA was washed twice with 70% ethanol and suspended
in 22 μl of DEPC-treated water. Reaction buffer, biotin-labeled ribonucleotides,
dithiothreitol, RNase inhibitor mix and T7 RNA polymerase were added to the cDNA
and incubated for 5 hours at 37˚C. The labeled cRNA was purified using a CHROMA
SPIN-100 column (Clontech; Mountain View, CA) and precipitated with ethanol
overnight at -20˚C.
After the cRNA pellet was suspended in 10 µL of RNase-free water, 10 μg was
fragmented by ion-mediated hydrolysis at 95˚C for 35 min in 100 mM Tris-acetate
(pH8.1), 500 mM potassium acetate, 150 mM magnesium acetate. Using the Affymetrix
Fluidics Station 450 and its standard EukGEWS2v5 protocol, the fragmented cRNA was
hybridized to the C. glabrata NimbleExpress GeneChip arrays for 16 hours at 45˚C and
then washed at 25˚C with 6X SSPE (1X SSPE: 0.18M NaCl, 10 mM NaH2PO4, 1 mM
EDTA (pH 7.7)) + 0.01% Tween-20 followed by a stringent wash at 50˚C with 100 mM
MES (2-(N-morpholino) ethanesulfonic acid), 0.1 M NaCl, 0.01% Tween-20. The arrays
were stained with phycoerythrein-conjugated streptavidin (Molecular Probes; Eugene,
OR) and the fluorescence intensities were determined using the GCS 3000 highresolution confocal laser scanner (Affymetrix, Santa Clara, CA). These images were
analyzed using software resident in GeneChip Operating System v2.0 (GCOS;
Affymetrix). Sample loading and variations in staining were standardized by scaling the
average of the fluorescent intensities of all genes on an array to a constant target intensity
of 250. The signal intensity for each gene was calculated as the average intensity
difference, represented by [Σ (PM – MM)/number of probe pairs)], where PM and MM
denote perfect-match and mismatch probes.
Microarray Data Analysis
The scaled gene expression values from GCOS software were processed and
analyzed using GeneSpring 7.2 software (Agilent Technologies). Probe sets were
removed from analysis if they were called absent by the Affymetrix criterion and
displayed an absolute value below 20 in all experiments. The expression value of each
gene was normalized to the median expression of all genes in each chip as well as the
median expression of that gene across all chips in the study. Pairwise comparison of gene
expression was performed for each matched experiment.
Quantitative Real-Time RT-PCR
An aliquot of RNA samples used in the microarray experiments was saved for
follow-up quantitative RT-PCR studies along with a set of independently-obtained RNA
samples from the same strains analyzed by microarray. First-strand cDNAs were
synthesized from 2 μg total RNA using the SuperScript First-Strand Synthesis System for
RT-PCR (Invitrogen) as per the manufacturer’s instructions. All quantitative real-time
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PCR experiments were performed in triplicate using the 7000 Sequence Detection
System (Applied Biosystems, Inc.; Foster City, CA). Independent PCRs were performed
using the same cDNA for both the gene of interest and 18S rRNA, using the SYBR
Green PCR Master Mix (Applied Biosystems). Gene-specific primers were designed for
the gene of interest and 18S rRNA using Primer Express software (Applied Biosytems)
(Table 4-1). The PCR conditions were as follows: AmpliTaq Gold activation at 95˚C for
10 minutes, 40 cycles of a combination of denaturation at 95˚C for 15s and
annealing/extension at 60˚C for 1 min. A dissociation curve was generated at the end of
each cycle to verify that a single product was amplified using the software provided with
the 7000 Sequence Detection System. The system software monitored the change in
fluorescence of SYBR Green I dye in every cycle, and the threshold cycle (CT) above
background for each reaction was calculated. The CT value of 18S rRNA was subtracted
from that of the gene of interest to obtain ∆CT value. The ∆CT of an arbitrary calibrator
(e.g. fluconazole-susceptible isolate or untreated sample) was subtracted from the ∆CT
value of each sample to obtain a ∆∆CT value. The gene expression level relative to the
calibrator was expressed as 2-2∆∆CT. Statistical analysis was performed using Microsoft
Office Excel 2007. Relative changes were compared using the Student’s t-test. The
statistical significance threshold was fixed at α = 0.05.
In order to find putative targets of PDR1, UPC2, RLM1, and CRZ1 we used the
Yeastact (Yeast Search for Transcriptional Regulators And Consensus Tracking) program
available at http://www.yeastract.com/index.php (137, 206). This program allows for the
identification of transcription factor regulatory associations with target genes in S.
cerevisiae based on more than 1000 bibliographic references. All genes (S. cerevisiae
homologs) upregulated in response to fluconazole were uploaded to this program and
direct or indirect target genes were searched. The promoters of these genes (1000bp
upstream from start codon) were also searched for putative S. cerevisiae binding motifs
(Pleiotropic Drug Response Element (PDRE); SRE (steroid response element); CDRE
(Calcineurin Dependent Response Element); RRE (Rlm1p response element).
RESULTS
Global Changes in Gene Expression in Response to Fluconazole
An understanding of the initial stress responses of C. glabrata to fluconazole
should allow for a better understanding of intrinsic azole resistance and tolerance in this
organism. To identify genes that respond to fluconazole treatment, we used gene
expression profiling to examine the initial response of C. glabrata in the presence of
fluconazole. We exposed ATCC strain 200989 to 64 μg/ml fluconazole (2X MIC) for 2.5
hours. Genes were considered to be differentially expressed if the expression of that gene
changed reproducibly by at least ≥ 1.5 in the fluconazole-treated strain compared to the
untreated strain. There were 714 genes, approximately 13% of the entire C. glabrata
genome, was upregulated in response to fluconazole. Among these genes were S.
cerevisiae homologs that are involved in transport, lipid metabolism, cell wall
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Table 4-1. Primers used for quantitative real-time PCR expression analysis.
Primer/Gene
18S rRNA

Primer paira

F, 5′-TCGGCACCTTACGAGAAATCA-3′
R, 5′-CGACCATACTCCCCCCAGA-3′
F, 5′-TTTGACTCTGTTATGAGCGATTACG-3′
CgPDR1
R, 5′-TTCGGATTTTTCTGTGACAATGG-3′
F, 5′-CATACAAGAAACACCAAAGTCGGT-3′
CgCDR1
R, 5′-GAGACACGCTAACGTTCACCAC-3′
F, 5′-CCATCGGTGCTTGTGTAATGTTA-3′
CgYOR1
R, 5′-TTGAGAGGCGTGGAAAAAATG-3′
F, 5′-AAGTGCTTCTTCCGCCTCATT-3′
CgYBT1
R, 5′-AACAGGAGCTGGTGTAGTACCCA-3′
F, 5′-TGGCCTACTTCGGATTCTGTG-3′
CgFLR1
R, 5′-CCAAAAGGATGATGTATGCAAAAAT-3′
F, 5′-TTCTCTGGCTGCCGAATCA-3′
CgUPC2
R, 5′-ATCTTGCCTTTTTGCTCATCATAA-3′
F, 5′-TGGATTTTTTCTCCCATCTGGA-3′
CgCSR1
R, 5′-ACCACAGGGTCAAGCCATTTT-3′
F, 5′-TCTGGACGCAACGGGTTC-3′
CgSAC7
R, 5′-ACTCCTCAAGCGAGACACCAA-3′
F, 5′-TCCTGTTTGTCATTAGGGTTAGGG-3′
CgRTA1
R, 5′-TGGCAATTTTGTTCTTATTCCTCAG-3′
a
F, Forward; R, Reverse.

Amplicon
size (bp)
52
51
71
68
67
54
51
53
52
51
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maintenance, and response to stress (Figure 4-1). Also upregulated were the
transcriptional regulator PDR1, and homologs of the S. cerevisiae transcriptional
regulators UPC2, CRZ1, RLM1, CIN5, and YAP1. Many targets and binding motifs of
these transcription factors have been identified in S. cerevisiae. We used the World Wide
Web based program, Yeastract, to identify putative targets of these transcriptional
regulators (137, 206). The Yeastract program allows for analysis of transcription factor
associations based on Chromatin immunoprecipitation (ChiP) as well as the effects of
deletion of the transcription factor in S. cerevisiae. Furthermore, because of the
evolutionary relatedness of S. cerevisiae and C. glabrata and the fact that binding motifs
are usually highly conserved, the promoter region (defined for this purpose as 1000 bp
immediately upstream from the start codon of the ORF) of each putative target gene was
examined for a match to the consensus S. cerevisiae sequences for these transcription
factors. Tables 4-2, 4-3, and 4-4 list the genes found to be putative targets of these
transcriptional regulators as well as contain at least one putative binding motif.
Other genes of S. cerevisiae homologs found to be responsive to fluconazole
treatment include genes involved in response to stress such as DDR48 (DNA damageresponsive protein), and YIM1 (protein of unknown function). Additionally, several other
stress response genes were upregulated in response to fluconazole treatment including
genes encoding calcium-regulated signaling proteins CCH1 (voltage-gated high-affinity
calcium channel), CMP2 (calcineurin A), PMR1 (Ca2+/Mn2+ P-type ATPase), CMK2
(calmodulin-dependent protein kinase) and the aforementioned transcription factor,
CRZ1. There were 905 genes, approximately 17% of the C. glabrata genome, were
down-regulated by ≥ 1.5 fold in response to fluconazole (Figure 4-2). Real-time RT-PCR
was used to confirm the expression of selected genes (Figure 4-3).
Effects of CgPDR1 on Global Gene Expression Responses to Fluconazole
It has previously been shown that CgPDR1 is induced after treatment with
fluconazole, suggesting a role for CgPdr1p in the initial stress response to fluconazole
(215). To assess the role of Pdr1p on the stress response to fluconazole, we used a
previously described strain in which CgPDR1 had been disrupted (200989∆pdr1), and we
repeated the above experiment (63). Genes were defined as being CgPdr1p-dependent if
the expression of that gene decreased by 50% after disruption of CgPDR1 in the presence
of fluconazole in two independent experiments. Surprisingly, only six genes were found
to be Pdr1p-dependent (Table 4-5); however, only two of these genes were also
upregulated in response to fluconazole. Among these were the aforementioned gene
CgCDR1.
DISCUSSION
Most C. glabrata isolates demonstrate intrinsic resistance to azole antifungals.
Moreover, C. glabrata exhibits tolerance to azoles which allows this organism to survive
in the presence of drug at growth-inhibiting concentrations. In an effort to identify genes
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Figure 4-1. Distribution of genes upregulated by ≥ 1.5 fold in response to fluconazole. Genes were annotated and assigned to
functional categories based on the gene ontology (GO) annotation of its S. cerevisiae homolog.
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Table 4-2. C. glabrata putative target genesa of Pdr1p upregulated by ≥ 1.5 fold in response to fluconazole.

a

C. glabrata
designation

S. cerevisiae
homolog

Description

Fold
changeb

PDREc

CAGL0F08745g
CAGL0C00275g
CAGL0M08426g
CAGL0K10164g
CAGL0K00715g
CAGL0A00451g
CAGL0M08822g
CAGL0G05962g
CAGL0M01760g
CAGL0K09702g
CAGL0K12958g
CAGL0G00242g
CAGL0F02717g
CAGL0A01199g

TMA10
HSP31
YJL163c
SED1
RTA1
PDR1
HSP78
YHR140w
PDR5
YNL134c
YML131w
YOR1
PDR15
DIP5

Protein of unknown function that associates with ribosomes
Possible chaperone and cysteine protease
Putative protein of unknown function
Major stress-induced structural GPI-cell wall glycoprotein
Lipid-translocating exporter (LTE) family of protein
Zinc cluster transcription factor
Oligomeric mitochondrial matrix chaperone
Putative integral membrane protein of unknown function
Plasma membrane ATP-binding cassette (ABC) transporter
Putative protein of unknown function
Putative protein of unknown function
Plasma membrane ATP-binding cassette (ABC) transporter
Plasma membrane ATP binding cassette (ABC) transporter
Dicarboxylic amino acid permease

28.3
7.4
7.2
4.9
4.3
3.8
3.7
3.6
3.5
3.5
3.5
3.2
2.6
2.5

-644
-932
-450
-996
-379;-300
-701;-557
-298
-276
-969; -515; -387; -227; -133
-549
-594
-648
-557;-521
-737

Transcription factor targets identified using Yeastract website (http://www.yeastract.com/index.php) (124, 193).
Fold change defined as the ratio of fluconazole-treated 200989 versus untreated 200989.
c
PDRE (TCC(GA)(CT)G(GC)(AG).
b
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Table 4-3. C. glabrata putative target genesa of Upc2p, Crz1p, Rlm1p, and Cin5p upregulated by ≥ 1.5 fold in response to
fluconazole.
C. glabrata
designation

S. cerevisiae
homolog

Putative Upc2p targets
CAGL0K03421g
PGM2
CAGL0I02970g
ERG24
CAGL0L10714g
ERG2
Putative Crz1p targets
CAGL0F08745g
TMA10
CAGL0J04158g
WSP1
CAGL0K00715g
RTA1
CAGL0A00517g
PMC1
CAGL0C04961g
ECM27
CAGL0J03432g
ARK1
CAGL0M08206g
YJL171c
CAGL0M02211g
PEP4
Putative Rlm1p targets
CAGL0F08195g
MGA1
CAGL0H02563g
YDR524c
CAGL0H08844g
DDR48
CAGL0J04466g
YLR414c
CAGL0M12320g
FLC2
CAGL0M04191g
YPS1
CAGL0J00539g
SLT2
CAGL0G09449g
CRH1
CAGL0J11506g
CHS1
CAGL0G08646g
POG1

Description

Fold
changeb

Phosphoglucomutase
C-14 sterol reductase, acts in ergosterol biosynthesis
C-8 sterol isomerase, acts in ergosterol biosynthesis

3.9
1.8
1.7

Protein of unknown function that associates with ribosomes
Protein of unknown function
Lipid-translocating exporter (LTE)
Vacuolar Ca2+ ATPase
Non-essential protein of unknown function
Serine/threonine protein kinase
GPI-anchored cell wall protein
Vacuolar aspartyl protease

27.3
6.8
3.3
2.6
2.6
2.3
2.3
2.0

Protein similar to heat shock transcription factor
ADP-ribosylation factor
DNA damage-responsive protein
Putative protein of unknown function
Putative FAD transporter
Aspartic protease
Serine/threonine MAP
Putative chitin transglycosidase
Chitin synthase I
Putative transcriptional activator

7.8
4.5
4.1
3.7
3.6
3.5
3.4
3.4
3.2
2.9

Binding motifc
SREc
-806
-127
-926; -738
CDREc
-917‡
-805†
-659‡
-62‡
-659†
-470‡
-520†
-321‡
RREc
-328
-144
-975
-299
-121
-129
-269
-406
-197
-295
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Table 4-3 (continued).
C. glabrata
designation

S. cerevisiae
homolog

Description

Fold
changeb

Binding motifc

Putative Rlm1p targets, continued

CAGL0B03619g
Vacuolar proteinase B (yscB)
2.7
-391
PRB1
CAGL0J01463g
Cell wall mannoprotein
2.6
-219
CWP1
CAGL0L00935g
Protein involved in nucleocytoplasmic transport of mRNA 2.3
-130
APQ12
CAGL0M08206g
GPI-anchored cell wall protein
2.3
-60
YJL171c
CAGL0E01969g
Divalent metal ion transporter
2.2
-496
SMF1
CAGL0G04433g
Pheromone-regulated protein
1.9
-955
PRM10
CAGL0M03663g
Component of the RIM101 pathway
1.8
-212
RIM21
CAGL0H05621g
MADS-box transcription factor
1.8
-483
RLM1
Putative Cin5p targets
CREc
CAGL0K10164g
GPI-cell wall glycoprotein
3.9
-143
SED1
CAGL0K08162g
Glycerol-3-phosphate/dihydroxyacetone phosphate
3.2
-574;2190
GPT2
CAGL0G02937g
Major of three pyruvate decarboxylase isozymes
2.0
-444;-429
PDC1
CAGL0F07799g
Specificity factor required for Rsp5p ubiquitination
2.0
-613
EAR1
CAGL0J01353g
Protein of unknown function
1.8
-318
YTA12
CAGL0H05621g
MADS-box transcription factor
1.8
-393
RLM1
CAGL0E05610g
Pyruvate kinase
1.6
-937
CDC19
CAGL0K10890g
Widely conserved NADPH oxidoreductase
1.6
-517
OYE2
CAGL0M03377g
Glycogen branching enzyme
1.6
-900
GLC3
CAGL0D05698g
Mitochondrial outer membrane protein
1.6
-363
MMM1
a
Transcription factor targets identified using Yeastract website (http://www.yeastract.com/index.php).
b
Fold change defined as the ratio of fluconazole-treated 200989 versus untreated 200989.
c
SRE (5’-TCGTATA-3’) (217), CDRE (5’-GAGGCTG-3’)† or (GNGGC(G/T)CA) ‡ (227), RRE (5’-NTA(A/T)TAG-3’) (56), CRE
(5’-TTACTAA-3’)(67).
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Table 4-4. C. glabrata putative target genesa of CgAp1p upregulated by ≥ 1.5 fold in response to fluconazole.
C. glabrata
designation
CAGL0F08745g
CAGL0K04609g
CAGL0C02321g
CAGL0I06644g
CAGL0L00759g
CAGL0J00561g
CAGL0F07029g
CAGL0A04081g
CAGL0H06721g
CAGL0K10164g
CAGL0G08338g
CAGL0M11682g
CAGL0H07359g
CAGL0J03762g
CAGL0G09449g
CAGL0B03883g
CAGL0H04983g
CAGL0K08162g
CAGL0D00770g
CAGL0I03806g
CAGL0M02167g
CAGL0M10417g
CAGL0H06699g
CAGL0A04477g
CAGL0I10626g
CAGL0E02035g
CAGL0M06611g
CAGL0I01210g
CAGL0M13189g
CAGL0K12034g
CAGL0E03025g
CAGL0A02574g
CAGL0L12012g

S. cerevisiae
homolog
TMA10
VHT1
PHM8
SED1
HIS1
YHI9
MET13
SRP40
UBP7
SED1
YLR241w
YLR108c
PHO8
MET7
CRH1
YMC1
PSA1
GPT2
IDP1
BPL1
PRM4
RCR2
GUT2
UBP13
YGR125w
MCH4
AVT7
CTM1
MSN4
ENA1
YGR146c
TRP4
TMT1

Description
Protein of unknown function that associates with ribosomes
High-affinity plasma membrane H+-biotin symporter
Protein of unknown function
GPI-cell wall glycoprotein
ATP phosphoribosyltransferase
Protein of unknown function
Major isozyme of methylenetetrahydrofolate reductase
Nucleolar, serine-rich protein
Ubiquitin-specific protease
GPI-cell wall glycoprotein
Putative protein of unknown function
Protein of unknown function
Repressible alkaline phosphatase
Folylpolyglutamate synthetase
Putative chitin transglycosidase
Mitochondrial protein
GDP-mannose pyrophosphorylase
Glycerol-3-phosphate/dihydroxyacetone phosphate
Mitochondrial NADP-specific isocitrate dehydrogenase
Biotin:apoprotein ligase
Pheromone-regulated protein
Vacuolar protein
Mitochondrial glycerol-3-phosphate dehydrogenase
Putative ubiquitin carboxyl-terminal hydrolase
Putative protein of unknown function
Protein with similarity to monocarboxylate permeases
Putative transporter
Cytochrome c lysine methyltransferase
Transcriptional activator related to Msn2p
P-type ATPase sodium pump
Putative protein of unknown function
Anthranilate phosphoribosyl transferase
Trans-aconitate methyltransferase,

Fold
changeb
27.3
10.2
7.2
6.0
6.0
5.9
5.5
4.7
4.1
3.9
3.5
3.5
3.4
3.4
3.4
3.3
3.2
3.2
3.1
3.1
3.0
2.9
2.8
2.8
2.7
2.7
2.7
2.7
2.6
2.6
2.6
2.6
2.6

A
-526
-143
-760;-225
-490
-377;-59
-574
-47
-

Binding motif c
B
C
-443
-864;-474
-452
-173
-132
-485
-95
-243
-357
-408
-469
-102
-470
-730
-170
-

D
-246
-708
-723
-482
-558
-155
-537;-281
-117
-285
-920
-39
-699;-134
-346
-678
-26
-607
-785;-211
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Table 4-4 (continued).
C. glabrata
designation
CAGL0J01463g
CAGL0M13651g
CAGL0L02321g
CAGL0L02607g
CAGL0M01760g
CAGL0K12958g
CAGL0E02409g
CAGL0H05687g
CAGL0C02167g
CAGL0G05698g
CAGL0E01771g
CAGL0D02728g
CAGL0E04026g
CAGL0M08734g
CAGL0L01265g
CAGL0L04598g
CAGL0A00781g
CAGL0G02937g
CAGL0M11484g
CAGL0J08118g
CAGL0J06402g
CAGL0H08954g
CAGL0J01353g
CAGL0H05621g
CAGL0F07359g
CAGL0F04697g
CAGL0H04587g
CAGL0G05918g
CAGL0G05335g
CAGL0G07293g
CAGL0M04741g
CAGL0H05599g
CAGL0C02409g

S. cerevisiae
homolog
CWP1
PRC1
MET14
YHR202w
PDR5
YML131w
CSI2
SSU1
YFR039c
GDH2
MKC7
FMP34
CBP2
YDR262w
UTR1
DCS1
VPS8
PDC1
ARO1
IST1
LYS21
MRM2
YTA12
RLM1
YGL117w
YLR257w
AVT6
CHS7
TPS2
USA1
MPD1
YDC1
ZRG8

Description
Cell wall mannoprotein
Vacuolar carboxypeptidase Y (proteinase C)
Adenylylsulfate kinase
Putative protein of unknown function
Plasma membrane ABC transporter
Putative protein of unknown function
Protein of unknown function
Plasma membrane sulfite pump
Putative protein of unknown function
NAD(+)-dependent glutamate dehydrogenase
GPI-anchored aspartyl protease (yapsin)
Putative protein of unknown function
Mitochondrial protein
Putative protein of unknown function
ATP-NADH kinase
Non-essential hydrolase involved in mRNA decapping,
Membrane-associated protein that interacts with Vps21p
Major of three pyruvate decarboxylase isozymes
Pentafunctional arom protein
Protein with a role in the multivesicular body sorting pathway
Homocitrate synthase isozyme
Mitochondrial 2' O-ribose methyltransferase
Protein of unknown function
MADS-box transcription factor
Putative protein of unknown function
Putative protein of unknown function
Vacuolar amino acid transporter
Protein of unknown function
Phosphatase of the trehalose-6-phosphate synthase/phosphatase
Protein involved in ER-associated protein degradation (ERAD)
Member of the protein disulfide isomerase (PDI) family
Alkaline dihydroceramidase
Protein of unknown function

Fold
changeb
2.6
2.6
2.6
2.6
2.5
2.5
2.4
2.4
2.4
2.4
2.4
2.2
2.2
2.1
2.1
2.1
2.0
2.0
2.0
1.9
1.9
1.9
1.8
1.8
1.8
1.8
1.7
1.7
1.7
1.7
1.7
1.7
1.7

A
-633;-333
-259
-565;-203
-203
-444;-429
-319
-318
-393
-

Binding
B
-570
-952
-304
-111
-718
-288
-

motif c
C
-540
-616
-382
-72
-712
-588
-

D
-703;-173
-671
-741
-12
-909
-91
-713
-399
-576
-845
-688
-447
-666;-75
-862
-172
-899
-169
-498
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Table 4-4 (continued).

a

C. glabrata
designation
CAGL0H04103g
CAGL0A01243g
CAGL0A01826g
CAGL0F06633g
CAGL0J04752g
CAGL0L10912g
CAGL0M04675g
CAGL0E05610g
CAGL0K10890g
CAGL0H03223g
CAGL0I01012g
CAGL0D01584g

S. cerevisiae
homolog
UFO1
GIT1
HXT5
UBX4
TUS1
TPO4
YOR285w
CDC19
OYE2
GUP1
PEP12
JID1

Description
F-box receptor protein
Plasma membrane permease
Hexose transporter with moderate affinity for glucose
UBX (ubiquitin regulatory X) domain-containing protein
Guanine nucleotide exchange factor (GEF)
Polyamine transport protein
Protein of unknown function
Pyruvate kinase
Widely conserved NADPH
Plasma membrane protein involved in remodeling GPI
Target membrane receptor (t-SNARE)
Probable Hsp40p co-chaperone

Fold
changeb
1.7
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.5

A
-400
-937
-517
-

Binding
B
-

motif c
C
-930
-

D
-133
-795
-294
-34
-31
-484
-242
-701;-25
-376

Transcription factor targets identified using Yeastract website (http://www.yeastract.com/index.php).
Fold change defined as the ratio of fluconazole-treated 200989 versus untreated 200989.
c
Binding motifs A 5’-TTACTAA-3’(67), B 5’-TGACTCA-3’(67), C 5’-TGACTAA-3’(149), D 5’-T(G/T)ACAAA-3’(84).
b
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Figure 4-2. Distribution of genes downregulated by ≥ 1.5 fold in response to fluconazole. Genes were annotated and assigned to
functional categories based on the gene ontology (GO) annotation of its S. cerevisiae homolog.
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Figure 4-3. Quantitative real-time RT-PCR analysis of relative gene expression in
200989 and 200989∆pdr1 treated with fluconazole versus 200989 treated with DMSO
(control). Data are shown as mean ± standard error. Relative changes were compared
using the Student’s t-test. Gene expression values with an asterisk indicate statistical
significance (P < 0.05) in all three experiments.
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Table 4-5. C. glabrata genes found to be Pdr1p-dependent in response to fluconazole.

a

C. glabrata
designation

S. cerevisiae
homolog

CAGL0M01760g
CAGL0C02915g
CAGL0D03652g

PDR5
YOR268c
SPT21

CAGL0K07700g

BUD27

CAGL0E02937g

CGR1

CAGL0H09064g

FUR1

Description
Plasma membrane ABC transporter
Putative protein of unknown function
Protein required for normal transcription at
several loci including HTA2-HTB2 and
HHF2-HHT2
Protein involved in bud-site selection,
nutrient signaling, and gene expression
controlled by TOR kinase
Protein involved in nucleolar integrity and
processing of the pre-rRNA for the 60S
ribosome subunit
Uracil phosphoribosyltransferase

Fold changea
200989F/ 200989∆pdr1F/
200989D
200989D
2.8
0.6
2.2
1.0

PDREb
134, 227, 387, 515, 969
-

0.7

0.3

-

0.6

0.1

-

0.3
0.4

0.1
0.2

-

Fold change defined as the ratio of fluconazole-treated 200989 versus untreated 200989 or 200989∆pdr1 versus untreated 200989.
b
PDRE (TCC(GA)(CT)G(GC)(AG).
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that may contribute to these phenotypes, we examined the response of C. glabrata to
fluconazole treatment using genome-wide gene expression profiling.
As expected, fluconazole treatment induced the expression of CgPDR1 and many
known genes encoding homologs of the S. cerevisiae ScPdr1p and ScPdr3p target genes.
In S. cerevisiae, ScPdr1p and ScPdr3p have been named the master regulators of drug
resistance, including resistance to azoles (141). In C. glabrata, CgPdr1p has been
identified as the single homolog of ScPdr1p and ScPdr3p (215). This zinc cluster
transcription factor is known to regulate the ATP binding cassette (ABC) transporters
CgCDR1 and CgPDH1 which are also upregulated in the present study (215). The role of
CgPdr1p in azole resistance has been studied extensively. Gain-of-function mutations in
this transcriptional regulator have been shown to be responsible for the up-regulation of
these ABC transporters and subsequent decrease in susceptibility to fluconazole (68, 210,
212, 215). Recently it was shown that the regulation of C. glabrata Pdr1p is similar to
regulation of multidrug resistance (MDR) in vertebrates by the PXR nuclear receptor as
Pdr1p directly binds to fluconazole resulting in activation of drug efflux pumps (207).
Consistent with this finding, in a previous study expression of CgPDR1 and its target
genes, CgCDR1 and CgPDH1 are induced after treatment with fluconazole (215).
Furthermore, in this same study disruption of CgPDR1 in a fluconazole susceptible
isolate (fluconazole MIC of 16 μg/ml) resulted in fluconazole hypersusceptibility
(fluconazole MIC of 2 μg/ml) suggesting that CgPDR1 plays an important role in the
intrinsic fluconazole resistance of this species. To date, no study has conclusively studied
the role of CgPdr1p in azole tolerance.
A recent study identified 22 genes that were essential for S. cerevisiae survival in
the presence of fluconazole (91). Among the genes identified was the CgCDR1 S.
cerevisiae homolog ScPDR5. Disruption of ScPDR5 in S. cerevisiae rendered fluconazole
fungicidal to this mutant. Alternatively, disruption of CgCDR1 in C. glabrata in a
fluconazole susceptible isolate (MIC 16 μg/ml) had no effect on fluconazole MIC;
however, trailing growth, a phenomenon typical of Candida species, was eliminated
(178, 216). The effect of CgCDR1 on the minimum fungicidal concentration (MFC) has
not been measured in C. glabrata. Because disruption of CgPDR1 but not CgCDR1
results in azole hypersensitivity, these results suggest that other CgPdr1p targets may be
playing a role in intrinsic resistance. In order to determine which fluconazole-responsive
genes are regulated by Pdr1p, we identified genes that respond to fluconazole in a Pdr1pdependent fashion by assessing which genes are no longer differentially expressed in
response to fluconazole treatment in a pdr1 C. glabrata strain. As expected, CgCDR1
was found to be upregulated in a CgPdr1p-dependent fashion; however, other known
ScPdr1p-ScPdr3p target genes were not. This suggests that there are fluconazoleresponsive transcriptional factors, in addition to CgPdr1p, are able to regulate CgPdr1p
target genes. In fact, of the putative Pdr1p targets listed in Table 4-2, TMA10 and RTA1
are also putative Crz1p targets. Also, of all the genes YOR268c was also found to be
Pdr1p-dependent. The function of this gene is unknown, but a S. cerevisiae strain
disrupted for the homolog of this gene was found to be selenomethionine resistant (23).
Surprisingly, only five other genes were found to be Pdr1p dependent; however, none of
these were activated in response to fluconazole.

89

Fluconazole acts by inhibiting lanosterol demethylase (ERG11) in the ergosterol
biosynthesis pathway. A S. cerevisiae homolog of UPC2 which is known to induce
transcription of both sterol biosynthesis genes and DAN/TIR genes was also upregulated
in response to fluconazole. In addition, homologs of ScUpc2p target genes were also
induced in the present study in response to fluconazole. These included genes encoding
proteins involved in the ergosterol biosynthesis pathway (ERG1, ERG2, and ERG24) and
heme biosynthesis (HEM13 and HEM14). It has been suggested that in S. cerevisiae
heme may play an important role in sterol biosynthesis and regulate the transcription of
several genes involved in this process (161). Upregulation of genes involved in sterol
biosynthesis is consistent with inhibition of this pathway by fluconazole and has also
been observed in S. cerevisiae and C. albicans (2, 118). Also upregulated in response to
fluconazole were the homologs of S. cerevisiae Upc2p target genes involved in cell wall
maintenance (DAN4, TIR1, and TIR3).
Another interesting observation is the up-regulation of homologs of the S.
cerevisiae genes involved in calcium signaling (CCH1, CMP2, CRZ1, GSC2, and PMR1).
In S. cerevisiae, CCH1 encodes a voltage-gated high-affinity calcium channel involved in
calcium influx in response to some environmental stresses. A study in C. glabrata found
that strains defective in the putative plasma membrane calcium channel (Cch1-Mid1)
were not only defective in calcium uptake in response to fluconazole exposure but also
showed a significant loss of viability upon prolonged fluconazole exposure (98). The
authors concluded that in the absence of calcium signaling, fluconazole has a fungicidal
effect on C. glabrata suggesting a role for calcium signaling in tolerance to azoles.
Calcium influx leads to stimulation of the heterodimer protein phosphatase calcineurin
which is encoded by CMP2 (catalytic A subunit) and CNB1 (calcium-binding regulatory
unit) (Figure 4-4). In C. glabrata disruption of CNB1, the calcium-binding subunit of
calcineurin, resulted in not only increased fluconazole susceptibility but also fungicidal
activity to fluconazole in C. glabrata (136). The homolog of the S. cerevisiae gene CNB1
is not upregulated in the present study; however, CMP2 which encodes one isoform of
the catalytic subunit A of calcineurin is upregulated. Calcineurin dephosphorylates the
transcription factor CRZ1 which then activates its target genes which include GSC2
(encodes β-1, 3-glucan synthase) and PMR1 (encodes a Golgi-localized Ca2+/Mn2+
importer). In S. cerevisiae, disruption of CRZ1 enhanced azole sensitivity; however,
disruption in of the CRZ1 homolog in C. glabrata does not (136). Thus, the precise
mechanism calcineurin-dependent azole tolerance in C. glabrata remains to be
discovered. Of note, of the Crz1p putative targets listed in Table 4-3 one gene encoding
the S. cerevisiae homolog RTA1 is also upregulated. In S. cerevisiae, RTA1, which is also
known to be regulated by ScPdr1p and ScPdr3p, encodes a protein member of the fungal
lipid-translocating exporter family and is involved in 7-aminocholesterol resistance. In C.
albicans, over-expression of RTA2, which encodes a S. cerevisiae homolog of RTA1, in a
C. albicans strain with deletions of CDR1, CDR2, and MDR1 conferred increased
resistance to azoles suggesting a role for this protein family in azole resistance (92).
However, the role of RTA1 in azole tolerance has not been studied in S. cerevisiae or C.
glabrata.
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Figure 4-4. Proposed model for the calcium-signaling pathway in C. glabrata. Calcium
influx leads to stimulation of the heterodimer protein phosphatase calcineurin.
Calcineurin dephosphorylates the transcription factor CRZ1 which then activates its target
genes which include GSC2 (encodes β-1, 3-glucan synthase) and PMR1 (encodes a
Golgi-localized Ca2+/Mn2+ importer).
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In S. cerevisiae, the calcineurin and cell wall integrity (CWI) pathways function
in parallel to induce FKS2 (CgGSC2) function in response to heat (229). The CWI
pathway is the major signaling pathway regulated cell wall assembly. Of note, several
genes encoding proteins involved in the CWI pathway were differentially expressed in
response to fluconazole. Among these genes was the S. cerevisiae homologs MID2 which
encodes a sensor for cell wall integrity signaling, SAC7 which encodes a GTPase
activating protein for Rho1p, RLM1 which encodes a MADS-box transcription factor
which is phosphorylated and activated by the MAP-kinase Slt2p, which is also
upregulated in response to fluconazole (Figure 4-5). Recently, in S. cerevisiae SLT2 has
been found to be essential for survival in the presence of fluconazole. Disruption of SLT2
in S. cerevisiae decreased the MFC suggesting a role for SLT2 in fluconazole tolerance
(91). In S. cerevisiae, Rlm1p is the transcription factor that regulates much of the
transcriptional change upon Slt2p activation (93). We identified several putative Rlm1p
targets involved in cell wall maintenance upregulated in response to fluconazole in this
study such as the cell wall proteins CRH1 (putative chitin transglycosidase), CHS1
(Chitin synthase I), CWP1 (Cell wall mannoprotein), and YJL171c (GPI-anchored cell
wall protein). The activation of the cell wall integrity pathway may be vital in the
presence of fluconazole for maintaining the structure of the cell wall to counteract the
effects of reduced ergosterol production.
Also upregulated in response to fluconazole treatment were two bZIP
transcription factors, YAP1 (CgAP1) and CIN5. CgAP1 and CIN5 both belong to the YAP
(yeast activator protein) family of bZIP trans-activators that have been implicated in
various forms of stress response in S. cerevisiae (180). In fact, YAP1 is known as the
major regulator of oxidative stress in S. cerevisiae. In C. glabrata, a homolog of the S.
cerevisiae YAP1 has been identified (CgAP1) and its function in multidrug resistance has
been studied (37). Disruption of CgAP1 had no effect on fluconazole resistance. Also, a
target of CgAP1 was identified, the major facilitator superfamily transporter FLR1.
Interestingly, FLR1 in the present study was found to be down-regulated in response to
fluconazole. In S. cerevisiae, FLR1 can be activated by not only Yap1p but also Pdr3p
(29). In fact, of all putative Pdr1p direct and indirect target genes identified using
Yeastact in this study, 43 genes were identified as also being putative Yap1p direct or
indirect targets. Of note, PDR5, the S. cerevisiae homolog of CgCDR1 was among these
genes. This supports the hypothesis that other fluconazole-responsive transcriptional
factors, in addition to CgPdr1p, are able to regulate CgPdr1p target genes. The roles of
these other transcriptional regulators (UPC2 and RLM1) in azole tolerance are under
investigation.
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Figure 4-5. Cell wall integrity pathway in S. cerevisiae (116). Signals are initiated at the
plasma membrane through cell surface sensors (Wsc1-4p and Mid2p). These sensors
stimulate nucleotide exchange on Rho1p which then activates the Pkc1p-MAP kinase
cascade. The MAP kinase, Slt2p, is activated by Pkc1p and downregulated by the MAP
kinase phosphatases, Msg5p, Ptp2p, and Sdp1p. Slt2p then phosphorylates and activates
Rlm1p. C. glabrata homologs of these genes that are upregulated in response to
fluconazole in the present study are in red and homologs downregulated in response to
fluconazole in the present study are in green.
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CHAPTER 5. SUMMARY
Over the past two decades, Candida glabrata has become the one of the most
common causes of fungal infections in humans, only second to Candida albicans. The
azole class of antifungals is the most widely used antifungal for treatment of Candida
infections. However, development of high-level resistance to the azoles has been reported
in oral and bloodstream isolates from head and neck radiation patients, stem cell
transplant patients, and human immunodeficiency virus (HIV) patients(122, 174, 175). C.
glabrata, in addition, exhibits intrinsic increased susceptibility to the azoles, including
fluconazole and can develop tolerance due to the fungistatic nature of azole antifungals.
The fungistatic activity of fluconazole not only hampers its efficacy in
immunocompromised patient populations but may also contribute to the development of
high-level azole resistance.
Azole resistance in C. glabrata has been associated with the upregulation of the
ABC transporters, CgCDR1 and CgPDH1. We have identified a transcriptional regulator
of these transporters, CgPdr1p. Disruption of CgPDR1 not only resulted in decreased
expression of these transporters, but also resulted in azole hypersusceptibility in a
laboratory-derived fluconazole resistant C. glabrata isolate (Figure 5-1). This phenotype
was attributed to a previously identified putative gain-of-function mutation. We next
identified novel gain-of-function mutations in fluconazole-susceptible and –resistant
matched sets of clinical isolates. These mutations conferred different levels of
fluconazole susceptibility. Through genome-wide profiling, we also identified a core set
of commonly differentially-expressed genes as well as genes uniquely regulated by
specific mutations.
We have also demonstrated that the transcriptional regulator, CgPdr1p, in C.
glabrata not only influences the development of azole resistance but also influences
intrinsic resistance to azoles as disruption of CgPDR1 in a fluconazole-susceptible isolate
rendered the strain hypersusceptible to fluconazole. However, disruption of CgCDR1 had
minimal effect on the fluconazole susceptibility in the same susceptible isolate suggesting
other CgPdr1p targets contribute to intrinsic resistance. An understanding of the initial
stress response to fluconazole may not only facilitate a better understanding of intrinsic
resistance but also how this organism is able to survive at growth inhibiting
concentrations of fluconazole (tolerance). As seen previously, our microarray data
revealed that C. glabrata responds to the exposure to fluconazole by overexpressing
CgPDR1 and two of its known target genes, CgCDR1 and CgPDH1, as well other
putative CgPdr1p target genes. However, disruption of CgPDR1 only decreased the
expression of CgCDR1 in response to fluconazole suggesting other transcriptional
activators are able to regulate CgPdr1p target genes. Indeed, several other transcriptional
regulatory pathways were also upregulated in response to fluconazole that have
redundant Pdr1p targets in S. cerevisiae. It is possible that these transcriptional
regulatory pathways also contribute to this phenotype that are independent of the
regulation of CgPdr1p targets. The roles of these additional transcriptional regulators in
azole tolerance are under investigation.
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Figure 5-1. Mechanism of CDR1 induction by Pdr1p. Fluconazole enters the cell by an
unknown mechanism. It then inhibits lanosterol demethylase in the ergosterol
biosynthesis pathway leading loss of normal sterols in the plasma membrane and a toxic
metabolite. CgPdr1p is then activated either by gain-of-function mutations in CgPdr1p
itself or by fluconazole directly binding to CgPdr1p thereby activating this transcriptional
regulator by an unknown mechanism. CgPdr1p binds to the PDRE in the promoter of
CgCDR1 allowing for transcription of this gene and ultimately efflux of fluconazole out
of the cell.
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Two of the transcriptional regulators, CgPdr1p and CgUpc2p, identified in these
studies belong to a class of fungal specific transcriptional regulators, the zinc-cluster
proteins. Development of a drug that inhibit these transcription factors could be used in
combination with the azoles that not only overcome intrinsic resistance but also make this
class fungicidal which may also attenuate the development of azole resistance in C.
glabrata. Furthermore, this information can possibly be used for the timely diagnosis of
the more azole resistant Candida species such as C. glabrata and also possibly for
identification of resistance mechanisms in this species. Currently the diagnosis of
candidiasis relies on blood cultures or tissue biopsy specimens which may require 2-5
days for growth and identification. Furthermore, antifungal susceptibility testing requires
another 48 hours for results. Therefore, development of molecular diagnostic tests that
can not only quickly identify the Candida species, but also predict the susceptibility of
the organism to an array of antifungals is needed. Early diagnosis and species
identification leads to earlier initiation of optimal treatment which has been shown to
improve clinical outcome (69). Clearly, further studies regarding the role of CgPdr1p
hyperactive alleles and other azole-responsive transcription regulators on the downstream
targets responsible for azole tolerance and development of high level resistance are
needed. The hope is that such studies will lead to improved therapies and patient
outcomes.
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